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Abstract 
Introduction: 
Renal Ischaemia-Reperfusion injury (IRI) is a complex mechanism involving the interplay 
between endothelium, leukocytes and the complement system. To evaluate the role of these 
three key mediators, a rat model was used to evaluate changes seen in renal IRI. Two 
interventional agents: Anti-Thymocyte Globulin (ATG) and Soluble Complement 
Receptor-1 (sCR1) were used to modulate leukocyte and complement response in this IRI 
model with a view to assess, and define IRI mechanism. 
Methods: 
The Ischaemia-Reperfusion (IR) model involved unilateral left renal ischemia (n=10) for 40 
minutes, followed by 48 hours of reperfusion. ATG (n=8), ATG Isotype (n=8) and sCR1 
(n=8) were given IV prior to the laparotomy followed by IR model. The sham group (n=6) 
served as controls. Blood CD3 lymphocyte counts and CH50 complement assay were used 
to check efficacy of ATG and sCR1 respectively. The kidneys retrieved at 48 hours were 
analysed for histology, immunohistochemistry and RT-qPCR studies.  
Results: 
The IR group showed significant injury compared to the sham group. ATG treatment 
offered significant histological protection mainly via decreased leukocyte infiltrate and 
endothelial protection compared to the IR and Isotype controls. CH50 assay showed 
complete ablation of complement activity at the time of reperfusion, with return to 
normality at 24 hours. sCR1 treatment conferred protection from IRI predominantly via 
suppression of the complement cascade (C3, C9), reduced leukocyte infiltrates and 
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endothelial protection.  RT-qPCR showed down-regulation of injury molecules – KIM-1 
and NGAL in both the intervention groups. 
Conclusion:  
Modulation of leukocytes and complement system using single dose ATG and sCR1 led to 
significant endothelial protection, resulting in amelioration of renal ischaemia-reperfusion 
injury. The complement system was ablated at the time of reperfusion and was 
reconstituted by 24 hours, thus indicating that suppression of complement system during 
the phase of IR provides an avenue for mitigating IRI.   
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Ischaemia refers to deprivation of blood, oxygen and essential nutrients to an organ. 
Reperfusion injury refers to the damage that ensues in the tissue following the restoration 
of the blood supply after a period of ischaemia. The absence of oxygen and nutrients from 
blood creates a condition whereby the restoration of circulation results in oxidative damage, 
inflammation, and immune mediated damage to the organ. Ischaemia-Reperfusion injury 
(IRI) involves multiple mediators, and the focus of this research project is to evaluate the 
role of three mediators: Endothelium, Complement System and Leukocytes.  
1.1. Clinical Overview 
In clinical settings, many organs are exposed to the harmful effects of IRI. For example, 
when a patient suffers a myocardial infarction, the myocardium is deprived of essential 
oxygen, and subsequent reperfusion leads to morbidity and mortality depending on the size 
of the infarct. The primary goal of treatment for an acute myocardial event is to establish 
early reperfusion, and current clinical trials are looking into ways of reducing the effects of 
the ‘lethal reperfusion injury’ (1). Similarly, in acute embolic stroke, current therapies are 
based on principles of reducing the ischaemic event, and controlling the reperfusion injury 
phase. Intravenous thrombolysis and intra-arterial therapies aim to recanalise the occluded 
arteries at the earliest, thus improving clinical outcomes (2). Cardio-pulmonary arrest, 
trauma, vascular surgery and many other clinical scenarios are inherently linked with 
ischaemia and reperfusion. Solid organ transplantation is another clinical domain where the 
transplanted organ is invariably exposed to the sequelae of IRI. Kidney is one of the more 
common organs exposed to IR, and can occur following ischaemia, transplantation and 
secondary to sepsis and medications.  
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Renal ischaemia- reperfusion injury is an invariable component of renal transplantation and 
is shown to be responsible for delayed graft function, primary non-function (total lack of 
function) or long term malfunction of a proportion of solid organ grafts (3, 4). DGF is 
usually defined as patients requiring dialysis in the first week post transplantation (apart 
from treating hyperkalemia). Reported incidence of DGF varies between 2% to 50% of 
recipients of cadaveric donations in the first week following transplantation, while in 
recipients of live donor kidneys, the reported incidence is 2% -5% (5-8). DGF and 
dependence on dialysis in the initial post-transplant period can increase dialysis-related 
morbidity, prolong hospital stay and increase costs. DGF increases the risk of acute 
rejection, and in the setting of DGF and AR, the long term graft survival is reduced (9).  
Renal IRI in the transplant setting is complex as many variables affect the outcomes of the 
transplanted kidney. This includes the donor, the organ (retrieval and preservation) and the 
recipient. Donor treatment prior to transplantation has many ethical issues, and the focus of 
current research has been towards attenuating the IRI in the transplant organ. IRI involves 
complex interactions of innate intrinsic mechanisms and immune mediators. Understanding 
the molecular and immunological consequences of IR will pave way for innovative 
therapeutic strategies aimed at attenuating ischaemia and reperfusion-associated tissue 
inflammation and organ dysfunction (10).  
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1.2. Pathophysiology of IRI 
The pathophysiology of IRI has been defined predominantly thorough animal studies, 
which has been supplemented by study of the changes observed in biopsies of native and 
transplant kidneys exposed to IR. The proposed mechanisms for the cellular, biochemical 
and the molecular changes in a kidney following IR are discussed in this section. 
1.2.1. Ischaemia- Reperfusion sequel overview 
Ischaemia-reperfusion is an inflammatory state where complex molecular and cellular 
processes take place. Ischaemic insult damages the endothelial barrier leading to partial 
disappearance of the cell-cell borders and interruption of the cell-cell contacts, leading to 
endothelial disintegration and increased vascular permeability (11). Damaged endothelial 
cells release cytokines and chemokines that facilitate endothelial interaction with 
leukocytes and platelets. Upregulation of cytokines like TNF-alpha, Interferon-gamma, IL-
1, IL-2 and IL-8 in turn upregulate adhesion molecules such as E-Selectin, P-Selectin, 
ICAM-1 and VCAM-1, thus triggering the infiltration of inflammatory cells (12). IRI also 
leads to upregulation of neutrophil chemotactic mediators including PAF (Platelet 
activating factor) and leukotrienes. Neutrophils in turn release chemotactic substances like 
IL-8 which promote neutrophil migration and activation, leading to glomerular injury (13). 
Leukocytes accumulate in the reperfused organ and release proteolytic enzymes that further 
damage the endothelium leading to oedema and capillary plugging (14, 15). The tubular 
epithelium, which is metabolically very active, maintains a critical oxygen tension is often 
the site of IR injury. It secretes proinflammatory cytokines (TNF alpha, IL-8, IL-6, TGF-
beta etc.) that recruit and activate inflammatory cells. It is also involved in T-cell 
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recruitment via expression of receptors for complement, toll-like receptors (TLR), MHC-II 
and co-stimulatory molecules that regulate T-cell activity (16). 
Reperfusion leads to initiation of blood flow, however due to endothelial cell swelling, 
interstitial oedema and capillary vasoconstriction, a ‘no-reflow’ phenomenon occurs that 
further potentiates tissue damage (17). Reactive oxygen free radicals and pro-inflammatory 
cytokines/ chemokines further augment endothelial damage. Endothelial damage leads to 
glycocalyx loss, disruption of the cytoskeleton and alteration in endothelial cell-cell 
contacts leading to breakdown of perivascular matrix, leading to increased vascular 
permeability (16, 18). Neutrophils are believed to be the early mediators of parenchymal 
damage, while macrophages and monocytes are considered late mediators, and prolong the 
injury phase (17). The complement system is also activated following IR, and the 
complement cascade further aids the inflammatory process. C3a and C5a are potent chemo-
attractants drawing the inflammatory cells to the site of injury. Membrane Attack Complex 
(MAC) causes cellular damage by inserting into the cell membrane, and in kidneys, the 
tubular epithelial cells are a major target for complement-mediated attack (19). IR leads to 
several biochemical changes at a cellular level, and they are discussed below. 
Ischaemic injury 
Ischaemia deprives an organ of essential nutrients, and leads to accumulation of metabolic 
products. This leads to anoxic injury of renal tubular cells, leading to a decrease in 
mitochondrial energy production (20). The anoxic environment contributes to anaerobic 
glycolysis and inhibition of the NA/ATPase pump (5). In states of normal perfusion and 
oxygen delivery, adenosine triphosphate is eventually broken down into hypoxanthine, but 
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in the presence of anaerobic glycolysis, further degradation of hypoxanthine is not possible 
and this leads to accumulation of hypoxanthine, and reduction in ATP content (21). This 
increase in hypoxanthine triggers the conversion of nicotinamide-adenine-dinucleotide 
reducing xanthine dehydrogenase to the oxygen radical producing xanthine oxidase, 
leading to formation of oxygen free radicals that contribute to tissue injury (22-24). 
Dephosphorylation of ATP to ADP leads to a sequence of events that leads to altered 
cellular permeability leading to loss of substrates that could have been used for synthesis of 
high energy phosphates on reperfusion (25).  
The ATP synthetase activity can be restored after 1 hour of cold ischaemia, but periods 
greater than 24-hours leads to irreversible loss of synthetase activity with lethal cell injury 
(26). Combination of anaerobic glycolysis and accumulation of lactic acid lowers 
intracellular pH, culminating in the failure of the sodium-potassium pump and deregulation 
of sodium and water homeostasis (22). Failure of the pump leads to accumulation of Na+ 
ions leading to termination of the Na+ /Ca2+ antiporter pump activity. This leads to rise in 
intracellular calcium levels, which is further augmented by ATP depletion (27). Excess 
intracellular calcium is linked to opening of the mitochondrial transition pore (mPTP) 
leading to necrotic cell death (28). Failure of the Na+ /Ca2+ antiporter pump leads to 
mitochondrial and nuclear swelling, and eventual cell rupture causing loss of electrolyte 
homeostasis. Subsequent increased protease and phospholipase activity are also damaging 
to neighboring cells (5, 29, 30).  
Intracellular binding of iron to its carrier protein is also inhibited due to ischaemic insult, 
leading to increase in free iron that acts a catalyst for generation of oxygen radicals and 
reactive oxygen species (ROS) (31). Oxidative stress is also further accentuated by the 
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reduction in anti-oxidant enzymes (e.g.: catalase, superoxide dismutase glutathione 
peroxidase etc.) which leads to inhibition of the expression of cytochromeioxidase subunits 
that further increase ROS production upon reperfusion (32). Oxygen free radicals also 
contribute to production of nitric oxide (NO) that can transform into peroxynitrite, a potent 
oxidant (21). However, the role of nitric oxide in ischaemic injury is controversial. NO acts 
as a potent vasodilator, and so augments renal medullary blood flow during ischaemia 
contributing to renal protection (33, 34). This action must be weighed against the capacity 
of NO to disrupt the cytoskeleton and cellular adherence, leading to proximal tubular cell 
detachment and tubular obstruction (5, 35, 36). 
In response to renal ischaemia, cytoprotective mechanisms are also invariably activated. 
The immediate response to ischaemia is an overall decrease in the cellular metabolic 
activity (37). At the molecular level, transcription of genes whose products are 
cytoprotective (38) or linked to cellular regeneration (39) (for example, Heme oxygenase-1 
and VEGF ) are also activated (40). In summary, the net effect of these processes is that at 
the end of the ischaemic phase, proximal tubular cells are ATP depleted, and show 
evidence of mitochondrial injury and down-regulated antioxidant defenses (27). 
Reperfusion injury 
Reinstitution of blood flow to an ischaemic kidney leads to a sequence of pathological 
processes together referred to as reperfusion injury. Reperfusion injury depends on the 
severity and the length of the ischaemic insult, and can take hours to days to develop. 
Reperfusion leads to rewarming, reoxygenation and a return to aerobic metabolism (5). 
Intracellular pH returns to baseline leading to massive sodium influx with mitochondrial 
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calcium overloads that lead to the activation of the calpains. Calpains hydrolyze target 
proteins leading to mitochondrial dysfunction and cell death (41). Increase in perfusion 
pressure causes direct endothelial damage, and also triggers an inflammatory response that 
exacerbates pre-existing renal injury (42).  
Following reintroduction of oxygen, Reactive Oxygen Species (ROS) are generated in high 
concentration. ROS are formed by incomplete reduction of molecular oxygen and include 
superoxide anion (O2-.), hydrogen peroxide (H2O2), hydroxyl radical (OH.), and singlet 
oxygen. Extensive evidence links ROS to the tissue damage associated with reperfusion 
injury (43, 44). ROS causes direct oxidative damage to nucleic acids and proteins. ROS can 
also modify glomerular permeability to proteins (through activation of proteases and 
reduction of proteoglycan synthesis), and cause reduction in glomerular blood flow and 
filtration rate through liberation of vasoconstrictory lipids (prostaglandins and platelet 
activating factor) (45). In the normal kidney, the actions of ROS are mitigated by 
antioxidant enzymes, but reperfusion injury subdues the ‘scavenging effect ‘of these 
protective enzymes (21, 46). The combination of ROS and high intracellular calcium leads 
to mitochondrial matrix changes, causing rupture of cellular membranes and activation of 
pro-apoptotic caspases (25). Reperfusion also activates repair and regeneration processes, 
and the fate of an organ either as recovery or death will be characterized by various cellular 
events characterized by necrosis (traumatic cell death due to acute cellular injury), 
apoptosis (process of programmed cell death) or autophagy (catabolic mechanism that 
involves degradation of unnecessary or dysfunctional cellular components) (25, 27). 
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1.2.2. Pathological changes 
The pathophysiological changes following IR involve complex interactions between the 
inflammatory mediators and the renal architecture. Tubular injury is a characteristic feature 
of IRI, usually presenting as acute tubular necrosis (ATN). The tubular cells in the proximal 
tubules (straight portion) and the ascending loop of Henle are more susceptible to hypoxic 
insult due to ischaemia, and these cells show changes in the form of apical blebs and loss of 
the brush border membrane, eventually leading to loss of polarity and integrity of the tight 
junctions (47). Hemodynamic alterations lead to reduction in the glomerular filtration rate 
(GFR), which is compounded by formation of casts and debris that obstruct the tubule 
lumen, leading to back-leak of filtrate through the damaged epithelium (48). The inhibition 
of the NA/ATPase pump accelerates cell death by both necrosis and apoptosis, and the 
sloughing of cells leads to cast formation and obstruction of the tubular lumen. Tubular and 
interstitial damage leads to inflammation and haemorrhage, with widespread necrosis 
indicating a more severe injury (49). 
Tubulointerstitial inflammation is also a hallmark of renal IRI. The inflammatory response 
following IRI leads to synthesis and release of multiple cytokines including TGF-beta, a 
profibrotic cytokine with pleiotropic actions that together drive tubulointerstitial fibrosis 
and atrophy (50). Fibrosis and atrophy in the tubulointerstitial compartment of the kidney is 
a pathological hallmark of chronic kidney disease, and is a predictor of progression to end-
stage renal disease (51).   
Glomerular damage is also seen following IRI. The glomerular barrier is composed of three 
layers: the fenestrated endothelium with its glycocalyx, the glomerular basement membrane 
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(GBM), and the podocytes with their interdigitating foot processes (52). Following IR, 
ROS and inflammatory mediators cause alterations in the endothelial glycocalyx layer, 
flattening and spreading of the podocyte foot processes, and creation of large pores in the 
glomerular basement membrane, that collectively cause proteinuria (53). IRI has also 
shown to be contribute towards degradation of the GBM (54). Glomerular damage 
following IRI can be histologically seen as thickening of the glomerular capsule and 
retraction of glomerular tuft, but in severe IRI, glomerular fibrosis can be seen (55). 
Ischaemia leads to endothelial cell damage and smooth muscle damage. The endothelial 
damage can be visualised as endothelial cell swelling in mild IRI, with disruption and loss 
seen in severe IRI (56).  
Recovery from renal IRI requires tubular regeneration and repair. Experimental models 
indicate that repair is promoted by growth factors, integrins and extracellular matrix 
proteins that promote tubular cell survival and proliferation. This aids in the recovery and 
reversal of AKI (57). Recent studies have focused on using stem cells and other 
interventions to improve outcomes after renal injury, mainly by providing factors that 
promote renal tubular repair. This avenue offers promise for future interventions. 
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1.3. Mediators of Renal IRI 
In addition to the direct injury from ischaemia and hypoxia, the inflammatory response in 
IRI also plays a significant role. The mediators discussed in this section are linked in 
modulating both the inflammatory and the immune response.  
1.3.1. Inflammatory Mediators 
1.3.1.1. Cytokines 
The cytokines are cell signaling proteins that aid cell to cell communication, predominantly 
in immune responses and inflammatory states. In renal IRI, cytokines are produced mainly 
by the leukocytes and renal tubular cells, and mediate and propagate AKI by attracting 
leukocytes and other inflammatory mediators to the site of injury. Cytokines such as TNF-
alpha, IL-1, MCP-1, IL-8, PDGF and VEGF have been shown to be produced by the PTC 
(58). Pro-inflammatory cytokines IFN-gamma, TNF-alpha, IL-1, IL-2, IL-6, GMCSF and 
TGF-Beta 1 are increased in the ischaemic AKI and renal injury rodent models (59, 60). IL-
18 and IL-6 are also released from the PTEC and have been used as urinary biomarkers for 
AKI, and significant elevations of IL-6 and IL-8 were associated with mortality in an ITU 
setting (61, 62). 
In an injury state, the pro-inflammatory cytokine response is also tempered by protective 
anti-inflammatory cytokines like IL-10, IL-11, IL-13 and specific cytokine receptors (for 
IL-1, TNF, IL-18) (63). In renal IRI, there is also secretion of protective cytokines such as 
IL-4, IL-10, IL-13, and VEGF that aid in reducing renal injury by inhibiting inflammatory 
and cytotoxic pathways of AKI (64). IL-10 was shown to protect against ischaemic and 
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cisplatin-induced AKI partly through its effect of inhibiting genes responsible for leukocyte 
activation and adhesion (65). IL-6 was shown to simultaneously promote a pro-
inflammatory injury response and a renal protective response via a mechanism of trans-
signaling (66).  
Mitigating the effect of cytokines with interventional agents seems attractive, however the 
literature evidence remains equivocal. Blocking IL-1 receptor with antagonist (IL-1Ra) or 
using IL-1 knock out mice did not offer protection from renal injury (67). Interleukin-18 
binding protein transgenic mice were shown to be protected against ischaemic AKI with 
IL-18 dependent cytokines (IL-3, IL-6, IL-15, macrophage colony-stimulating factor, MIP-
2, GMCSF, MCP-1) shown to be increased in the AKI group compared to the sham group 
(68). In summary, there are hosts of cytokines that are released following AKI that have 
both a pro-inflammatory and anti-inflammatory properties. It is likely that these 
contradictory results with cytokine blockade reflect the complexity of responses seen, and 
that the therapeutic efficacy of targeting specific mediators to improve renal outcome in IRI 
will depend on precise clinical/cellular context. 
1.3.1.2. Chemokines 
Chemokines are cytokine-like molecules that are subdivided into four subfamilies: CXC, 
CC, C and CX3C – based on spacing and number of cysteine residues in their 
sequences(69). They are induced by cytokines (like TNF-alpha, IL-1), complement system, 
ROS, and TLR related pathway in an inflammatory setting and mediate leukocyte 
recruitment and immune responses (11). In renal IRI, CXC chemokines have been shown to 
promote neutrophil infiltration, CXCR3 ligands are involved in recruiting Th1 cells and CC 
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chemokines induce mononuclear cell infiltration and macrophage activation (70). CCR1 
(chemokine receptor) has been shown to regulate macrophage and neutrophil movement 
into kidney in a murine IRI model, and treatment with CCR1 antagonist or using CCR1 
deficient mice showed decreased inflammatory infiltrates (71).  
CXCL1 has been proposed to be one of the mediators of ischaemic AKI as it is increased in 
post IRI kidneys, and a neutralizing antibody to CXCL1 has attenuated renal injury in 
rodent models through decreased neutrophil and inflammatory infiltrates (72, 73). CX3CL1 
(also known as fractalkine) acts as a chemo attractant for NK cells and monocytes in renal 
injury, and fractalkine expression is increased in endothelial cells following ischaemic AKI 
(74, 75). Though blockade of CX3CR1 with specific antibody did not reduce the injury in 
cisplatin induced AKI (76), inhibition of CXCR2 inhibitor (using repertaxin) attenuated 
injury in a syngenic transplantation model in rats (77). In summary, chemokines regulate 
cytokine and adhesion molecule expression, mediate leukocyte recruitment and contribute 
to angiogenesis and fibrosis in the reperfusion phase (78).  
1.3.1.3. Adhesion molecules 
Adhesion molecules aid leukocyte adhesion to the endothelium during the inflammatory 
process that follows IRI. The adhesion molecules are broadly classified into calcium 
independent (Immunoglobulin superfamily) or calcium dependent (selectins, integrins, 
cadherins). The role of adhesion molecules in renal IRI is well known, with rodent models 
undergoing interventions prior to IR showing suppression of adhesion molecules, and 
reduction of inflammatory infiltrates. A brief synopses of various adhesion molecules is 
provided below:  
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• ICAM-1 (Inter-cellular adhesion molecule: CD54) enhances leukocyte endothelial 
interaction, and guides leukocyte extravasation by binding to LFA-1 (79). In a study 
exploring ICAM-1 expression in rat kidney between IR and toxic AKI, increased 
expression of ICAM-1 along with monocyte and T-cell accumulation was seen in 
the inner strip of outer medulla very early after IR, compared to the toxic group 
where ICAM-1 expression was delayed with no leukocyte accumulation (80). 
Antibody to ICAM-1 administered prior to renal IR, and mutant mice genetically 
deficient in ICAM-1, were both protected against renal ischaemic injury (81, 82). 
 
• P-Selectin (platelets, endothelial cells), E-Selectin (endothelium) and L-Selectin 
(leukocytes, lymphocytes) have all been implicated in the IRI process. P-Selectin 
has been shown to be involved in leukocyte recruitment to the kidneys in a murine 
renal IRI model (83), and its inhibition attenuated IR injury in rodent models (84, 
85). P-Selectin is readily available within the endothelial cells in cytoplasmic 
deposits called Weibel-Palade bodies. Ultrasound imaging of P-Selectin-targeted 
contrast agent showed a significant increase in vascular P-Selectin expression 1 
hour post reperfusion in murine renal IRI model, predominantly in the cortex of the 
post-ischaemic kidney compared to the contralateral kidney (86). Blockade of 
ligands for all three selectins using a novel small molecule (TBC-1269) showed 
functional and structural protection from IRI in moderate (30 minutes IR), but 
minimal protection in severe IR (45 minutes) (85). 
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• L-Selectin mediates leukocyte rolling on endothelium and has been upregulated in 
experimental and human renal ischaemia/reperfusion models. IRI leads to severe 
endothelial damage that modifies heparan sulfate proteoglycans (HSPGs) in 
basement membrane, enabling the endothelium to bind L-Selectin (87). Though L-
Selectin blockade attenuated IRI in cardiac and skeletal muscles, in renal rodent 
models, it was shown not to confer any structural or functional protection from IR 
injury (88).  
 
• E-Selectin (CD62E) and its ligands are essential for recruitment of leukocytes in 
inflammation, and its role in neutrophil recruitment was shown in a study where 
basigin/CD147 (ligand for E-Selectin that promotes renal inflammation in 
ischaemia/reperfusion) deficient mice demonstrated striking suppression of 
neutrophil infiltration in the kidney after renal IR (89). Preventing leukocyte 
adhesion and infiltration confer protection from IR injuries (90-92). Inhibition of 
ICAM-1 and E-Selectin expression by a radical scavenger (lecithinized superoxide 
dismutase) in a experimental model led to decreased neutrophil adhesion to the 
endothelium (93). 
 
•  Platelet endothelial cell adhesion molecule (PECAM-1: CD31) PECAM-1 is a 
cell adhesion and signalling receptor expressed on hematopoietic and endothelial 
cells with pro-inflammatory and anti-inflammatory functions. PECAM-1 is known 
to inhibit platelet function and thrombus formation. Pro-inflammatory functions of 
PECAM-1 include the facilitation of leukocyte transendothelial migration, and anti-
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inflammatory functions include the dampening of leukocyte activation, suppression 
of pro-inflammatory cytokine production and the maintenance of vascular barrier 
integrity (94). Increased expression of PECAM-1 has been seen following renal IR 
in mice (95). NO-dependent vasodilator molsidomine injected 15-minutes before 
reperfusion prevented the IR induced renal dysfunction, with reduced inflammatory 
cell infiltration along with decreased expression of adhesion molecules (ICAM-1, 
PECAM-1, VCAM-1 and P-Selectin) (96).  
 
• Vascular cell adhesion molecule (VCAM-1: CD106): VCAM-1 is found in very 
low levels on the cell surface of resting endothelial cells and other vascular cells 
such as smooth muscle cells and fibroblasts. It binds to very-late antigen-4 (VLA-4) 
integrin on the cell surface of leukocytes, mediating its adhesion to the 
vascular endothelium (97). IL-1 and TNF-alpha increase expression of VCAM-1, P-
Selectin and other cell adhesion molecules on the vascular endothelial cells, 
however, knockout mice deficient in both IL-1 and TNF-alpha receptors were also 
shown to increase expression of ICAM and VCAM in renal IR implicating other 
pathways of activation (98, 99). Endothelial VCAM-1 expression contributed to T-
cell infiltration at sites of inflammation(100), and was also shown to mediate 
mononuclear cell infiltration into the perivasculature after kidney transplantation in 
a rat model (101).  
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Adhesion molecules play a key role in the process of IRI. Rodent models using antibodies 
to adhesion molecules have shown promise, but whether they can be translated into clinical 
practice remains to be seen. 
1.3.1.4. Cells mediating inflammatory response 
Leukocytes are derived from a multi-potent hematopoietic stem cell, and are often 
classified into two broad categories depending on the granules in their cytoplasm: 
• Granulocytes – neutrophils, basophils, eosinophils 
• Agrnaulocytes - lymphocytes, monocytes, macrophages 
Dendritic cells are also considered part of leukocytes and are cells of myeloid/lymphoid 
lineage. They are predominantly involved in the immune pathways, and have more recently 
been considered to have a role in mediating inflammation. 
Ischaemia-reperfusion injury is a complex interrelated sequence of events that classically 
involves the vascular endothelium and activated leucocytes (102). Leukocytes adhere, 
marginate and infiltrate through into the interstitium leading to microvascular congestion 
and ‘no-reflow’ phenomenon. Tissue injury is further augmented with the release of pro-
inflammatory cytokines. Leukocyte adhesion to endothelium and rolling have been 
visualised in primate limb IR studies (103). Experimental models employing perfusion of 
kidneys with leukocyte and platelet depleted blood (using white cell filters) have shown 
some promising results in relation to improved renal blood flow and creatinine clearance 
(104, 105). The relative importance of different leukocyte subtypes mediating IR is difficult 
to pin-point as all the individual cells have been shown to be recruited into the IR process at 
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various time intervals, and the contribution of each cell in the ischaemic or the reperfusion 
process varies (106, 107). In renal IRI, the individual cells have been evaluated in isolation 
to determine the effect on the IR, and have shown mixed results. The following paragraphs 
succinctly review the role of the leukocytes involved in the IRI process. 
Neutrophils 
Following IR, neutrophils attach to the activated vascular endothelium and release reactive 
oxygen species that can damage the tubular cells and accentuate IRI (102, 108). The 
recruitment of neutrophils to the inflammatory site is governed by a variety of adhesion 
molecules. Selectins are involved in mediating the initial rolling of cells followed by 
integrins that enable neutrophils to attach firmly to the endothelium. The final migration 
throughout the endothelial wall is mediated by adhesion molecules like PECAM and ICAM 
(13). Chemokines are potent neutrophil chemo-attractants, and studies have shown the 
primary mediators of IRI injury to be the neutrophils (109-111). Ischaemic, nephrotoxic 
and endotoxemia induced acute kidney injury have consistently showed enhanced 
neutrophil infiltration, but the precise kinetics of neutrophil trafficking is not fully defined 
(11, 112). CXC chemokines are known to direct neutrophils to tissue sites of inflammation, 
and pre-treatment with CXCL1 neutralizing antibody showed reduced neutrophil 
infiltration into the ischaemic kidneys with attenuation of the IR injury (113). 
Mutant mice genetically deficient in ICAM-1 were protected from renal IRI mainly via 
attenuation of neutrophil-endothelial interactions, leading to decreased inflammatory 
infiltrates (81). In the early reperfusion phase following IR, kidney IFN-gamma-producing 
cells were comprised largely of CD11b neutrophils and CD1d-restricted NKT cells, and 
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depletion of NKT cells led to decrease in IFN-gamma-producing neutrophils indicating a 
role for NKT cells driving neutrophil migration (114). CD44 is expressed by neutrophils 
and is rapidly upregulated by capillary endothelial cells after IR injury, and 
CD44 deficiency/ administration of anti-CD44 to mice lead to reduced influx of neutrophils 
into the post ischaemic tissue, along with preservation of renal function and morphology 
(115). Inhibitors of proinflammatory factors (P-Selectin, TNF alpha, ICAM 1), and other 
interventional agents used in renal IR models have consistently showed reduced neutrophil 
infiltration in the post ischaemic kidney, although the ‘protective effects’ of these agents 
were not exclusively attributed to neutropenia alone (60, 116-118). 
Studies have shown that reperfusion of ischaemic kidneys with neutrophils can worsen 
ischaemic injury (107, 119). Rodents rendered neutropenic by using antineutropil serum did 
not confer protection from IRI (120, 121). Administering a monoclonal antibody (MoAb 
60.3- blocks neutrophil adherence to rabbit endothelial cells) in rabbits or anti-
neutrophil serum administration in rats did not offer functional or morphological protection 
from renal IRI (122). In summary, the role for neutrophils in renal IRI still needs to be 
accurately elucidated, as it’s seen in IRI kidneys, however mitigating the function or 
reducing the influx did not show benefits.  
Macrophages 
Macrophages are major players in the innate and adaptive immune response of renal IRI. 
The macrophages reside in the interstitial extracellular compartment of the kidneys, and 
interact with substances transported from the tubule lumen into peritubular capillaries. 
Apart from being a cellular mediator of immunity, they are also involved in the 
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inflammatory process that takes place in a IRI setting, and is involved in the injury/repair of 
post-ischaemic kidneys (64, 123). In the kidney, macrophages are well-known sources of 
pro-inflammatory caspases and cytokines (IL-18, IL-1, TNF-alpha, MCP-1). Osteopontin 
(macrophage chemoattractant) knockout mice showed reduced macrophage infiltration, 
enhanced apoptosis in the injury phase and decreased collagen I and IV expression in the 
regeneration phase of post-ischaemic AKI (124). In a mice model, CCR2- and CX3CR1-
dependent mechanisms were shown to be involved in the migration of inflamed monocytes 
to the renal IRI site, and the injury was further accentuated by secretion of cytokines like 
TNF-alpha, IL-6, IL-1 and IL-12 by the inflamed monocytes (125). In this study, 
macrophage numbers in the ischaemic kidney increased at 1-hour post reperfusion and 
persisted for 7 days.  
Macrophage depletion using clodronate prior to renal IR demonstrated protective benefits 
from IRI (90, 126, 127). This effect was attributed to the depletion of CXCL1 (neutrophil 
and T-lymphocytes chemo attractant) chemokine, and macrophages are the main source of 
CXCL1 in the ischaemic kidney (11). Different types of macrophages have been described 
that promote (M1) and inhibit inflammation (M2) (128). Lee et.al showed that depletion of 
macrophages before IR diminished mice kidney injury, with pro-inflammatory (M1) 
macrophages recruited into the kidney in the early phase (48 hours) after IR, and non-
inflammatory (M2) macrophages seen at later time points, suggesting that macrophages 
underwent a switch from a pro-inflammatory to a trophic phenotype that supported kidney 
repair (129). Macrophages are known to have various subsets, and targeting only ‘activated 
macrophages’ has been shown to be beneficial in the IRI setting (130).  
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T-Lymphocytes 
Presence of lymphocytes in the post-ischaemic human kidney biopsies alerted to its 
possible role in IRI (131). T-cells and macrophages were localized predominantly in outer 
stripe of outer medulla, the zone of most severe injury (112). Proximal tubular epithelium 
and dendritic cells (presenting antigen to native T-cell and expressing co-stimulatory 
molecules) have been implicated in the activation and regulation of T-cells in IRI (132). 
Ascon et.al showed increased trafficking of CD3+ T cells and CD19+ B cells in both sham-
operated and IRI mice 3-hours after renal IRI, thus alluding to the possibility that even 
abdominal surgery itself can lead to lymphocyte changes in kidney (133). Blocking of 
chemotaxis factors CXCR3 and CCR5 in a rat renal IRI model showed decreased 
infiltration of T cells and NKT cells in the kidneys, and had lower tubular injury scores 
compared to the controls (134). Upregulation of lymphocyte-related cytokines and adhesion 
molecules (CD11/CD18, ICAM-1) in experimental IRI models have further supported the 
role of T-lymphocytes in IRI (135).  
Takada et.al showed that blockade of T cell CD28-B7 co-stimulation with CTLA4Ig 
prevented the early and late consequences of IRI, and lead to significant inhibition of T cell 
and macrophage infiltration and activation in situ (136). Though the exact role of T-
lymphocytes in the IRI has to be ascertained, it has been hypothesised that T-lymphocytes 
may mediate neutrophil infiltration into ischaemic kidneys as evident by decreased 
neutrophil infiltration and decreased tubular necrosis in CD4+ and CD8+ deficient mice 
undergoing IRI compared to their WT controls (135). T-cell deficient (nu/nu mice) and 
CD4+ deficient mice were functionally and structurally protected from post ischaemic renal 
injury, compared to the WT control and CD8 deficient mice (99). Attenuation of IR effects 
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in other organs has also been observed with T- cell deficiency, or via T-cell depletion (137, 
138). Similarly, T-cell receptor (TCR) deficient mice showed reduced renal tubular injury, 
reduced TNF-alpha and IL-6 protein expression in kidney tissue compared to WT 
littermates after IR (139). Yokoto et.al demonstrated that T cell depletion [Antibodies to 
CD4 (GK1.5), CD8 (2.43) and pan-T cells (30.H12)] offered protection from renal IRI in 
mice, though the antibody combinations did not significantly alter other leukocyte 
populations (140).  
On the contrary, there have been studies that have shown that T-lymphocytes have a limited 
role in IRI. Peripheral CD4+ T-cell depletion did not confer functional or histological 
protection against AKI in a murine renal IRI model (141). Recombination-activating gene 
(RAG)-1-deficient mice (deficient in Ig and T-lymphocytes) when subjected to bilateral 
renal IR, showed ATN and neutrophil infiltration in the kidney compared to the WT mice 
(142). RAG-1 deficient mice lacking both B and T cells were not protected from renal IRI, 
and adoptive transfer of either B or T cells into RAG-1 deficient mice led to a significant 
protection of renal injury(143). Overall, T-cells are considered to have a more important 
role in the early inflammatory process than the late adaptive immune response (144), but a 
definitive role from these studies still needs to clearly defined. 
B-Lymphocytes 
B cells are involved in adaptive immune response and contribute to tissue pathology in 
immune-mediated disorders, not only by producing antibody, but also through other 
mechanisms which may involve antigen presentation, cytokine production and complement 
system activation (145). Knockout mice deficient in B-cells and models using complement 
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components that interact with B-cell receptor have shown protection from IRI in selected 
organs (heart, intestine, skeletal muscles) (17). The precise role and kinetics of B-cell 
recruitment in renal IRI models are yet to be elucidated. Infiltration of CD19+ B-cells were 
seen in both sham-operated and IRI mice 3-hours after renal IRI (133). B cell-deficient 
(µMT- mutation of the heavy chain of IgM (µ chain) that doesn’t allow differentiation of 
premature B cells to mature B cells) mice were conferred structural and functional renal 
protection compared to their WT in a 30-minute renal ischaemia model, and was attributed 
to lack of circulating natural antibodies (146). Depletion of peritoneal B-1 cells prior to 
renal IR was shown to confer protection via reduced mesangial IgM, along with increased 
production of the anti-inflammatory cytokine IL-10, but, µMT mice in this study suffered 
worse renal IR injury than the WT mice (147). RAG-1 deficient mice (lacking both B and T 
cells) subjected to IR failed to confer protection from IR injuries (143, 148). Hence, the 
precise role of B-cells in renal IRI is still to be ascertained.  
Regulatory T-Cells (Tregs) 
Tregs have anti-inflammatory and immunosuppressive properties, and are identified by the 
expression of CD4 and CD25 on cell surface, and up regulation of transcription factor 
FOXP3. Tregs can traffic to areas of inflammation to mitigate immune reactions, and can 
inhibit neutrophil ROS generation and pro-inflammatory cytokine production (149, 150). 
They reside in the kidney under normal conditions, and its role in IRI has been the focus of 
recent research. Partial depletion of Tregs using anti-CD25 antibody worsened ischaemic 
kidney injury, and adoptive transfer of Tregs into RAG-1 knockout mice prevented kidney 
IRI (151). In the same study, FoxP3(+) Treg-deficient mice was shown to accumulate a 
greater number of inflammatory leukocytes after renal IRI than mice containing Tregs, and 
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transfer of Tregs attenuated renal injury. The authors concluded that Tregs modulated 
injury through IL-10-mediated suppression of the innate immune system.  
Treg depletion starting a day after after ischaemic injury using anti-CD25 antibodies 
worsened renal tubular damage, and increased infiltrating T lymphocyte cytokine 
production at 3 days, which was reversed with the infusion of CD4(+)CD25(+), thus  
suggesting a role for Tregs in the healing process promoting repair (152). A 
pharmacological agent- sphingosine N,N-dimethylsphingosine (DMS) was shown to recruit 
Tregs to IRI kidneys and confer protection against IRI (153). Based on these studies, Tregs 
seem to have a beneficial effect in both the initiation and the repair phases of renal IRI, but 
further studies aimed at identifying mechanisms by which Tregs facilitate and promote 
renal recovery can hold immense potential in treating acute kidney injury (154).  
Natural killers cells (NK cells) 
NK cells interact with various components of the immune system and function as 
regulatory cells, from assisting in dendritic cell maturation to T-cell polarization (155). 
RAG-1 mice deficient in T and B cells were not protected from IRI, suggesting a role for 
NK cells or other innate immune responses (143). Rae-1, a cell surface receptor recognized 
by NKG2D on NK cells, is upregulated following kidney IRI (156). In an experimental 
renal IRI model, the PTEC were shown to upregulate the expression Rae-1 by activating 
the NKG2D receptor on NK cells, and furthermore, NK cell depletion in WT mice 
conferred protection (157). C57BL/6 OPN-deficient mice had reduced NK cell infiltration 
and lesser tissue injury compared to WT after IR, suggesting OPN expression by PTEC as 
an important factor in initial inflammatory responses involving NK cells in kidney IRI 
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(158). NK cells were rapidly recruited into kidneys 4-hours after IRI, which in turn 
recruited neutrophils by stimulating the CD137L signalling pathway in PTEC, leading to 
production of CXCL1 and CXCL2 (159).  
Natural Killer T cells (NK T cells) 
NKT cells are unique subset of T-lymphocytes with surface receptors and functional 
properties shared in common with conventional T-cells and NK cells (NK cell-associated 
marker NK1.1/ NKR-P1.9), and exist in the thymus and peripheral lymphoid organs. NKT 
cells have the ability to rapidly produce large amounts of cytokines, including Th1-type 
(IFN, TNF) and Th2-type (IL-4, IL-13), and can amplify and regulate functions of DCs, 
Tregs, B-cells, T-cells and NK cells (123). Conventional CD4+ T cells play a role in 
antigen-specific adaptive immunity that requires several days to be active, and as such 
cannot be part of the rapid immune response seen in IRI, hinting at a possible role of NKT 
cells as an early mediator (160). In an experimental model aimed at characterizing 
lymphocytic infiltrates, increased infiltration of NK1.1+ and CD4+ NK1.1+ cells compared 
with normal and sham-operated mice was observed 3 and 24-hours after renal IRI 
respectively (133). In a murine IR model, GR-1(+)CD11b(+) neutrophils, and CD1d-
restricted NKT cells were seen within three hours of reperfusion, and antibodies to block 
CD1d/deplete NKT cells/ mice deficient of NKT cells (Jalpha18(-/-)) markedly reduced IR 
injury (114). Chemotaxis factors CXCR3 and CCR5 are also expressed on CD4T cells and 
NKT cells. Blocking of chemotaxis factors CXCR3 and CCR5 by an antagonist (TAK) 
significantly reduced the infiltration of CD4+ T cells and CD8+ NKT cells, and showed 
functional and structural protection compared to the control and sham groups (134).  
	 26	
Dendritic cells 
Dendritic cells (DC) are primarily involved in adaptive immune response and possess 
surface receptors that recognize pathogen-associated molecular patterns, thus enabling them 
to respond to infection and inflammation (161). DCs originate from the bone marrow and 
remain in an immature form until stimulated by a focus. DCs are present throughout the 
renal interstitial space, and are interposed between the tubular epithelium and the 
peritubular capillaries in the healthy kidney (162). CD11c+ MHC class II+ DCs are the 
most abundant leukocyte subset in the normal mouse kidney, and upon stimulation can 
activate T-cells (123). Increase in the differentiation of peripheral monocytes into DCs with 
increased IL-12 and IFN-gamma production by DC-stimulated T cells, were seen two days 
after IRI compared to the sham group (163). Studies have shown that endothelial activation 
following ischaemia leads to DC adhesion which is partially mediated by ICAM-1, and 
DCs in turn activate alloreactive T-cells leading to allotransplant rejection (164). Cell 
suspensions from mouse IRI kidneys showed increased secretion of TNF, IL-6, MCP-1 and 
RANTES from resident DCs, and in vivo depletion of intrarenal DCs (Clordonate 
liposome-mediated depletion) substantially attenuated TNF secretion, there by attributing 
DCs as the predominant secretors of TNF within 24 hours of IRI (165).  
The role of DCs in renal IRI has been the focus of research in recent years. Paucity of DC-
specific cell surface markers and difficulty in distinguishing DC from other members of the 
monocyte/macrophage lineage probably explains the reason. The role of DCs in regulating 
balance between regulatory T-cells and effector T-cells at IR site can be a potential target 
for treating IRI (161, 166), and future IRI models using genetically engineered mouse with 
specific DC depletion can shed more light. 
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1.3.2. The Complement System  
The complement system is an integral part of the innate immune response and acts as a 
bridge between innate and acquired immunity. It consists of a series of proteins that are 
mostly (although not exclusively) synthesised in the liver, and exist in the plasma and on 
cell surfaces as inactive precursors (zymogens). The complement proteins are activated by, 
and work with IgG and IgM antibodies, hence the name “complement”. The complement 
system is more complex than many enzymatic cascades as it requires the formation of 
sequential non-covalently associated activated protein fragments. These in turn become 
convertases and cleave components for the next enzymatic complex in the cascade, and the 
rapid dissociation of these complexes (and loss of enzymatic activity) forms an integral part 
of the elegant regulation of complement activity.  
Complement mediates responses to inflammatory triggers through a co-ordinated sequential 
enzyme cascade leading to clearance of foreign cells through pathogen recognition, 
opsonisation and lysis (167). Complement binds to immune complexes and apoptotic cells, 
and assists in their removal from the circulation and damaged tissues (168, 169). A 
comprehensive review of the complement system can accessed via our publication: ‘The 
complement system: history, pathways, cascade and inhibitors’ (170), and only relevant 
sections are covered in this section. 
1.3.2.1. Pathways of Activation and Cascade 
There are three known pathways for complement activation: Classical, Alternative and 
Lectin pathway.  
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Classical pathway 
The classical pathway is initiated by IgM or IgG antigen/antibody complexes binding to 
C1q (first protein of the cascade) leading to activation of C1r, which in turn cleaves C1s. 
This in turn activates the serine proteases that lead to cleaving of C4 and C2, leading to 
formation of C4b2a (C3 convertase), which in turn cleaves C3 into C3a and C3b (171). 
While C3a acts as a recruiter of inflammatory cells (anaphylatoxin), C3b binds to the 
C4b2a complex to form C5convertase (C4b2a3b). The C5 convertase initiates the formation 
of the Membrane Attack Complex (MAC), that inserts into cells creating functional pores 
leading to its lysis (172). The classical pathway can also be activated by other danger 
signals like C-reactive protein, viral proteins, apoptotic cells and amyloid, thus providing 
evidence that classical pathway could be activated independent of antibodies (173-176). 
Alternative Pathway 
50 years after the discovery of the classical activation pathway, Pillemer et al (177, 178), 
proposed a highly controversial alternative activation pathway. The alternative pathway is 
not so much an activation pathway, as it is a failure to regulate the low level continuous 
formation of a soluble C3 convertase. The internal thioester bond of C3 is highly reactive 
and undergoes spontaneous hydrolysis resulting in a molecule known as C3 (H2O), which 
resembles C3b. This can then bind to factor B, and be processed into a short-lived soluble 
C3 convertase that can generate more C3b. If this C3b binds to a nearby surface that is 
incapable of inactivating it (such as bacteria/yeast cells or damaged host tissues), this then 
leads to amplification of the alternative pathway (179-181). The presence of complement 
regulators (Factor I and Factor H) in healthy cells ensures the spontaneous hydrolysis of C3 
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is kept in check. C3 activation takes place when C3b binds to Factor B, and is then cleaved 
by Factor D (182). The enzymatic action of Factor D acts as the rate limiting step of the 
alternative pathway and cleaves Factor B, the larger fragment of which remains bound to 
C3b to form the alternative pathway C3 convertase – C3bBb (171, 183). C3b is able to 
create new C3 convertase in the presence of Factor B and D, thus acting as an 
‘amplification loop’ for the classical and lectin pathways, in addition to the alternative 
pathway (175). The alternative pathway omits the components: C1, C2 and C4. 
Lectin Pathway 
40 years after the proposal of the alternative pathway, the MBL (Mannose-binding lectin)/ 
MASP (MBL associated Serine Protease) pathway was discovered. This pathway was 
characterised by using proteins isolated from rabbit liver and serum, but its function 
remained unclear initially (184, 185). Two forms of MBL (MBL-A and -C) are present in 
rodents compared to a single form in the humans. Studies linking the deficiency of MBL 
protein to immunodeficiencies in children led to its recognition as an important activator of 
the complement system (186, 187). The initiating molecules for this pathway are collectins 
(MBL and ficolin), which are multimeric lectin complexes. These bind to specific 
carbohydrate patterns leading to activation of the pathway through enzymatic activity of 
MASP (182). There are structural similarities shared between MBL and C1 complexes 
(MBL- with C1q-associated serine proteases, MASP-1 and MASP-2 with C1r and C1s 
respectively), leading to the belief that complement activation by MBL and C1 complexes 
are similar (188). MASP-2 cleaves C4 and C2 to form C3 convertase, while MASP-1 may 
cleave C3 directly bypassing the C4b2a complex, albeit at a very slow rate (189, 190).  
	 30	
Another serine protease, MASP-3 was shown to down-regulate the C4 and C2 cleaving 
activity of MASP-2 (191). Following the initial characterisation of MBL, 3 other lectins 
(known as ficolins) have been shown be associated with MASP: ficolin-1 (or M-ficolin), 
ficolin-2 (or L-ficolin) and ficolin-3 (or H-ficolin or Hakata antigen). The ficolins activate 
the lectin pathway by forming active complexes with MASP (192, 193). More recently, a 
new C-type lectin (CL-11) was shown to interact with MASP-1 and/or MASP-3 and could 
activate the lectin pathway(194). 
Complement cascade 
All three pathways lead to the generation of C3 convertase that cleaves the C3 protein into 
C3a and C3b. While C3a acts as an anaphylatoxin, C3b covalently binds to the activating 
surface and participates in the self-activation loop of complement activation via the 
alternative pathway. C3b also associates with C3 convertases (C4b2a or C3bBb) to form 
the C5 convertase, which cleaves C5 complement into C5a and C5b (195). Interaction of 
C5b with C6, C7, C8 and C9 leads to formation of C5b-9 / MAC, a multimolecular 
structure that inserts into the membrane creating a functional pore leading to cell lysis (172). 
MAC can cause lysis of some cells (e.g. erythrocytes) with a single hit, but some nucleated 
cells required multiple hits, or rather, multiple channel formation to cause cell lysis (196, 
197). However, studies have shown that when the number of channels assembled on the 
cells is limited, sublytic C5b-9 can activate transcription factors and signal transduction, 
leading to inhibition of apoptosis and cell homeostasis (198, 199). The complement cascade 
with the inherent inhibitors is shown in Figure 1. 1. 
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The anaphylatoxins (C3a and C5a) are key players in the recruitment of inflammatory cells, 
and release of mediators that amplify the inflammatory response. C5a binds to C5a receptor 
(C5aR or CD88) that is widely present on inflammatory and non-inflammatory cells, and 
increases neutrophil adhesiveness and aggregation (200, 201). C5a also lead to secretion of 
pro-inflammatory cytokines and lysosomal enzymes from the macrophages and monocytes, 
thus leading to chemotaxis (171, 202, 203). C5a was shown to be an important 
inflammatory mediator for the early adhesive interactions between neutrophils and 
endothelial cells in the acute inflammatory response, and upregulates various adhesion 
molecules (171, 204, 205). C3a does not act as a chemoattractant for neutrophils, but aids 
migration of eosinophils and mast cells (206, 207). C3a and C5a also act on their receptors 
expressed on innate immune cells such as dendritic cells, thus playing a role in initiating 
and regulating T-cell responses (208). In the IRI setting, MAC has been shown to mediate 
IR injury, and its inhibition was shown to attenuate the IRI effect (209, 210). 
Inherent regulation of pathways 
To prevent inadvertent injury by activated complement, the host tissues have developed 
intricate and elaborate mechanisms in the form of soluble and membrane bound 
complement regulators that inhibit complement activation. The two main regulation 
mechanisms are: Decay-acceleration activity (DAA) which increases the rate of 
dissociation of (C4b2a and C3bBb) C3 convertases, and Factor I cofactor activity (CA), 
which results in the factor I-mediated cleavage of covalently bound C3b and C4b into 
inactive fragments incapable of reforming the C3 convertases (211, 212).  
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Membrane Bound Complement Regulators 
The membrane bound regulators - DAF, CR1 and MCP belong to a gene super family 
called as regulators of complement activation’ (RCA) / Complement control proteins (CCP) 
and share a common structural motif called short consensus repeat (SCR). The SCR 
structure consists of around 60 amino acids held together by two disulfide bridges formed 
by cysteine residues (213). The structural moiety of the membrane bound complement 
regulators are depicted in Figure 2. 
1. CD 35 - Complement Receptor 1/ CR1: CD35 is a transmembrane glycoprotein that 
facilitates the decay of C3/C5 convertase in both the classical and alternate pathways, 
and acts as a co-factor for factor I in the degradation of C3b and C4b (214).  
2. CD46: CD46 acts as a cofactor for factor I mediated cleavage of C3b and C4b. 
Deficiency of CD46 is a predisposing factor for numerous diseases due to complement-
mediated 'self-attack' (215) 
3. CD55: CD55 is a glycosyl-phosphatidyl-inositol (GPI) anchored membrane protein 
that is widely expressed on vascular and non-vascular tissue cells. The main role of 
CD55 is the inhibition and acceleration of the decay of classical and alterative 
pathways C3 convertase (216).  
4. CD59 (Protectin): CD59 is a GPI-anchored membrane complement that is expressed 
on almost all cells in the body (217). CD59 is the only well-characterized membrane 
inhibitor acting at the terminal step, and prevents the assembly of the MAC by 
inhibiting the C5b-8 catalysed insertion of C9 into the lipid bilayer (218). 
5. CrrY- Complement receptor 1-related gene/protein Y: CrrY is a transmembrane protein 
specific to rodents, and possesses both DAA and CA properties, and mimics the 
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activities of the human DAF and MCP which regulate C3 deposition on host cells 
(219).  
Fluid phase or ‘soluble’ regulators 
1. C1 – Inhibitor (C1-INH): C1-Inhibitor (C1-INH) forms an irreversible complex 
with the serine proteases C1r and C1s and inactivates them. This leads to the 
disassociation of C1r and C1s from C1q in the complex. C1-INH can also bind to 
MASP-1 and MASP-2, and inactivate them leading to disruption of the lectin 
pathway (220, 221). Various animal IRI models have shown that C1-INH can 
protect liver, intestine, heart, and brain tissue from ischaemia-reperfusion damage 
(222). 
2. Factor I: Factor I cleaves C3b and C4b to form C3 and C4 fragments, thus blocking 
the formation of C3 and C5 convertase enzymes (220). The cofactors supporting 
factor I cleavage are factor H, CD35, CD46 and C4b-binding protein (223).  
3. Factor H: Factor H possesses multiple binding sites for C3b and accelerates the 
decay of the alternative C3 convertase through ‘competitive binding’ for factor B 
(224). It also facilitates the cleavage of C3b by supporting factor I activity. Impaired 
recognition of Factor H by host cell surfaces due to mutations and polymorphisms 
can lead to complement-mediated tissue damage and disease (225).  
4. C4bp (C4b-Binding protein): C4bp binds to C4b and accelerates the decay of the 
C3 convertase (226, 227). It also acts as a cofactor for the cleavage of C4b by 
Factor I.  
5. Carboxypeptidase-N: Carboxypeptidase-N was found to abolish the activity of the 
anaphylatoxins C3a and C5a (228). It cleaves carboxy-terminal arginines and 
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lysines from C3a and C5a, resulting in the formation of C3a (desArg) and C5a 
(desArg), both of which have markedly lower ability to signal through receptor 
binding (229). Carboxypeptidase-N plays in important role in protecting the body 
from excessive build-up of potentially deleterious peptides that can act as local 
autocrine or paracrine hormones (230). 
Figure 1.1: Pathways of complement activation - Classical, Alternative and Lectin pathway\ 
	
 
 
 
Figure 1.1: Pathways of complement activation - Classical, Alternative and Lectin pathway: IgM 
or IgG antigen/antibody complexes binding to C1q, the first protein of the cascade, initiate the 
classical pathway. The alternative pathway is not so much an activation pathway, as it is a failure 
to regulate the low level continuous formation of a soluble C3 convertase. The third pathway is 
known as MBL (Mannose-binding lectin)/MASP (MBL associated Serine Protease) pathway. The 
initiating molecules for the MBL pathway are multimeric protein-lectin complexes that bind to 
specific carbohydrate patterns uncommon in the host, leading to activation of the pathway through 
	 35	
enzymatic activity of MASP. The sites of action of the membrane bound complement regulators - 
CD35, CD46, CD55 & CD59 (green boxes) and the fluid phase regulators- C1-INH, Factor H, 
Factor I & C4bp (violet boxes) are represented with arrows. 
Insert: Membrane Attack Complex (MAC). The interaction of C5b with C6, C7, C8 and C9 leads to 
formation of C5b-9 or Membrane Attack Complex (MAC), a multimolecular structure that inserts 
into the membrane creating a functional pore leading to cell lysis. 
 
 
Figure 1.2: Membrane Bound Complement Regulators 
 
Figure 1.2: Membrane Bound Complement Regulators: DAF, CR1 and MCP belong to a gene 
super family called as regulators of complement activation’ (RCA) / Complement control proteins 
(CCP) and share a common structural motif called short consensus repeat (SCR). The SCR 
structure (circles) consists of around 60 amino acids held together by two disulfide bridges formed 
by cysteine residues. CD59 is a GPI-anchored membrane complement that is expressed on almost 
all cells in the body. CD59 is the only well-characterized membrane inhibitor acting at the terminal 
step, and prevents the assembly of the MAC 
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1.3.2.2. Complement and Renal Ischaemia Reperfusion 
Complement system plays an active role in mediating IRI. IRI studies have shown that each 
organ (heart, intestine, skeletal muscle, liver and brain) has its own complement activation 
pathway (classical/alternative/lectin) and various triggers mediate the IRI damage. The 
earliest evidence for its involvement was provided by Hill et.al who suggested a non-
immunologic role for C3 in the mediation of the acute inflammatory response in 
nonspecific tissue injury (231). IgM antibody mediated complement activation has been 
shown in intestine (232), myocardium (233) and skeletal muscle (234) studies, but its role 
in renal IRI is equivocal (148).  
Complement activation in ischaemic kidney 
Renal endothelial and epithelial cells are considered to be the targets for complement 
activation in IRI, with proximal tubular epithelial cells (PTEC) located at the 
corticomedullary zone being an important target (19, 235). The complement system is 
activated on ischaemic PTEC and induces the cells to produce pro-inflammatory 
chemokines. Locally produced complement is critical as large complement molecules 
cannot pass through the basement membrane, and circulating complement leads to vascular 
injury. Endothelial cells, mesangial cells, epithelial cells, tubular epithelial cells can all 
produce complement including C3, C4 and Factor B. Renal glomerulus possesses four 
membrane bound complement regulators – CD35, CD55 (DAF), CD46 and CD59, while 
PTEC has only CD 59 (236), which all play a role in regulation.  
Kidney transplantation into complement-inhibited rats reduced inflammation of the graft, 
and authors felt that locally synthesised complement proteins by the renal tubule had a 
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more important effect than circulating components (237). Local epithelial production of C3 
can be stimulated by inflammation and ischaemia, and this has been shown to promote 
local complement activation leading to acute kidney injury, raising the possibility that local 
production may contribute to the IR induced injury (238). 
Complement Pathways in Ischaemia-Reperfusion Injury 
The evidence for complement activation in renal IRI has shown involvement of all three 
activation pathways, either in combination or as ‘single pathway’ mediation. Complement 
activation is an early event in the process of reperfusion injury. Various pathways have 
been implicated in the renal IRI, with alternative pathway playing a predominant role 
compared to the other pathways. This was proved by Zhou et.al who showed that C3-, C5-, 
and C6-deficient mice were protected from renal IR injury, whereas C4-deficient mice were 
not protected (19). This was further supported by Thurman et.al who showed that Factor B 
deficient mice showed less functional and morphologic renal injury with minimal 
tubulointerstitial complement C3 deposition compared to their WT control after renal IRI 
(239). The same author substantiated his findings by using an inhibitory mAb to mouse 
Factor B effectively that prevented complement activation in kidney, and protected the 
mice from necrotic and apoptotic injury of the tubules (240). It is well known that Factor B 
plays a critical role in the alternative pathway, and deposits of factor B were seen at 
interstitial and tubular level following IRI (241). 
The role of Classical pathway mediated IRI is very limited. In a mice model of renal IRI, 
Park et.al showed that recombination-activating gene (RAG)-1-deficient mice were not 
protected from IRI, and immunoglobulins were not found in kidneys 30-hours post 
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reperfusion indicating that antibody mediated classical pathway was not involved in the 
pathogenesis (148). An experimental model evaluating complement activation by inducing 
hypoxia-reoxygenation in human and mouse PTEC showed that hypoxic human PTEC 
induced the classical pathway of complement (dependent on both IgM antibodies and C1q) 
while hypoxia-induced mouse PTEC activated the alternative pathway (242). This study 
highlights the important species-specific differences in complement activation by PTEC. In 
a swine IRI model, kidney biopsies examined at 15-minutes after reperfusion showed 
increased deposits of MBL and Factor B compared to C1q, implicating a predominant role 
for lectin and alternative pathways compared to classical pathway in the early reperfusion 
phase (241). However, in the same study when they analysed DGF transplant biopsies (7-
15 days), deposition of both C1q/C4d (classical pathway) and MBL/C4d (lectin pathway) 
were seen in the peritubular capillaries, interstitium and on the glomerular endothelium, 
implicating both the classical and lectin pathways. Using classical and lectin pathway 
inhibitor C1-INH pre ischaemia, they also showed reduction in C4d and C5b-9 deposition, 
along with reduction in infiltration of inflammatory cells. 
Lectin complement pathway’s (LCP) role was initially shown in cardiac IRI models that 
showed LCP mediated complement activation after tissue oxidative stress (243). Role of 
LCP in renal IRI was shown in a study using transgenic MBL deficient mice. Following 
renal IR, MBL deficient mice showed significant protection from IRI along with decrease 
in nephric C3 deposition, and decreased C3a (desArg) levels indicating less complement 
activation (244). In an earlier study, mice undergoing warm renal IR showed MBL (MBL-
A and MBL-C) deposits in tubular/interstitial cells and peritubular capillaries (245). This 
was more pronounced at 24-hours post-reperfusion and co-localised with C6 deposits. In a 
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study comparing allograft biopsies, it was shown that C4d-positive biopsies demonstrated 
diffuse H-ficolin and IgM deposition in the PTEC, compared to C4d-negative group, thus 
implying a role for lectin pathway activation by H-ficolin (246). MBL was shown to be 
critically involved in the early pathophysiology of renal IRI, and therapeutic inhibition of 
MBL was protective against kidney dysfunction, tubular damage, neutrophil and 
macrophage accumulation (247).  
In summary, renal IRI complement mediated damage is primarily via activation of the 
alternative and partly via lectin and classical pathways. Local synthesis of complement 
production also contributes to the pathogenesis, in addition to the systemic attack. 
1.3.3. Endothelium 
The endothelium forms the interface between the vessel wall and the circulating 
blood/lymph. Under optimal conditions, the endothelium dictates the vascular tone and 
perfusion, regulates the influx of inflammatory cells into tissue, and prevents coagulation 
(248). 
1.3.3.1. Endothelium in Renal IRI 
Following IR, regulatory function of endothelium is altered leading to a detrimental impact 
upon the renal function. In IR conditions, the endothelium changes from an anti-adhesive to 
a pro-adhesive state, usually due to the action of inflammatory cytokines (249). Following 
ischaemia, the small arterioles are prone to vasoconstriction due to the increase in 
vasoconstrictive mediators (thromboxane A2, angiotensin 2, prostaglandins etc.), coupled 
with decrease in vasodilatory mediators (bradykinin, acetylcholine, nitric oxide) (16). 
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Vasoactive cytokines (TNF-alpha, IL-beta, IL-6, IL-12, IL-15, IL-18, IL-32) and endothelin 
generated due to endothelium-leukocyte interaction further augment the vasoconstrictive 
effect (250). The ischaemic insult damages the endothelial barrier leading to partial 
disappearance of the cell-cell borders and interruption of the cell-cell contacts, leading to 
endothelial disintegration and increased vascular permeability (11). Damaged endothelial 
cells release cytokines and chemokines that facilitate endothelial interaction with 
leukocytes and platelets (12). Reperfusion leads to the ‘no-reflow’ phenomenon, which 
occurs due to endothelial cell swelling, interstitial oedema and capillary vasoconstriction 
that further potentiates tissue damage (17).  
Endothelial damage also leads to glycocalyx loss, disruption of the cytoskeleton, alteration 
in endothelial cell-cell contacts leading to breakdown of perivascular matrix and increased 
vascular permeability (16, 18). The reduction of renal blood flow to outer medulla leads to 
occlusion of vulnerable capillaries and damage to epithelial cells, especially in the pars 
recta (16). The ischaemic insult also leads to a inhibition of the VEGF pathway during the 
early injury and repair phase of renal ischaemia, leading to tubular injury and 
tubulointerstitial fibrosis (251, 252). Vascular endothelial damage coupled with 
vasoconstrictive response leads to reduction in renal blood flow and glomerular filtration, 
and eventual AKI (253, 254) . 
1.3.3.2. Markers of endothelial damage 
Endothelial cell injury can be evaluated by a variety of local and serum markers: 
thrombomodulin, P-selectin, E-selectin, intracellular adhesion molecule, vascular cell 
adhesion molecule and others, all of which have been used in animal and clinical studies 
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(255). The selectins and other adhesion molecules have been covered in the previous 
section.  
• Thrombomodulin (TM) is a transmembrane glycoprotein expressed on the surface 
of all vascular-endothelial cells with multidomain structure which is able to interact 
with thrombin, Protein-C and complement components, thus contributing to 
localized haemostatic and inflammatory response following injury (256). In the 
presence of cytokines and activated neutrophils/ macrophages, endothelial TM is 
enzymatically cleaved releasing soluble fragments which circulate in the blood, and 
plasma TM level is regarded as a molecular marker reflecting injury of endothelial 
cells (257). Soluble thrombomodulin administered pre-ischemia or 2-hours 
after reperfusion in a rat renal IRI model markedly reduced IR related 
renal dysfunction and tubular injury scores (258, 259).  
• Tissue Factor (TF) is a transmembrane glycoprotein present in the subendothelial 
cells and forms high affinity complex with coagulation factors VII/activated factor 
VIIa (FVII/VIIa), playing an essential role in essential role in the clotting system by 
activating the extrinsic coagulation pathway following vascular injury (260, 261). In 
renal IRI model, TF was stained on the GBM and endothelial cells, and was credited 
to play an important role in IRI as the microcirculatory incompetence due to TF 
mediated microthrombus causing necrosis was prevented by using TFPI (Tissue 
factor pathway inhibitor)(262). Similar protective effects on renal IRI have also 
been reported by using TF antisense nucleotides, thus confirming its presence as a 
marker for renal ischaemic injury (263). 
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• Shed components of glycocalyx (covers the luminal side and prevents leukocyte 
and thrombocyte adhesion) are probably the earliest sign of endothelial damage (18). 
Endothelial glycocalyx is a complex network of soluble components consisting of 
proteoglycans and glycoproteins (264). Many endothelial cell adhesion molecules 
(Selectins and ICAMS) are the major glycoproteins of the glycocalyx, and prevent 
erythrocytes and leukocytes from interacting with the vessel wall (265). 
Modifications of the glycocalyx appeared to be an early step in the inflammatory 
cascade of reperfusion injury, and inhibition of the glycocalyx modification using a 
adenosine A (2A) receptor agonist showed protection from IR injury (258).  
• Sutton et.al showed that following renal IRI, von Willebrand factor (vWF) was 
elevated along with microscopic evidence of disruption of the actin cytoskeleton of 
renal microvascular endothelium (266). Similar findings of disarray of the actin 
cytoskeleton in vascular smooth muscle cells and disappearance of vWF from 
vascular endothelial cells were found in cadaveric renal biopsies post reperfusion 
(252).  
• P-Selectin and E-Selectin have also been used as markers of endothelial activation, 
and have been discussed in the previous section on adhesion molecules. 
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1.4. Therapeutic approaches to minimise IRI 
As evident by the earlier chapters, there are many players in an ischaemia-reperfusion 
injury (IRI) in kidneys. Clinically, there are only a few avenues where interventions can be 
feasible. The following section provides a succinct overview of various strategies’ adopted 
to minimise IRI with special emphasis on complement and leukocyte modulation, which is 
the focus of my research project. 
1.4.1. Clinical Strategies 
In clinical studies, there are only a few studies looking at preventing ischaemic AKI 
prophylactically. One group are vascular patients undergoing aortic surgery, where a few 
patients need to have their renal vessels clamped leading to IRI. Though many patients 
recover, there is fraction of patients who required renal support post operatively (267). The 
other group where IRI could be targeted are renal transplantation group where the 
interventions could be broadly classified into optimisations aimed at the donor, the 
recipient and organ preservation and storage. 
1.4.1.1. Donor optimisation 
Following brain death, there are hormonal changes within the body leading to 
hemodynamic alterations including hypotension and organ hypoperfusion, which is 
modulated by circulating catecholamines levels and cytokine responses, and extensive 
complement activation (268). Optimising these physiological derangements prior to 
planned donation has been the focus in the intensive units across the globe. For example, in 
a retrospective matched-paired study, donor resuscitation with a rapidly degradable HES 
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preparation (with a molecular weight of 130 kDa, HES 130/0.4) had a significantly reduced 
DGF and lower creatinine levels at 1 year compared to resuscitation with a HES 200/0.6 
(269). Optimising the respiratory, cardiovascular, coagulatory and the systemic effects of 
brain death remain the basic principles of managing a DBD (Donation after brain death) 
donor.  
Unlike DBD kidneys, DCD (Donation after Circulatory Death) kidneys undergo warm 
ischaemia (systolic blood pressure less than 50 mm Hg and finishing with cold arterial 
flush) that coupled with cold ischaemia increases the risk of DGF and primary non-function. 
Though the length of time from the onset of warm ischaemia (WIT) to retrieval does appear 
crucial, however recent evidence suggests that the hemodynamic profile of the patient after 
withdrawal is more critical than the time from withdrawal to retrieval (270). The focus of 
optimization in DCD donors currently revolves around reducing the warm ischaemic insults 
that the kidney suffers. Regional perfusion (RP) of intra-abdominal organs can be achieved 
by placing a double-lumen catheter in the aorta, and perfusing the kidneys with cold or 
normothermic circulation. ECMO (extracorporeal membrane oxygenation) has been 
advocated for reduction of WIT and IRI. A systematic review showed that RP-DCD 
kidneys at 1 year had better patient and graft survival rates than standard DCDs, and were 
comparable to DBD outcomes. The author’s concluded that RP/ECMO could lead to 
significant reductions in DGF however ethical and legal issues prevented from having a 
worldwide consensus (271). 
In a study comparing three different techniques [in-situ perfusion (ISP), total body cooling 
(TBC) and normothermic recirculation (NR)] to reduce DGF and PNF (primary non 
function) in DCD kidneys, the incidence of DGF and PNF was significantly lower in 
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kidneys perfused with NR than those with ISP or TBC, and this has been observed in other 
clinical studies (272, 273). However, further critical clinical studies are required to confirm 
the short and long term effect on grafts with NR. With extended criteria being used for 
more donor recruitment, further clinical studies will be aimed at optimizing the DCD 
kidneys prior to retrieval.  
1.4.1.2. Ischaemic preconditioning 
The concept of ischaemic preconditioning originated in 1986 when Murray et.al 
demonstrated reduction in the size of the myocardial infarct by repeated short spells (5 
minutes) of ischaemia-reperfusion prior to 40-minutes of ischaemia, and hypothesized the 
role of triggers, mediators and effectors in reducing the injury via pre-conditioning 
mechanism (274). The various mechanisms involved the preconditioning mechanism has 
been reviewed by Selzner et.al and can be referred for understanding the mechanisms (275). 
Animal based experiments have shown that preconditioned tissues exhibited better 
electrolyte homeostasis and genetic reorganization with decreased levels of oxygen-free 
radicals and activated neutrophils (276). Furthermore, rodent models showed reduced 
apoptosis and better microcirculatory perfusion compared to the controls.  
Preconditioning can be carried out either directly at the renal pedicle or remotely. Remote 
ischaemic preconditioning (RIPC) can be performed by accessing peripheral arteries, and 
noninvasively by using BP cuffs. Though the animal models have shown reduction in 
injury with RIPC, no obvious benefits have been shown in clinical transplantation. RIPC 
have shown some benefits in cardiac and aortic aneurysm surgery, but further clinical 
studies are needed to prove its efficacy. 
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1.4.1.3. Organ preservation 
Following retrieval of organs, the donor cells and tissue are exposed to hypoxia and 
ischaemia until the time they are reperfused in the recipient. Hypothermic protection in the 
form of static cold storage or hypothermic machine perfusion (HMP) and normothermic 
machine perfusion (NMP) can to a certain extent combat the deleterious effects of 
ischaemia, but this has to be balanced between the benefits and the detrimental effects of 
cooling.  
Static cold storage: 
Static cold storage is the most widely used form of organ preservation around the world, 
and the machine perfusion kits have challenged its use in developed countries. The 
characteristics of various types of solutions (Intercellular/ Intermediate/ Extracellular) and 
there uses have been reviewed Bon et.al (277), and can be referred for further reading. 
Randomized trials of histidine-tryptophan-ketoglutarate (HTK), Celsior, and University of 
Wisconsin solutions showed equivalent risk of delayed graft function after kidney 
transplantation, but opined that more clinical trials were needed to justify a use of one 
solution over the other (278). Similarly, a retrospective study comparing 610 cadaveric 
renal transplants showed no difference in outcomes between UW and Celsior solutions 
(279). A systematic review and meta-analysis comparing preservation solutions for static 
cold storage of kidney allografts showed no difference between existing solutions (280). 
Intracellular and intermediate solutions are the current preferred choice for storage, 
however experimental data in animals have shown polythene glycols in storage solution 
have aided organ function recovery and reduced inflammation and fibrosis development in 
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the models (281). Additives into preservation solutions that aim at reducing inflammatory 
mechanisms and minimize the cold ischaemia effects offer an attractive option, and 
currently being evaluated in experimental and some human models. The various 
pharmacological and genetic interventions that are being currently trialed can be found in 
an article by Chatauret et.al. (282). 
Machine perfusion (MP): 
Machine perfusion kits have facilitated change from an emergency setting for transplants to 
an elective with reduced costs and improved outcome. It also provides access for 
administration of cytoprotective agents and/or immunomodulatory drugs (146). It also aids 
in assessments of quality of organ by analyzing perfusates and resistance pressures (283, 
284). Machine perfusion can be either with hypothermic or normotheric solutions, or blood. 
Hypothermic Machine Perfusion (HMP) maintains patency of the vascular bed and the 
cooling effects reduces the metabolic rate leading to decreased oxygen demands (285). A 
recent meta-analysis compared HMP versus static cold storage of kidney allografts on 
transplant outcomes. Seven RCTs (1475 kidneys) and 11 non-RCTs (728 kidneys) were 
included in the analysis. The study showed that HMP group had lower incidence of DGF, 
but no difference was observed in the PNF, acute rejection or patient survival (286). Similar 
findings of HMP affecting only DGF were observed in other systematic reviews (287, 288).  
Normothermic Machine perfusion (NMP) carries the benefit of avoiding cold ischaemic 
injury and is based on the principle that the organ can be maintained in a stable state close 
to its physiological state (289). There have been clinical reports of improved outcomes 
following normothermic perfusion in both kidney and liver transplants, and there is 
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ongoing research in this field. The ability to add interventional agents to the perfusion 
offers an attractive avenue for future research, but its review is beyond the perspective of 
my thesis. MP use is still hindered due to economical constraints compared to static 
storage, but the ability to predict graft quality and ability for intervention may change its 
outlook. Further clinical trials are needed to evaluate its effect in the current context of 
ECD donors.  
1.4.1.4. Recipient Optimisation 
Recipients offer another therapeutic option to minimize the IRI, however any interventions 
are still in very experimental stage. Neonephrogenesis (capacity of renal tissue to 
regenerate) involves giving recipients agents that promote cell repair and regeneration in 
the IRI kidney. Stem cells have shown potential in other organs, but its role in renal 
neonephrogenesis is still in very early experimental stage. In a recent review of role of 
mesenchymal stem cells (MSC) in renal IRI, majority of the studies in the showed 
substantial benefits in cell recovery/repair, but they were mostly in small animal models 
and called for larger animal/pre-clinical studies to evaluate the efficacy of MSC (290). 
Further research will be aimed to assessing the safety profile, mechanisms of action, 
reproducibility, drug delivery and short and long-term effects.  
1.4.2. Leukocyte modulation 
Leukocytes play an important role in the IR process, and suppressing the activity of each 
leukocyte cell has shown protective effects as discussed in the previous section (1.3.1.4). 
Anti-thymocyte globulin is one of the intervention agents being used in my study, and 
hence I have reviewed its effect on IRI in depth. 
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1.4.2.1. Leukocyte depletion and IRI 
Leukocyte depletion can be achieved either by using filters or by using drugs/molecules 
that cause leukopenia or inhibit leukocyte function. Activated protein-C (APC) is a major 
physiological anticoagulant with anti-inflammatory and anti-apoptotic activities in 
endothelial cells, has been shown to reduce leukocyte rolling and leukocyte adhesion in 
systemic endotoxemia (291). APC conferred protection in spinal cord IRI (292) and hepatic 
IRI models (293). Vinblastine induced leucopoenia in a liver IRI model showed 
significantly better recovery of blood flow and haemoglobin saturation than the control 
group after 45-minutes of ischaemia (294). APC was shown to inhibit the activation of 
leukocytes and confer protection against renal IRI, and its effects were similar to 
leukopenic (using nitrogen mustard) rats (295). Experimental models using leukocytes 
depleted blood for perfusing the kidneys in a swine model showed improved renal blood 
flow and creatinine clearance (104, 105). Though the decrease in neutrophil infiltration was 
a consistent finding, this methodology was unable to define which specific leukocyte subset 
was the main contributory factor.  
1.4.2.2. Anti-Thymocyte Globulin (ATG; Thymoglobulin) 
ATG is a lymphocyte depleting polyclonal antibody that is raised in rabbits/equines against 
human thymocytes. It binds primarily to peripheral blood lymphocytes, and displays 
differential specificity to antigens present on a variety of cells (including leukocytes) 
involved in immune responses, apoptosis, signal transduction, cell adhesion and trafficking 
(249, 296, 297). ATG shows differential binding to these cell populations, hence its varied 
effects. The immunosuppressive potential of polyclonal globulins was first demonstrated by 
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Woodruff et.al in the early 1950s (298, 299), and since then, has been extensively used in 
transplantation (induction, and in treatment of acute rejection), treatment of aplastic 
anaemia and in hematopoietic stem cell transplantation, and in other autoimmune diseases 
(300, 301). ATG has various modes of action due to effects on various cells, and these are 
not completely understood yet.  
1.4.2.2.1. Mechanism of action  
Leukocytes 
In a limb IRI model, ATG treated primates completely inhibited leukocyte rolling and 
vascular adherence compared to the controls (302). Similar findings of reduced 
microvascular leukocyte adhesion, decreased leukocyte count and better blood flow 
velocity between ATG-treated and ATG-free groups was shown by the same German 
research group in a later study (103). ATG possesses antibodies to intercellular adhesion 
molecules (Leukocyte function associated antigen-1 etc.) and also against chemokine 
receptors (CCR5, CCR7 and CXCR4), thus inhibiting the leukocyte response to chemo- 
attractants (303).  
The predominant effect of ATG is through T-cell depletion. ATG treatment led to dose-
dependent lymphocytopenia in the blood along with T-cell depletion in spleen and lymph 
nodes, and reduction in B-cell and NK cell counts (304). Peripheral depletion of T-cells and 
other leukocytes has been attributed to complement dependent-lysis and ADCC (apoptosis 
and antibody-dependent cellular) induced cytotoxicity (305). ATG was also shown to 
reduce the expression of adhesion molecules on neutrophils and lymphocytes which have 
been shown to be beneficial in IRI (306). IL-4 regulates the differentiation of T-helper 
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lymphocytes into Th2 phenotype, and is also involved in cellular activation, both of which 
are features of IRI. In a primate limb IRI model, ATG was shown to inhibit the production, 
and release of IL-4 by activated lymphocytes compared to the non-treatment group (307). 
ATGs can modulate immune response by affecting the function of different immune 
effectors such as B lymphocytes, regulatory T lymphocytes (Treg), natural killer (NK)-T 
lymphocytes and dendritic cells (DC) (249).  
Endothelium and Adhesion molecules 
A study looking at the effect of immunosuppressive drugs on endothelial cell activation in a 
mice skin IRI model, ATG was shown to significantly increase the plasma concentration of 
VCAM-1 and P-Selectin (308). An in-vitro study looking at the effects of ATG on TNF-
alpha stimulated human umbilical endothelial cells showed a trend towards reduced 
percentage of gated cells in the ATG treated group (before TNF-alpha stimulation) for 
CD54 and CD62E, though it was not significant (309). In a study evaluating the effect of 
ATG on primate limb IRI, ATG caused reduction in the expression of adhesion (ICAM-1, 
VCAM, PECAM, CD11b, CD62E) and inflammatory (IL-1, IL-6, TNF-α) molecules, both 
in endothelium and reperfused tissue (310). This was confirmed in a recent study where 
ATG caused pronounced activation of both circulating platelets and stationery endothelial 
cells (308). However, no studies have specifically looked into effect of ATG on the 
endothelium, or its markers. 
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1.4.2.2.2. ATG and Renal IRI 
Animal models 
In a study evaluating the effects of mouse anti-thymocyte globulin (mATG) on warm 
kidney IRI in mice, three different renal IR models (30 min bilateral, 60 min bilateral and 
45 min unilateral) with differing times of ATG administration (pre-treatment [3 days prior 
to IR] vs. post treatment [after reperfusion]) were used. Though there was consistent 
depletion of T-cells in blood, ATG did not confer functional or structural protection from 
the IR injury (311). ATG has also been used in transplant models, which differs from the 
IRI model. ATG given pre- (2 hours) or peri- (end of surgery, prior to reperfusion) 
transplant, showed that pre-transplant group offered IR protection through reduced graft 
infiltrating inflammatory cells (leukocytes, macrophages, T-cells, LFA-1+ cells), reduced 
tubular injury and better graft function compared to the isotype control (312). ATG treated 
Wistar donor kidneys were transplanted into bilaterally nephrectomised recipient rats, and 
the transplanted kidney was analysed 24 hours later. This rATG offered protection from 
renal IRI with functional and structural protection (313). Similar to previous study, there 
was no significant effect of ATG on ICAM-1 in the QPCR array.  
Effect of ATG on IRI in clinical transplant studies 
ATG has been routinely used in transplantation for induction, and treatment of rejection 
episodes. DGF (renal) is a clinical representation of IRI, and studies evaluating ATG with 
regards to DGF prevention have been only reviewed. A randomised study looking into the 
effects of intra-operative vs. post-operative ATG administration, intra-operative ATG 
administration was shown to significantly reduce the incidence of DGF (14.8% vs. 35.5%), 
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along with demonstration of better early graft function (314). A retrospective analysis of 40 
DGF patients comparing a Cyclosporine-based (n = 17) regimen since the day of transplant 
vs. ATG and delayed CsA administration, the latter group had accelerated renal function 
recovery, decreased rejection rates and significantly reduced treatment costs compared to 
the cyclosporine only regimen group, with the effects partly attributed to ATG (315). Live 
related renal transplantation is associated with relatively lower incidence of DGF. A single 
centre experience of using ATG induction for 214 live-donor patients showed a five-year 
patient survival of 96% and graft survival of 82%. Interestingly, none of the patients 
experienced DGF compared to the national average of 5%, and only 5% developed acute 
rejection (316). In a clinical trial evaluating various immunosuppressive protocols on 
neutrophil sequestration, intra-operative ATG resulted in marked leucopoenia of all white 
blood cell lineages, with considerable systemic neutrophil and monocyte activation 
(increase in plasma lactoferrin concentration and neutrophil and monocyte CD11b 
expression) (317).  
From the animal and clinical studies, it is evident that ATG can have a favourable response 
in attenuating the IR injury. However, the effects of ATG in renal IRI studies have not been 
consistent, with some studies showing no protection. Moreover, the effects on adhesion 
molecules and leukocytes have been summarised from different species (primate, murine, 
rat) and overall effects in one model has not been evaluated. Our study evaluates the effects 
of ATG on leukocytes and endothelium in a renal IRI model. 
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1.4.3. Complement system modulation 
In this research project, two interventional agents are being used that can modulate 
complement system and these are reviewed below.  
1.4.3.1. Soluble CR-1 (sCR1) 
CD35/Complement Receptor-1 is a transmembrane glycoprotein that facilitates the decay 
of C3/C5 convertase in both the classical and alternative pathways, and acts as a co-factor 
for Factor I in the degradation of C3b and C4b (214). Expression of CD35 on erythrocytes 
is believed to be crucial in handling circulating immune complexes, and abating the 
development of autoimmunity. Wiesman et.al developed soluble CR1 as a complement 
inhibitor by preparing a truncated, soluble form of membrane-associated CR1 that lacked 
the transmembrane and cytoplasmic domains, but retained the C3b- and C4b-binding 
functions and Factor I cofactor activities (257). In the same study, sCR1was shown to 
inhibit the activation of classical and alternative pathways in vitro and suppressed 
complement activation in vivo, and reduced inflammatory tissue damage in a model of 
myocardial infarction associated with reperfusion injury.  
sCR1 has since been used as a ‘complement inhibitor’ in various studies. sCR1 attenuated 
myocardial IRI via reduction in the accumulation of leukocytes within the infarct zone, 
along with the reduction of the generation of C5a, and suppression of C5b-9 attack complex 
(318). sCR1 inhibited inflammation and demyelination in antibody-mediated demyelinating 
experimental allergic encephalomyelitis (319). In hepatic IRI, sCR1 attenuated hepatic IRI 
with fewer C3 deposits, decreased leukocyte adherence and significantly better liver 
function tests compared to control groups (320-322). sCR1 has also been shown to 
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attenuate intestinal IRI via decreasing complement activity and reduced neutrophil 
infiltration into the injured tissues (323, 324). In swine models of lung transplantation, 
sCR1was shown to block complement activation in the allograft and reduced post-
transplantation reperfusion oedema, improved ventilation but did not improve 
hemodynamic parameters (325, 326).  
There is very limited evidence evaluating the role of sCR1 in renal IRI. In a rat renal 
transplant model, sCR1-treated recipients had marked reduction in tissue C3 and MAC 
deposition along with inhibition of plasma complement activity, in addition to reduced 
leukocytes infiltrate and decreased vascular injury at day 5 after transplant (327). In another 
report by the same group, sCR1 treated recipients (Lewis to DA rat renal allograft) showed 
reduction in vascular injury and cellular infiltration, with reduced complement deposition 
(328). Alternative and lectin pathways predominantly mediate renal IR, and some studies 
even favour the classical pathway. In theory, sCR1 should attenuate renal IR as the 
degradation of C3b and C4b is common to all pathways, but paucity of studies can either 
reflect unreported poor outcomes or lack of interest in exploring this avenue.  
1.4.3.2. MASP pathway inhibition 
Lectin pathway is activated by the binding of multimolecular lectin complex with a 
carbohydrate moiety on pathogens or aberrant glycosylation patterns on apoptotic, necrotic 
or oxygen-deprived cells (329). The three MBL-associated serine proteases MASP-1, 
MASP-2 and MASP-3, along with MAp19 (competes with MASP for binding with the 
carbohydrate moiety) are able to bind to the carbohydrate recognition subcomponents 
(ficolins, CL-11, MBL) and activate the lectin pathway. MASP-2 cleaves C4 and C2 to 
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form C3 convertase, while MASP-1 may cleave C3 directly bypassing the C4b2a complex, 
albeit at a very slow rate (189, 190). Another serine protease, MASP-3 was shown to down-
regulate the C4 and C2 cleaving activity of MASP-2 (191).  
MASP-2 was identified in 1997, where it was shown to have a structure similar to MASP-1 
and the two C1q-associated serine proteases, C1r and C1s (330). Using a transient 
expression system, a recombinant form of MASP-2 that bound strongly to MBL was 
capable of activating complement, while an equivalent recombinant form of MASP-1 had 
no enzymatic activity when tested alone or in combination with rMASP-2 (188). 
Recombinant MASP-2 was shown to have a C1s-like esterolytic activity, and specifically 
cleaved complement proteins C2 and C4, while recombinant MASP-1 had a lower and 
more restricted esterolytic activity, suggesting that MASP-2 in association with MBL was 
able to activate the lectin pathway (331). sMAP (small MBL-associated protein (sMAP), 
truncated form of MASP-2 associated with MBL/ficolin-MASP complexes) deficient 
mice showed decreased expression of MASP-2, and injection of recombinant sMAP and 
MASP-2 reconstituted the MBL-MASP-sMAP complex in deficient serum, suggesting that 
MASP-2 was essential for the activation of C4 and sMAP played a regulatory role in the 
activation of the lectin pathway (332).  
MASP-1 and MASP-3-deficient mouse showed significantly lower activity of both C4 and 
C3 deposition on mannan-agarose, and a significant delay for activation of MASP-2, and 
reconstitution of recombinant MASP-1 in MASP-1/3-deficient serum was able to promote 
the activation of MASP-2 (333). MASP-1 (and probably MASP-3) was shown to be 
required for conversion of the alternative pathway activation enzyme Factor D from its 
zymogen form into its enzymatically active form in a MASP-1- and MASP-3-deficient 
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mouse model, implying a role for MASP-1 in both the lectin and alternative complement 
pathways (334, 335). A recent study employing MASP-2 deficient mice showed protection 
from myocardial and intestinal IR injuries, and this was further supported by the use of an 
inhibitory monoclonal antibody (selectively binds to mouse and rat MASP-2) pre-ischemia 
that reduced intestinal tissue I/R damage more than twofold compared with mice treated 
with the isotype control antibody (329). Furthermore, this study also showed that lectin 
pathway could activate complement C3 in the absence of C4 via a unique MASP-2–
Dependent C4-Bypass, and lectin pathway-mediated activation of C3 in the absence of C4 
was demonstrated in vitro and shown to require MASP-2, C2, and MASP-1/3. 
The role of MASP-2 in renal IRI has not been explored. In this thesis, we evaluated the role 
of MASP-2 in renal ischaemia and reperfusion by using the same antibody as described in 
the previous study (329). 
1.4.4. Modulation of endothelium and IRI 
 Evidence that vascular protection benefits IRI was provided by Brodsky et.al who showed 
in a rat renal IRI model that transplanted endothelial cells (or surrogate cells expressing 
endothelial nitric oxide synthase) offered functional protection from IR injury (336). 
Experimental studies using molecules such as sphingosine 1-phospate (that maintains 
endothelial cell integrity and inhibits lymphocyte extravasations) or prostacyclin analogue 
iloprost have conferred protection against ischaemic acute renal failure (12, 337). Coating 
of renal endothelial cells with vaccinia virus complement control protein (VCP) via 
fusogenic lipid vesicle (FLVs) delivery system prior to renal IR in Fischer rats showed 
significantly better functional and structural protection with reduced C3 production 
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compared to controls (338). Interleukin 18-binding protein (IL-18BP), a natural inhibitor of 
IL-18, was shown to attenuate renal IRI by reducing apoptosis in the peritubular capillary 
endothelium, along with down regulation of inflammatory cytokines and decreased 
macrophage infiltration (339). Recent studies have also shown that bone marrow-derived 
endothelial progenitor cells and endothelial cells may contribute to endothelial repair in the 
kidney immediately after ischaemia-reperfusion (340).  
Adhesion molecules P-Selectin, E-Selectin and ICAM-1 have shown to be upregulated on 
the on the surface of endothelial cells following renal ischaemia. The rearrangements in the 
actin cytoskeleton following IRI enables rapid delivery of P-Selectin from its storage in 
Weibel-Palade bodies to the surface of endothelial cells (341, 342). Inhibition of these 
adhesion molecules via antibodies prior to renal IR have conferred protection, partly 
through protection of the endothelium by reducing leukocyte rolling and adherence, and by 
decreased neutrophil infiltration (81, 85, 343, 344). Selectins bind to sialylated and 
fucosylated receptors, and two enzymes, fucosyltransferase IV (FucT-IV) and VII (FucT-
VII), are important in the function of these receptors. Mice deficient in fucosyltransferases 
were protected from IRI via reduced Selectin expression and reduced neutrophil infiltration 
(345).  
It is evident that endothelium is a highly reactive tissue, and is involved in the early phase 
of inflammation following IR by serving as an interface between immune/inflammatory 
cells and renal parenchyma (160). Manipulating endothelial dysfunction offers an attractive 
proposition for treating ischaemic AKI, but the pure complexities and intricate relations 
that endothelium shares with a variety of mediators may make it hard for ‘isolated 
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treatment target’. In this study, we investigated the endothelial changes associated to IR, 
including Tissue Factor, Thrombomodulin and P-Selectin. 
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1.5. Project Objectives 
1.5.1. Hypothesis 
Ischaemia-Reperfusion Injury remains an important clinical problem that influences 
outcomes following kidney transplantation. My hypothesis is that interplay between three 
key players determines the outcomes following IRI: leukocytes, renal endothelium and the 
complement system. In the introduction chapter, I have reviewed relevant previous studies 
in the scientific literature, to evaluate what is known already about these interacting 
mediators. Subsequently I have performed experimental work, described in the following 
chapters, to advance understanding of these processes. To do this, I have developed and 
used a unilateral IRI model in the rat to test the potential protective effects of manipulations 
including leukocyte modulation and complement system modulation, and evaluating the 
effects of these modulatory agents on inflammatory cells, endothelium and complement 
system.  
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1.5.2. Summary of aims and objectives 
The aims of the project are: 
• To determine the nature of ischaemia-reperfusion injury and classifying the 
leukocyte infiltrates, evaluate endothelial damage and discuss the role of the 
complement system 
• To determine whether ATG can act as a ‘leukocyte modulator’ in this model, and 
evaluate whether it attenuates IR injury, as reports are inconclusive. We will also 
ascertain the effect of ATG on the leukocytes and the endothelium 
• Using sCR-1 and Anti-MASP-2 antibodies, we aim to modulate the effects of the 
complement system on renal ischaemia reperfusion, along with evaluating the 
effects on leukocytes and the endothelium 
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Animal models to investigate the mechanisms of ischaemia reperfusion injury are well 
documented in literature. The methodology section discusses in detail the model and the 
outcome measures (Histology, immunohistochemistry and quantitative polymerase chain 
reaction). 
2.1. Experimental subjects: Lewis Rats 
The animals used in the project were adult male Lewis rats, weighing 180-220 g, 8-12 
weeks old. The inbred lewis rats were supplied by Harlan Laboratories (UK). Lewis rats 
have a number of features that make them ideal for biological work. They are 
‘commercially viable’ for the project and their physiological systems are well worked out 
from previous studies (346). The lifestyle and requirements are easily met, and protocols 
for maintaining these animals in JBIOS have been well established. Lewis rats have been 
used in renal studies, and hence was an ideal study animal for the project (80, 136, 347, 
348). The rats were delivered one week before the experiments so as to enable 
acclimatisation. On arrival, the rats were checked by the experienced JBIOS staff and were 
housed in cages (maximum 4 per cage). They were kept in the conventional holding room 
in the JBIOS and had free access to standard rat chow and water. Following the 
experiments, the rats were housed in individual cages with free access to water (mixed with 
the analgesia) and food. At the end of 48 hours, the rats were sacrificed. The Lewis rats are 
generally very friendly and inquisitive in nature. They are easy to handle and are very 
playful. These characteristics were used to determine their post-operative recovery phase. 
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2.2. Operative model 
This study was carried out at the Joint Biological Services Cardiff Unit (JBIOS, Heath) 
under Home Office License number 30/2506. The project licence was in the name of Mr 
R .C Chavez (Supervisor) and I was the Personal Licensee on this project. The care of 
animals was followed according to the Animals (Scientific Procedures) Act 1986 (ASPA). 
2.2.1. Operating theatre and setup 
The operative set up was based on the inputs from the Named Animal Care and Welfare 
Officer (NAWCO) and on guidelines issued by the Home Office, UK and Laboratory 
Animal Science Association (LASA), the emphasis being on aseptic surgery. Operations 
were carried out in designated operating rooms (Sterile Experimental Procedures – SEP) in 
the JBIOS unit. The operating table was placed under the ‘laminar flow system’ to aid 
sterility. The operating surgeon used sterile gown and gloves. Chlorhexidine spray was 
used to clean rat skin after shaving prior to making skin incision. An overhead lamp was 
used for lighting. The gas chamber for induction and the ventilator machine were on the 
main table itself enabling minimal transfer time to the operating board. A corkboard 
covered with a sterile drape acted as an operating table. This board enabled insertion of pins 
that enabled retraction of all four limbs (post anaesthetisation) using rubber bands, which 
aided surgery. Standard surgical instruments were used in the procedure, and a 
microvascular clip was used for clamping the renal vessels. Vicryl sutures were used for 
closure. Prior to each operation, the instruments were deep cleaned and were immersed in a 
solution of water mixed with Rely+On Virkon Tablets (Antec Internation, Du PONT, UK) 
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for 30 minutes. Following this, the instruments were washed off and sprayed with alcohol 
spray prior to usage. This cycle was repeated before each operation.  
2.2.2. Anaesthesia 
Anaesthetic mixture of Isoflurane (IVAX Pharmaceuticals, UK) and oxygen was used. The 
rat was initially placed in the anaesthetic chamber where Isoflurane (initially at 4 litres) 
with oxygen (2 litres) was administered. In a span of 4-6 minutes, the rat was deeply 
anesthetised (confirmed by tail pinch and side-side movement – no response). The rat was 
then moved to the operating table where the face of the rat was placed in a tunnel delivering 
the anaesthetic mixture. The rate of Isoflurane was altered in keeping with the heart rate 
and the breathing pattern of the rat (usually between 1.5-3 litres). At the end of procedure, 
anaesthesia was turned off and the rat was recovered on oxygen until awake.  
2.2.3. Analgesia 
Temgesic (Buprenorphine) mixed in water was used for analgesia. This was recommended 
by NAWCO (Named Animal Welfare officer) at JBIOS as it had an established track 
record with minimal side effects. Temgesic is an opioid analgesic, and has been proven to 
provide good analgesic cover in rat studies (349, 350). One tablet of temgesic was crushed 
and mixed in 500 millilitres of water. The analgesia was started 24 hours prior to surgery, 
and was continued until the day of retrieval. The rats did not demonstrate any visible side 
effects (sedation, pica effects) of the medication. 
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2.2.4. Blood collection from rats 
The guidelines for blood collection are published by The National Centre for the 
Replacement, Refinement and Reduction of Animals in Research (NC3RS), and were 
adhered to in this study (351). Tail tip under anaesthesia was used to collect blood while the 
rat was alive, and from the central abdominal veins during terminal anaesthesia. Rats are 
considered to have around 64 ml of blood per kg of bodyweight. A rat weighing 200 g 
would therefore have a total blood volume (TBV) of approximately 64 ml/kg x 0.2 kg = 
12.8 ml. Other formulas suggested include: BV (ml) = 0.06 X BW + 0.77 (12.77 mls for 
200 gm rat) (352). Suggested limit for blood withdrawal from a rat are: 
• Suggested limit <10% TBV (= 1.28 ml) on any single occasion AND <25% 
TBV (= 3.2 ml) in 28 days 
• For repeat bleeds at short intervals, suggested limit 1% TBV (= 0.1 ml) in 24 hours 
2.2.5. Delivering Drugs 
The penile vein was chosen for intravenous administration of drugs, and has been shown to 
be a reliable rote for injections (353, 354). In our study, the drug was always administered 
when the rat was under general anaesthetic, and no side effects were encountered. 
2.2.6. Organ retrieval and storage 
Both the kidneys were retrieved at 48 hours. Each kidney was initially divided into two 
halves and the kidney examined for IRI. The most consistent macroscopic finding in IR 
kidneys was: 
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• Left kidney generally oedematous compared to the right kidney 
• Presence of reddish streaks in the outer cortex 
Each half of kidney was then divided into 2 halves again, thus ending with four quarters. 
One quarter was preserved in formalin (10% Neutral-Buffered Formalin), and the rest three 
quarters were snap frozen. Rat spleen and liver were used as positive controls for 
immunohistochemistry, and these were also snap frozen. 
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2.3. Operating techniques 
The methodology adopted to carry out the IRI studies was adapted from previous studies, 
and from the supervisor’s experience (266, 294, 355). Once the rat was anaesthetised, the 
rats were weighed and then transferred to the operating table. The midline hair was shaved 
using an electric razor. The rat skin was then cleaned with chlorhexidine spray prior to the 
procedure.  
2.3.1. Ischaemia- Reperfusion 
10’ blade scalpel was used to make the midline skin incision. The rectus sheath and the 
peritoneum were opened using scissors. The cecum was positioned into the right upper 
quadrant (usually a midline structure), and the stomach was pushed into the left upper 
quadrant (from the left lumbar region). This enabled the visualisation of the left kidney. 
The left kidney was gently elevated and the renal pedicle (both artery and vein) was 
clamped with a vascular clip for a pre-defined ischaemic time. Ischaemia was confirmed by 
noticing change in the colour of the kidney. The natural colour of the kidney is pinkish in 
nature, and this turned to dark brown in colour on application of the vascular clip, thus 
confirming ischaemia. Laser Doppler flowmetry was used to confirm ischaemia in the first 
few cases, but was subsequently abandoned given the obvious macroscopic changes in the 
kidney after clamping.  
The laparotomy wound was then covered with saline soaked sterile gauze, with frequent 
observations at the colour of the kidney. The rat heart rate and breathing pattern were 
visually observed during the procedure, and the anaesthetic quantity delivered varied 
accordingly. Following the pre-defined time for ischaemia, the vascular clamp was 
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subsequently removed in order to establish reperfusion, which was again confirmed with 
the change in colour of the kidney. Normal saline drops equivalent to the interventional 
groups injected volume was then sprayed into the peritoneal cavity prior to closure. The 
laparotomy wound was then sutured in two layers using 3’0 vicryl. The rat was then 
transferred onto the cage (which was placed on a heating pad), and then transferred to the 
conventional holding room once mobile in the cage. 
The rat was checked at the end of the day, and the next day post operation. Vital parameters 
like breathing pattern, skin texture (indicates hypothermia/hypotension) and passage urine 
and faeces (cage inspection) indicated satisfactory post-operative recovery. Wound was 
reviewed every day, and any incidences of infection or dehiscence recorded. On the day of 
retrieval (48 hours), under terminal maximal anaesthesia, the midline laparotomy was 
reopened. Both the kidneys were inspected to ensure adequate perfusion, confirmed by the 
colour of the kidneys. Any capsular hematoma or patchy perfused kidneys were recorded. 
The mediastinum was then opened, and the descending aorta/heart was punctured so as to 
ensure death by exsanguination. Once death was confirmed, both the kidneys were 
retrieved. The dead rat was then disposed in an orange bag and placed in the carcass freezer. 
Figure 2.1 represents pictorial representation of the operative technique including the 
observation of ischaemia following the application of vascular clip.  
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Figure 2.1: Pictorial representation of the operative technique 
	
Figure 2.1: Pictorial representation of the operative technique.  
Photo A: Shows the midline laparotomy wound with edges retracted by clips. Sterile cotton buds 
are used to elevate the left kidney into wound just prior to clamping. The kidney is normal pinkish 
colour indicating good perfusion. 
Photo B: Shows the midline laparotomy wound with edges retracted by clips. The vascular clip is 
now clamped onto the left renal pedicle. The left kidney is now dark brown in colour, indicating 
ischaemia phase. 
Photo C: Shows the reperfusion phase following the removal of the renal pedicle vascular clamp. 
Note the kidney is now back to its original pinkish colour, but is now oedematous following 
reperfusion. 
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Photo D: Two halves of left kidney post retrieval at 48 hours. Note the reddish streaks on the outer 
renal cortex indicating ischaemia-reperfusion injury,  a phenomenon not observed on contra lateral 
right kidneys ( picture not shown). 
 2.3.2. Sham Operation 
All the steps were similar to the IRI group, except no vascular clip was placed on the left 
kidney. Normal saline drops were also placed in the abdominal cavity similar to the IR 
group. The laparotomy wound was covered with saline soaked gauze for 40 minutes, and 
wounds closed at end.  
2.4. Intervention groups 
The main hypothesis of this research project is to understand whether leukocyte and 
complement modulation affects renal ischaemia perfusion injury. To achieve this, we have 
used certain agents that are known to affect the leukocytes and complement system, and 
these are detailed below. The protocol sheets for all the groups are attached in Appendix 1. 
2.4.1. Leukocyte modulation using ATG 
As discussed in the previous section, ATG influences the function of a variety of 
leukocytes. The ATG used in our study was a ‘rabbit anti-rat thymocyte immonuglobulin 
(rATG)’ produced analogously to commercial ATG (Thymoglobulin®), kindly provided by 
Genzyme Corporation (Cambridge, MA, USA). Briefly, rabbits were immunized with a 
mixture of thymocytes of four strains of rats (Sprague Dawley,F344 Fisher, Lewis and 
Long Evans). Thymocyte suspensions were prepared using thymi from several donor rats. 
Fifty New Zealand White rabbits were immunized twice, two weeks apart, and terminally 
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bled two weeks after the last immunization. Total rabbit IgG obtained from the serum was 
pooled and purified similarly to Thymoglobulin® Genzyme, Cambridge, MA, USA). 
Control rabbit Ig was purified from whole normal rabbit serum (312). 
ATG protocol: 
The ATG dose used in this study was 10mg/kg body weight. Following general anaesthesia, 
a time zero blood sample (T0) was taken, and the required does of ATG was then injected 
into the penile vein. Following a period of 20 minutes, laparotomy and left renal pedicle 
clamping for 40 minutes was done as described earlier in the IR operative protocol. A 
second blood sample was taken at 48 hours under terminal anaesthesia. The protocol 
flowchart is attached in the Appendix.  
2.4.2. Complement Modulation 
Complement modulation was achieved by using two drugs: Soluble Complement Receptor 
-1 and a novel antibody to MASP-2 pathway. 
2.4.2.1. Soluble Complement Receptor 1 (sCR1) 
The sCR1 utilized in this study was a kind gift of SmithKline Beecham, Pharmaceuticals, 
Harlow, Essex, UK and has been used by previous investigators, including my supervisor 
(320, 327) This agent was soluble human complement receptor type 1, residues 42-1973 of 
human CR1, glycosylated, expression of plasmid pBsCR1c/pTCSgpt in Chinese hamster 
ovary cells (DUXB11). The dose used was similar as previous publications on sCR1 
(5.3mg/ml): 25-mg/kg body weight. A time zero blood sample from tail tip (T0) was 
obtained followed by injection of sCR1 at the desired dose in the penile vein. Following 20 
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minutes, IR operative protocol was performed, and a second blood sample prior to 
reperfusion (T1) was obtained. Further blood samples were obtained at 24 (T2) and 48 (T3) 
hours. The protocol flowchart is attached in the Appendix.  
2.4.2.2. Anti-MASP-2 antibody and Isotype Control 
The anti-MASP-2 antibody was provided by Omeros Inc., Seattle, WA and was used to 
evaluate its efficacy in intestinal IR model(329). Its preparation is as follows: recombinant 
antibodies against MASP-2 (AbDH3 and AbD04211) were isolated from Human 
Combinatorial Antibody Libraries (Serotec; AbD) using recombinant human and rat 
MASP-2A as antigens. An anti-rat Fab2 fragment that potently inhibited lectin pathway-
mediated activation of C4 and C3 in mouse plasma was converted to full-length IgG2a 
antibody. Polyclonal anti-murine MASP-2A antiserum was raised in rats. In this group 
similar protocol to sCR1 group was followed with T0, T1, T2 and T3 blood samples, and 
the protocol flowchart is attached in the Appendix. 
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2.5. Identification and Coding 
Each rat had codes in this experimental set up that were numbered consecutively (01-77). 
Following anaesthesia, the rat-tail was marked with a permanent marker to identify it 
during the 48-hour period. Once the rats were in the cage, a tag was attached to each cage 
showing the rat identification details, operative details and contact number of the research 
fellow (in case of emergency). This tag also enabled to list the observations like wound 
check, rat behaviour etc which could be seen by the JBIOS staff as well.  
Once the kidneys were retrieved, they were placed in formalin containers or cryotubes. 
These tubes were marked using a fine-tip permanent marker, either as R01 (R= right 
kidney) or L01 (L= Left Kidney). These codes were then subsequently used to for marking 
the H&E and Immunohistochemistry slides, and for QPCR experiments. For spleen and 
liver samples, the rat number and tissue were written on the cryotubes (64-spleen). Hence, 
each experimental rat was identified by a code for the experiment and analysis of results. 
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2.6. Blood and serum analysis 
In the next few sections, the methodology adopted for analysing blood and serum samples 
will be discussed.  
2.6.1. ATG efficacy, CD3 count analysis and Flow Cytometry 
ATG has been routinely used in clinical transplantation for induction treatment, and 
treatment of rejection episodes. As discussed before, the predominant effect of ATG is via 
T-Lymphocyte depletion. Hence, peripheral T-lymphocyte CD3 count has been used as a 
reliable marker for testing the efficacy of ATG, and titrating the concentration of ATG 
dosage given to the patient (356-358). ATG has also been shown to reduce the peripheral 
T-cell CD3 count in rodent models (297, 311). Hence, we used peripheral CD3 count to 
check efficacy of ATG in lewis rats. Flow cytometry was used to analyse the CD3 count 
and was carried out by Dr.Brad Spiller according to pre-agreed protocol.  
Flow Cytometry protocol for CD3 count analysis: 
100 microliters of venous blood was collected into 50 mM EDTA (final concentration) 
collection tubes. Anti-coagulated blood was added to an equal volume of PBS prior to 
careful overlaying on 500 microlitres of histopaque (50% 1077 and 50% 1119 density) in a 
sterile 1.5 ml eppendorf microfuge tube to separate out the mononuclear leukocytes. 
Following 20-minute centrifugation at 450 x g (no with no brake on deceleration) 
erythrocytes and polymorphonuclear leukocytes passed through the histopaque and 
mononuclear leukocytes were collected and washed into flow cytometry buffer by pelleting 
(3 min at 3,000 xg) and resuspension to a density of 1 million cells/ml. One hundred 
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microlitres of these mononuclear cells were incubated with either 10ug/ml (final 
concentration) of FITC-conjugated IgG1 isotype control (Cat no: MG101, Invitrogen,), 
FITC conjugated mouse monoclonal anti-Rat CD45 (Cat no: 554877clone OX-1, BD 
Pharmingen) or FITC conjugated mouse monoclonal anti-rat CD3 (Cat No: 557354 clone 
1F4, BD Pharmingen, 557354) diluted in flow cytometry buffer (PBS, containing 15 mM 
EDTA, 1% bovine serum albumin and 30 mM sodium azide).  
Cells were incubated for 30 min at 4 C in the dark prior to removing unbound antibody by 
washing 3 times in flow cytometry buffer. Cells were analysed on a BD Facscalibur and 
mononuclear cells were gated on by forward and side scatter parameters to isolate from any 
minor contamination of erythrocytes. 10,000-gated cells were analysed for percent positive 
CD3 and CD45 (shift above isotype background control) and recorded for each time point 
for each rat. Figures 2.2, 2.3 and 2.4 represent the methodology used to analyse the CD3 
count 
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Figure 2.2: Measuring B and T cell populations by flow cytometry 
 
Figure 2.1: Graphic representation of measuring CD45 cells using flow cytometry 
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Measuring B and T cell populations by flow cytometry 
1. Histopaque –separated nucleated cells and background FITC fluorescence 
2. Histopaque –separated cells and stained with FITC-CD45 to visualise all  
leukocytes, then set gate to identify size/granularity profile for CD45+ cells 
Marker Left, Right Events % Gated % Total Mean Median
All     1,  9647 10032 100.00 29.51 437.88 339.82
M1    65,  9647 9877 98.45 29.06 444.51 339.82
File: Prabhu's return.007 Log Data Uni ts: Linear  Values
Sample ID: pre-ATG cd45-fitc histopaq4 Patient ID: R033 0hr
Tube: Panel: 
Acquisition Date: 29-Nov-11 Gate: G2
Gated Events: 10032 X Parameter: FL1-H (Log)
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3. Set a gate around this population and create histogram to only analyse 
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Figure 2.3: Examining T-cell depletion following ATG administration 
 
Figure 2.2: Graphic representation of CD45 and CD3 cells pre-ATG treatment, and depletion of 
CD3 cells evident post ATG administration. 
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Examining T-cell depletion following ATG administration 
1.  Stain cells with FITC-CD45 (all leukocytes) and FITC-CD3 (T-cell specific) 
      pre-administration of ATG. 
100% of cells 
express CD45  
46.8% of cells 
express CD3 
(46.8% are T-cells) 
2.  Repeat analysis on blood obtained 48 h post-ATG administration. 
Only 67% of cells 
in this region 
now express 
CD45 marker 
All CD3 T-cells 
have been depleted 
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Figure 2.4: Examining T-cell effects following IgG control administration 
 
Figure 2.3: Graphic representation of CD45 and CD3 cells pre-ATG Isotype treatment. 
Compared to figure 2.2, no significant depletion of CD3 cells seen post ATG isotype 
administration. 
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Examining T-cell effects following IgG control administration 
100% of cells 
express CD45  
58.9% of cells 
express CD3 
(58.9% are T-cells) 
2.  Repeat analysis on blood obtained 48 h post-ATG administration. 
Again 75% of 
cells in this 
region now 
express CD45 
marker (non-
specific effect of  
Rabbit IgG) 
49.5% of cells still 
express CD3 (i.e. 
no significant loss 
of CD3- T-cells) 
1.  Stain cells with FITC-CD45 (all leukocytes) and FITC-CD3 (T-cell specific) 
      pre-administration of control IgG. 
	 80	
2.6.2. sCR1 efficacy and CH50 Complement Assay 
Complement haemolytic activity is a functional test of the classical complement pathway, 
lectin and alternative pathway of complement in plasma or serum. The classical pathway 
method (CH50) is based on the lysis of sensitised sheep erythrocytes in the presence of 
Ca++ and Mg++. The assay was carried out in collaboration with Dr. Spiller, who has 
published on this methodology (359). Rat blood was collected via tail tip into 500ul tubes, 
and placed on ice. The sample was then spun at 1300 G for 15 minutes at 5 degree 
centigrade, leading to separation of serum layer. The amber cells were then aspirated into 
fresh tubes, and the serum sample was then labelled and stored at -70 deg centigrade. 
96 well CH50 assay: 
Making the sheep EA: 
• Sterile transfer 1 ml of sterile sheep RBC (Code: SB068: TCS Biosciences ltd; Lot- 
49657) into an eppendorf tube. Wash 3 times with 1 ml Phosphate Buffered 
SALINE (10X solution, BP 399-20, Fischer Scientific limited, Lot – 102355) in a 
bench top centrifuge(5000 rpm, 3 minutes) . 
• Dilute 200 microlitres of packed RBC into 5 mls of PBS and add 5 ml of PBS 
which has 20 ul of Amboceptor (2 ml, Catalog Number: 9002; Institut Virion\Serion 
GmbH) added to it. 
• Incubate for 15 minutes at 370 centigrade. Wash once in 10 mls of PBS (1000 g x 5 
minutes), once in VBS (Veronal Buffered Saline, NC9460913; Fischer Scientific 
limited) resuspend to 20 ml in VBS, to give 1% final suspension. 
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Assay: in a 96-well round bottomed plate (MICR-TPF, Elkay Lab) 
• Add 50 ul of VBS to 2x rows per sample of 96 well plate. Serially dilute 50 ul of 
serum sample through 12 dilutions for each row. Add 50 ul of sensitized sheep EA 
and incubate at 37 C. 
• Dispense 50 ul of VBS to each of the wells in row A ie. A 1-12 
• Check the plate at every 9 minutes, and if changes seen (haemolysis vs. no 
haemolysis macroscopically), then read in microplate reader (MRX TC Revelation, 
Dynex Magellan Biosciences) at every 9 minutes for 30 minutes at 415 nm.  
2.6.3. Anti-MASP-2 antibody and Lectin Pathway assessment 
Omeros Corporation (USA) provided the anti-MASP -2 antibody and its’ isotype. They 
also provided guidance for methods to check the ablation of lectin pathway activity in 
serum, which was adapted in our lab under the guidance of Dr Brad Spiller. Functional 
activity of the lectin pathway in rat serum was assessed by detection of C4b deposition on 
mannan-coated plates. For obtaining serum samples, rat blood was collected via tail tip into 
500ul tubes. The sample was then mixed well, and placed on ice. The sample was then spun 
at 1300 G for 15 minutes at 5 degree centigrade, leading to separation of serum layer. The 
amber cells were then aspirated into fresh tubes. The serum sample was then labelled and 
stored at -70 deg centigrade. 
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Ex-vivo assessment of Lectin pathway:  
In a 96-well plate, 50 microlitres of mannan (from Saccharomyces cerevisiae -Cat: M7504, 
Sigma- Aldrich) solution [50ug/ml: 50 mgs of mannan in 1 ml of PBS. 1:1000 dilution] 
was added to each well prior to being sealed with an adhesive plate seal and incubated 
overnight at 37deg to enable coating of each well with mannan. Each well was washed with 
complement fixation buffer prior to addition of dilutions of rat serum (diluted in 
complement fixation buffer) and a further incubation at 37 deg for 1 hour.  The plate was 
then washed with fresh complement fixation buffer to remove unbound serum proteins and 
the plate blocked.  Blocking solution consisted of 10% w/vol of skim milk protein diluted 
in complement fixation buffer (10 grams of dried skimmed milk, Marvel, Premier 
International Foods (UK) Ltd in 100 mls of water with one Complement Fixation Tablet 
(Cat: BR0016, Oxoid Limited, UK)). After blocking non-specific binding sites, the bound 
rat C4b was detected with a 1/100 dilution of polyclonal anti-rat C4 (Hycult Technologies, 
Cat: HP8023) diluted in PBST (Phosphate Buffered Saline - Cat: BP 399-20, Lot – 102355, 
Fischer Scientific Ltd), with a further incubation of 1 hour at 37 degrees.  
Following 1 hour, the wells were washed 3x with PBST 200 ul, and the bound anti-C4 
antibody detected with 1/1000 dilution of Peroxidase AffiniPure Donkey Anti-Rabbit IgG 
(Cat:  711-035-152, Jackson Immuno-Research Lab) added to each well, incubated for 1 
hour and then washed 3x with PBST, and final 1x wash with PBS. Peroxidase antibody 
(directly proportional to the amount of C4 deposited on the plate) was then developed by 
the addition of OPD-Easy substrate (Acros organics) and the reaction stopped with an equal 
volume of 2N H2SO4 when the maximum signal was achieved. The plate was then read in 
microplate reader at 490 nm (MRX TC Revelation, Dynex Magellan Biosciences). 
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2.7. Pathology 
2.7.1. Histology 
Paraffin embedded renal tissues were Hematoxylin & Eosinophil (H&E) stained by Central 
Biotechnology Services (CBS), Cardiff. These slides were then analysed by a pathologist 
(Dr Gilda Chavez) who was blinded to the treatment groups. Jablonski’s acute tubular 
necrosis score has been used routinely to characterise renal injury, however, it was felt that 
a more comprehensive scoring was required that included endothelial, glomerular and 
tubulointerstitial damage as part of the scoring scale. The scoring scale was devised on 
literature evidence, and has been validated by our research group by using correlation 
histology scoring with the qPCR of kidney injury molecules (KIM-1 and NGAL) and has 
been presented at the European Transplant Congress (ESOT, Brussels 2015) and currently 
is being submitted for publication. 
The histology scoring scale adopted for this study is detailed in Table 2.1. The main 
parameters of evaluation were changes seen in Tubular, Glomerular, Endothelial and 
Tubular-Interstitial. The relevant literature evidence used to arrive on formulating this score 
is also referenced in the table. 
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Table 2.1: Histology scoring system 
Tissue type Damage Score 
Tubular (52-53) No damage 0 
 Loss of Brush Border (BB) in less than 25% of tubular 
cells. Integrity of basal membrane 
1 
 Loss of BB in more than 25% of tubular cells, 
Thickened basal membrane. 
2 
 (Plus) Inflammation, Cast formation, Necrosis up to 
60% of tubular cells 
3 
 (Plus) Necrosis in more than 60% of tubular cells. 4 
Endothelial (55) No damage 0 
 Endothelial swelling 1 
 Endothelial disruption 2 
 Endothelial loss 3 
Glomerular (56-58) No damage 0 
 Thickening of Bowman capsule 1 
 Retraction of glomerular tuft 2 
 Glomerular fibrosis 3 
Tubulo/Interstitial(54) No damage 0 
 Inflammation, haemorrhage in less than 25% of tissue. 1 
 (Plus) necrosis in less than 25% of tissue 2 
 Necrosis up to 60% 3 
 Necrosis more than 60% 4 
 Overall score 14 
Table 2.1: Histology scoring scale used to characterise renal ischaemia reperfusion injury. The 
marking scale range was from 0-14, and mean scores were used for statistical calculations. The 
references for arriving at this score are also listed.  
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2.7.2. Immunohistochemistry (IHC) 
The IHC staining on the slides were carried out by CBS, Cardiff, and I assisted them in 
some of the staining methods in order to gain an understanding of the methodology. Frozen 
and paraffin section slides were used for IHC depending on the antibodies.  
2.7.2.1.Primary and Secondary antibodies 
Based on the resources at CBS, DAKO EnVision™ Detection Systems Peroxidase/DAB, 
Rabbit/Mouse (Cat no: Code K5007, DAKO) were used as secondary antibodies. The 
EnVision™ reagent of this kit is a peroxidase-conjugated polymer backbone, and carries 
secondary antibody molecules directed against rabbit and mouse immunoglobulins. The 
primary antibodies chosen were either rabbit or mouse in origin. The primary antibodies 
chosen in this study along with their source are detailed below. 
Complement system markers: 
As discussed in the introduction chapter, activated complement generates three major types 
of effectors (360) 
1. Anaphylatoxins (C3a and C5a) 
2. Opsonins (C3b, iC3b, and C3d) which bond to target cell surfaces and immune 
complexes to facilitate their removal  
3. Terminal membrane attack complex (MAC, C5b-9)  
In our study, we are using IHC markers for C3b and C9 to assess complement-mediated 
damage. CD59 is the only well-characterized membrane inhibitor acting at the terminal step, 
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and prevents the assembly of the MAC by inhibiting the C5b-8 catalysed insertion of C9 
into the lipid bilayer (218), and this was also evaluated. The complement IHC markers were 
kindly gifted by Dr Paul Morgan, Cardiff University. 
Endothelial markers: 
1. Tissue factor Antibody (FL-294): Cat: SC-30201: Santa Cruz Biotechnology 
2. Thrombomodulin antibody (H-300): Cat : SC-9162, Santa Cruz Biotechnology 
3. P-Selectin: Cat: 3633R-100, BioVision, Cambridge Bioscience 
CD (Cluster of Differentiation) markers for Leukocytes: 
1. Neutrophils: CD15 (C3D-1) -Cat: sc-19648, Santa Cruz Biotechnology 
2. Macrophage: CD68 - Cat: OASA04073, Aviva Systems, Cambridge Bioscience 
3. T-Lymphocytes: 
CD 3 - Cat: 201401, BioLegend, Cambridge Bioscience 
CD4 - Cat: 201501, BioLegend, Cambridge Bioscience 
CD8 - Cat: OASA04086, Aviva Systems, Cambridge Bioscience 
2.7.2.2. Positive and negative controls 
Native rat tissue, which are considered abundant source of marker in question, served as 
positive controls. The right kidneys from the experimental groups served as negative 
controls. These are detailed below 
• Complement system: Rat liver from Wistar rats served as positive control for 
complement system (C3, C9, CD59)  
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• Endothelium: Rat spleen and liver from Wistar rats served as positive control for 
Thrombomodulin, Tissue factor, P-selectin  
• Leukoctyes: Rat spleen/liver served as positive control for leuckocyte markers 
2.7.2.3. Scoring key 
The scoring key for IHC slides were: 
• C3, C9, CD59: scored 0-4 (vascular and stromal staining) based on intensity of 
staining 
• P-Selectin, Tissue Factor, Thrombomodulin: scored 0 – 4 depending on intensity of 
staining 
• Cellular markers (CD15, C68, CD3, CD4, CD8) were counted: n/ avg 5x HPF 
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2.8. Molecular Analysis 
Real Time Reverse Transcription Polymerase Chain Reaction (RT-qPCR) 
In Real-time PCR (qPCR), specific sequences within a DNA or cDNA template can be 
amplified (thousand-to a million fold), thus enabling detection of target molecules that get 
doubled with each amplification cycle. The fluorescence-based real-time reverse 
transcription PCR is widely used for the quantification of steady-state mRNA levels, gene 
expression analysis, pathogen detection and analysis of chromosome aberrations (361). The 
starting point for PCR is good quality messenger RNA (mRNA). Reverse transcription of 
RNA leads to formation of cDNA, which in turn is used as a template in qPCR reactions to 
detect and quantitate gene expression products. Gene expression/ mRNA analysis refers to 
the process by which information from a gene is used in the synthesis of a functional gene 
product, and with qPCR, researchers are able to assess changes (increase/decrease) in the 
expression of a particular gene by measuring the abundance of the gene-specific transcript 
(362). Real time PCR incorporates fluorescent dyes in the reaction mixture enabling 
monitoring of increase in amplification products throughout the reaction, enabling 
measurements to be taken in the exponential phase of the reaction, before the reaction 
plateau (363).  
In ischaemia-reperfusion injuries, qPCR is being increasingly used as a modality to report 
variations in cytokine/chemokine levels and changes in genetic expression between the 
treatment groups. The qPCR offers a powerful technique to analyse results, especially 
effect of new drugs/agents on modulating ischaemia reperfusion injury (313, 364, 365). 
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Considering qPCR offers an avenue to explore a host of genes that are involved in IRI, we 
have used qPCR in our studies to analyse specific genes of interest. 
This experimental set up used a two-step quantitative reverse transcriptase PCR: 
• The first step is extraction of RNA from the one quarter of frozen kidney tissue, 
followed by Reverse Transcriptase reaction to create cDNA copies.  
• The final step involves the qPCR reaction using the SYBR Green mastermix and 
primers for the specific genes in questions.  
The qPCR experiments were conducted in the Laboratory based in Institute of Nephrology, 
Cardiff under the guidance of Dr Rob Jenkins and Dr Donald Fraser.  Good Laboratory 
practice was followed during these experiments. 
(http://www3.appliedbiosystems.com/cms/groups/mcb_support/documents/generaldocume
nts/cms_042557.pdf). 
The steps in the qPCR experiments are described below: 
2.8.1. Methodology: RNA extraction and Reverse Transcription reaction 
2.8.1.1. RNA Extraction 
The frozen sample of kidney was weighed in a petri dish, and then suspended in the 
TRIzol® Reagent (Cat No: 15596-026, Invitrogen). The RNA extraction was carried out 
according to protocol (http://products.invitrogen.com/ivgn/product/15596026 ). 
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The steps are briefly explained below: 
• Homogenizing samples  
1 mL TRIzol® Reagent was used for 50–100 mg of tissue sample. The weight of 
the quarter piece of kidney varied from 100 to 300 mgs, and the TRIzol® Reagent 
was used accordingly (i.e. 1-3 ml). The sample was then homogenized using a 
power homogenizer, resulting in a clear pink solution. Following each sample, then 
homogenizer was cleaned by running it in three solvents sequentially: 1mmol 
Sodium Hydroxide followed by 100% ethanol, and finally in nuclease free water. 
These solvents were placed in individual 20 ml vials. The homogenizer was then 
wiped with a paper tissue. 1 ml of the resulting solution was used for the phase 
separation step, and the rest of the solution is stored at -700 to be used in the future. 
This step was carried out in clean conditions in the Astec Monoair Hood system 
• Phase separation  
The homogenized sample was then moved into the qPCR bench and was incubated 
for 5 minutes at room temperature to permit complete dissociation of the 
nucleoprotein complex. 0.2 mL of chloroform (Cat- C2432, Sigma-Aldrich) per 1 
mL of TRIzol® Reagent was then added to the homogenized sample, and mixed by 
inverting the tubes a few times. This sample was then incubated for 3 minutes at 
room temperature. The sample was then centrifuged at 12,000 × g for 15 minutes at 
4°C in the Eppendorf Centrifuge machine. Following centrifugation, the mixture 
separated into a lower red phenol-chloroform phase, an interphase, and a colourless 
upper aqueous phase. The aqueous phase of the sample contained the RNA, and this 
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was then pipetted out into a new eppendorf tube (1.5 ml tube). The interphase and 
organic phenol-chloroform phase was saved for DNA and protein isolation. 
• RNA Isolation Procedure  
0.5 mL of 2-Propanol (Cat: I9516, Sigma-Aldrich) was then added to the aqueous 
phase, per 1 mL of TRIzol® Reagent used for homogenization. This sample was 
then incubated at room temperature for 10 minutes. The sample is briefly vortexed, 
and then centrifuged at 12,000 × g for 10 minutes at 4°C. Following centrifugation, 
the RNA forms a gel-like pellet (whitish fleck) on the side and bottom of the tube.  
• RNA wash  
The supernatant from the tube is pipetted out carefully, leaving only the RNA pellet 
at the bottom of the tube. The pellet is then washed with 1 mL of 75% ethanol 
(Ethanol absolute- catalog no. 1.08543.0250, Merck KGaA; diluted to 75% by 
adding 7.5ml + 2.5ml of RNAse free Water) per 1 mL of TRIzol® Reagent used in 
the initial homogenization. The sample is then vortexed briefly, followed by 
centrifugation at 7500 × g for 5 minutes at 4°C. The wash is then discarded and the 
above step repeated (two times). The wash is then discarded, and the RNA pellet is 
air dried for 5–10 minutes under a HOOD. The pellet is then resuspended in 
RNAse-free water (50 ul) to develop a RNA stock solution. This solution was then 
diluted in 1/10th dilution (10 ul of RNA stock+ 90 ul of RNAse free water) to be 
used for the qPCR reactions, and the stock solution stored at -700c.  
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2.8.1.2. Assessing quality and quantity of RNA 
RNA quality and quantity is important prior to the reverse transcription. Nanodrop 
Spectrophotometer (Thermo Fisher Scientific) based at CBS, Cardiff was used for this 
purpose. The procedure for carrying out the test and analysing the results is adopted from 
the manufacturer’s protocol (http://www.nanodrop.com/library/nd-1000-v3.7-users-
manual-8.5x11.pdf). 
2.8.1.2.1. Nanodrop Spectrophotometer 
The Nanodrop Spectrophotometer (Thermo Fisher Scientific) enables determination of the 
concentration and purity of nucleic acid. This is determined by the following outputs from 
the spectrophotometry, and the data is shown in the Appendix 3. 
• ng/ul: sample concentration in ng/ul based on absorbance at 260 nm  
• 260/280: The ratio of sample absorbance at 260 and 280 nm is used to assess the 
purity of DNA and RNA in the given sample. A ratio of ~1.8 is generally accepted 
as “pure” for DNA; a ratio of ~2.0 is generally accepted as “pure” for RNA. If the If 
the ratio is lower than 1.8, it may indicate the presence of protein, phenol or other 
contaminants that may lower the qPCR reaction efficiency 
• 260/230: ratio of sample absorbance at 260 and 230 nm acts as a secondary measure 
of nucleic acid purity. The ratio ranges commonly between 1.8-2.2. If the ratio is 
lower, this may indicate the presence of co-purified contaminants like phenol rings 
(salt guanidine isothiocyanate, phenol etc.), which can inhibit enzymatic reactions. 
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The methodology for carrying out Nanodrop Spectrophotometry is as follows. 
• The receiving fibre of the machine is cleaned with a tissue and 1 ul of RNAse free 
water is pipetted onto it. On the computer desktop, the nanodrop icon is clicked 
(nuclei acid box chosen) and the sampling arm (second fibre optic cable) is then 
brought into contact with the liquid sample. Once this is done, the run logo is 
clicked on the computer to calibrate the machine. Following the dry run, the 
sampling arm is lifted, cleaned with a paper tissue and 1 ul of the RNA solution 
(1/10th dilution) is pipetted to the end the receiving fibre. The sampling arm is then 
gently positioned on the receiving fibre, over the solution. On the computed desktop, 
the relevant sample number is entered, RNA-40 is chosen as the sample type and 
the ‘measure icon’ is clicked to run the analysis. The results are stored on the 
computer, and this data was copied on to the memory stick, and analysed using MS 
Excel software.  
2.8.1.2.2. Agilent 2100 Bioanalyzer: RNA Integrity (RIN): 
The RIN analysis was carried out by Dr Megan Musson, CBS, Cardiff. Agilent Bioanalyzer 
is another methodology that helps in determining the quality of RNA by assigning a RIN 
(RNA Integrity Number) to it. It also helps determining to what extent the RNA in the 
sample is degraded, as RNA extracted from tissues exhibit varying degrees of degradation. 
The principle and the methodology of RIN analysis to assess integrity (as compared to 
traditional denaturing gel method) has been published by the Schroeder et.al from Agilent 
Technologies (366). 
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5 ul of 1/10th dilution of RNA stock was pipetted into a new 0.5 ml eppendorf for the 
analysis purposes. 1-4ul of the sample was loaded onto a chip (12 at a time) and inserted 
into the Bioanalyzer machine, which delivers results in 45 minutes. Further information 
about this procedure can be accessed at (http://www.genomics.agilent.com). The RIN 
values of all the samples are shown in Figure 1 at the end of this chapter. 
2.8.1.3. Reverse Transcription 
Reverse transcription involves formation of a complementary DNA (cDNA) from a 
messenger RNA (mRNA) template, and this reaction is catalysed by enzymes: reverse 
transcriptase and DNA polymerase. The methodology was as per protocol: 
http://www3.appliedbiosystems.com/cms/groups/mcb_support/documents/generaldocumen
ts/cms_042557.pdf 
Reagents used: 
1. High Capacity cDNA Reverse Transcription Kit (Cat No: 4368814, Invitrogen), 
consisting of the following reagents: 
• 10× RT Buffer 
• 10× RT Random Primers 
• 25× dNTP Mix (100 mM) 
• MultiScribe® Reverse Transcriptase 
• RNAse inhibitor (Cat No: M0307S, New England Biolabs) 
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Procedure: 
The aim of this experiment is to create a single-stranded cDNA from total RNA. The first 
step is to create the 2xRT master mix (per 20ul reaction) in a 1 ml eppendorf tube. 
Component Volume/Reaction ( ul) 
10× RT Buffer 2 
25× dNTP Mix (100 mM) 0.8 
10× RT Random Primers 2 
MultiScribe® Reverse Transcriptase 1 
RNase Inhibitor 1 
Nuclease-free H2O 3.2 
Total Per Reaction 10 
In my experiments, the master mix was prepared for 30 samples at a time, and the above 
volumes were multiplied into 35x (5ul extra to avoid pipetting loss). The mastermix was 
then placed on ice. Nanodrop Spectrophotmeter provides quantity of RNA as ng/ul. This 
concentration is converted to ul/ug. The resulting volume is then made up to 10 ul by 
adding nuclease free water. This solution is made up in one single RNA tubes 
corresponding to individual ratcode. To this sample, 10 ul of mastermix is added, pipetting 
up and down at least 2xtimes to mix, leading to a final volume of 20 ul per reaction/tube. 
The eppendorfs are then placed on ice. The heat stable RNA tubes were then placed in the 
thermal cycler for the reverse transcription reaction to take place. The cDNA formed at the 
end of this reaction is then stored at -200centigrade in the freezer. 
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2.8.2. qPCR Primers and SYBR Green mastermix 
The primers used in this study were designed by Dr.Rob Jenkins, and were ordered from 
Invitrogen, Life Technologies. Each gene of interest had a forward and reverse primer that 
was used in making the Power SYBR Green master mix. The primers used in this study are 
listed below in Table 2.2: 
Table 2.2: qPCR Primers  
Gene Forward Primer Reverse Primer 
REFERENCE GENES  
PGK1 CGT GAT GAG GGT GGA CTT CAA ACA ACC GAC TTG GCT CCA TT 
HPRT1 ACA GGC CAG ACT TTG TTG GA TCC ACT TTC GCT GAT GAC ACA 
YWHAZ TCT GCA ACG ACG TAC TGT CTC CCT CAG CCA AGT AGC GGT AG 
TBP1 TCC ACC GTG AAT CTT GGC TG CAG CAA ACC GCT TGG GAT TA 
ACTB CGC GAG TAC AAC CTT CTT GC CGT CAT CCA TGG CGA ACT GG 
B2M ACT GAA TTC ACA CCC ACC GA TAC ATG TCT CGG TCC CAG GT 
GAPDH GCA TCT TCT TGT GCA GTG CC TAC GGC CAA ATC CGT TCA CA 
TARGET GENES  
NGAL GGG CTG TCC GAT GAA CTG AA CAT TGG TCG GTG GGA ACA GA 
KIM-1 CGG CTA ACC AGA GTG ACT TGT TAC AGA GCC TGG AAG CAG 
ICAM-1 AGC GAC ATT GGG GAA GAC AG CTC GCT CTG GGA ACG AAT ACA 
VCAM-1 ACG AGT GAA TCT GGT TGG GAG AAC AGT AAA TGG TTT CTC TTG AAC  
IL-18 GAC CGA ACA GCC AAC GAA TC ARA GGG TCA CAG CCA GTC CT 
TNF-A ATG GGC TCC CTC TCA TCA GT GCT TGG TGG TTT GCT ACG AC 
Table 2.2: Primers with the forward and reverse configuration for reference and 
target genes used in the RT-qPCR experiments. 
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SBYR Green: 
For qPCR, either TaqMan® Chemistry or SYBR® Chemistry can be used. Though 
TaqMan has higher specificity and higher reproducibility, it is very expensive, and a 
different probe has to be used for each target reference gene. No probes are required for 
SYBR Green based assay, thus considerably reducing the cost of the assay. In our study, 
we have adopted SYBR® dye based platform, where the SYBR dye detects PCR products 
(formed through DNA polymerase amplifying the target sequence to create PCR products) 
by binding to the double-stranded DNA formed during PCR. As more PCR products are 
formed with each cycle, the SYBR dye binds to all the double-stranded DNA, which is 
reflected by an increase in the fluorescence intensity directly proportional to the amount of 
PCR product. One of the main disadvantages is generation of false positive signals as 
SYBR dye binds to even non-specific double-stranded DNA sequences, which we have 
negated by using well-designed primer and performing melt curve analysis as part of the 
qPCR.  
Master Mix preparation: 
Power SYBR® Green PCR Master Mix (5ml, Cat: 4367659, Invitrogen) was used. A 
mastermix was prepared per reaction to be used with the cDNA, and the composition is 
MasterMix ul/Reaction 
Power SYBR® Green PCR Master 
Mix 10ul 
Forward Primer 0.6ul 
Reverse Primer 0.6ul 
Nuclease free water 4.8ul 
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The primers were usually stored at -200centigrade. The primers were defrosted on ice, and 
centrifuged. Nuclease free water was added to this primer in the tube, vortexed and 
centrifuged. Based on the reaction numbers, then the desired quantity of forward and 
reverse primer was added to the SYBR Green master mix solution. 
Preparing the plate: 
For the qPCR reaction, MicroAmp Fast optical 96-well reaction plate (Cat: 4346906, 
Applied Biosystems, Life Technologies) was used. 16ul of SYBR master mix was then 
pipetted into each well according to the various groups. The cDNA tubes, which were 
preserved at -200 were defrosted on ice. Following defrosting, the samples were gently 
vortexed and placed in a centrifuge machine. The tubes were then placed on ice. 4ul was 
then drawn out from the RNA tubes using a pipette, and then mixed with master mix in one 
single well. In one well (usually the last row), 4 ul of water was added to 16ul of mastermix 
and this served as a no-template control (NTC). NTC contains all the reaction components 
apart from the cDNA, and any amplification detected in these wells can be due to primer-
dimers or contaminants. Once all the desired cDNA samples were mixed with the SYBR 
green master mix, the plate was covered with MicroAmp Optical Adhesive Film (Cat – 
4311971, Applied Biosystems, Life Technologies). A soft rubber plate was then used to 
gently press the adhesive film against the plate. The plate was then covered in a foil, and 
carried over to the qPCR machine on ice. Duplicates of each gene of interest were carried 
out to ensure no variations. 
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qPCR Machine: 
The qPCR Machine used in these experiments was: 7900 HT Fast Real-Time PCR System, 
Applied Biosystems and was placed in the CBS unit. Prior to loading the plate in the 
machine, it was centrifuged at 9000G x 3 minutes. This machine was linked to a computer 
placed next to it that controlled the experiment. On the desktop, the analysis mode chosen 
was: Standard curve. The gene of interest was added onto the software, and SYBR chosen 
as the fluorescence method. The qPCR run was ‘standard’ in nature, and a dissociation 
stage was added to the cycle for melting curve analysis. As SYBR green binds to all 
double-stranded DNA, melting curve analysis reveals if any other contaminating DNA, 
primerdimers or PCR products from misannealed primer are present in the PCR reaction, 
usually evident by multiple peaks. If there is only a single peak on the melting curve 
analysis, it implies that the desired amplicon was only detected. The reaction lasted for 2 
hours, and the results were reported as Ct (threshold cycle) values. The Ct value is used to 
calculate the initial DNA copy number, and the Ct value is inversely related to the starting 
amount of the target. 
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2.8.3. qPCR Analysis 
Once the cT (cycle threshold) values are obtained, the determination of gene expression can 
be quantified either via absolute or relative quantification method. Absolute quantification 
is a methodology where samples of known quantity are serially diluted and amplified to 
generate a standard curve, and this in turn allows quantification of unknown samples 
against this curve. In relative quantification, the expression of gene of interest is compared 
between treated and untreated samples, and expressed as fold change (increase or decrease) 
using a reference gene as a control for experimental variability. For our experiments, I have 
chosen the relative quantification method of normalising to a reference gene. 
2.8.3.1. Normalising to a reference gene: 
It is critical in qPCR to minimise any experimental variations and inconsistencies. Sources 
of variability can arise at each step of the experiment, from amount of starting sample to 
RNA isolation and reverse transcriptase, to qPCR amplification. Normalisation aims at 
addressing these variabilities, and the three main approaches include 
(http://www.biotechniques.com/protocols/PCR/Real-time_PCR/Normalization-Methods-
for-qPCR/biotechniques-115492.html): 
• Normalising to a sample quantity 
• Normalising to RNA or DNA quantity 
• Normalising to a reference gene 
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Of all the methods, the most widely used and reliable technique is to normalize RNA levels 
to an internal reference gene (367). The assumption in this method is that the reference 
gene is abundantly present in the tissue, and levels of expression don’t vary between the 
treated and untreated groups. In our study, we have adopted this method as there are 
multiple groups with different treatments and differing RNA concentration and normalising 
against reference gene would minimise variability.  
There are a variety of genes that have been used as reference genes in renal IRI models. 
Based on the literature evidence (368-371) and opinion of Dr Rob Jenkins/ Dr D Fraser, the 
following genes were evaluated as reference genes, and the results are discussed in the next 
chapter. 
• GAPDH 
• rRNA 
• PGKQ 
• HPRT1 
• YWHAZ 
• TBP 
• Beta -2 –Microglobulin 
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2.8.3.2. Genes of interest 
Based on the aims of the study, the following genes of interest were identified and used in 
the study. 
Kidney injury markers: 
§ Kidney Injury Molecule (KIM-1): 
KIM-1 is expressed in renal PTEC and facilitates apoptotic and necrotic cell 
clearance. KIM-1 is a membrane glycoprotein that contains both a six-cysteine 
immuno- globulin-like domain and a mucin domain in its extracellular portion, and 
has two spliced variants: KIM-1a expressed in the liver and Kim-1b, which is the 
predominant form in the kidneys (372). Following renal injury, KIM-1 is shed from 
the tubular cells into the urine and extracellular space, and this phenomenon has 
been consistently showed in literature leading to KIM-1 being used a biomarker for 
kidney injury (373, 374). KIM-1 has been shown to be elevated in urine within 12 
hours following acute renal injury, and in biopsies of acute renal failure patients 
(375). KIM-1 has been shown to be elevated with ischaemia in rats and other 
species using qPCR studies (313, 376), and correlated well with kidney injury and 
recovery (with intervention agents), leading to its use in our study,  
§ Neutrophil Gelatinase- associated Lipocalin (NGAL): 
NGAL is produced by neutrophils, and is a stress response protein that is 
upregulated on injury, and released into urine and plasma from the kidney. The 
proximal tubule, thick ascending limb and collecting ducts appear to be sources of 
urinary NGAL and was identified in proximal tubules on both IHC and qPCR (377). 
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Evidence for NGAL as marker for kidney injury was initially from mice renal IRI 
studies where upregulation of NGAL was seen following IR, with administration of 
purified recombinant NGAL resulting in improvement of morphologic and 
functional parameters (378). In a recent meta-analysis, serum and urine NGAL 
levels were found to be independent predictors of AKI and outcomes (379). There is 
very limited studies evaluating NGAL in rat renal IRI (380), and hence was used as 
a second marker in our study. 
Cell Adhesion Molecules markers: 
• Inter-cellular adhesion molecule (ICAM-1) 
ICAM enhances leukocyte endothelial interaction, and was seen very early after IR 
in murine model, with antibody to ICAM-1 protecting from ischaemic injury in the 
renal IRI model (81, 82). qPCR studies in renal IRI have shown elevated levels of 
ICAM-1 following ischaemic insult, with certain intervention agents showing 
downregulation, but this is not consistently seen with all agents (313, 381).  
• Vascular cell adhesion molecule (VCAM-1: CD106 ): VCAM-1 is found in very 
low levels on the cell surface of resting endothelial cells and mediates leukocyte 
adhesion to the vascular endothelium (97). Similar to ICAM, VCAM expression has 
also shown to be upregulated in murine 24-hour reperfusion model with 
intervention agents then showing downregulation of VCAM-1 (382). As with 
ICAM-1, there is limited evidence of VCAM-1 downregulation with intervention 
agents, and we hope to evaluate this further. 
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Cytokine markers: 
§ TNF-alpha 
§ IL-18 
The role of TNF-alpha and IL-18 has been extensively discussed in the introduction 
chapter. In essence, they are pro-inflammatory cytokines that are upregulated 
following renal IRI, and qPCR is one of the methods to evaluate these two makers.  
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2.9. Analysis 
2.9.1. Log book and excel database 
A logbook was maintained which detailed all the operations carried out. Each rat 
experiment was recorded and the details included were: 
• Rat identification 
• Rat weight 
• Date of operation 
• Treatment arm 
• Intraoperative findings and procedure 
• Unexpected events 
• Post operative follow up – wound, rat behaviour 
• Retrieval findings 
The logbook details were also maintained in a excel database, and was accessible to the 
supervisor also.  
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2.9.2. Statistical analysis 
The size of experimental groups is estimated by power calculation (Dupont WD and 
Plummer WD: PS Power and Sample Size Calculation. This calculation was also based on 
published results of comparable experiments (202, 266). To ascertain changes between 
groups, the minimum number per group is 6, and the number of rats/experiments in each 
group is tabulated below: 
• 40 minute unilateral left IR with 48 hours of reperfusion: n=10 
• Sham group (48 hours): n=6 
• ATG + 40 minute unilateral left IR with 48 hours of reperfusion: n=8 
• ATG isotype +40 minute unilateral left IR with 48 hours of reperfusion: n=8 
• sCR1 +40 minute unilateral left IR with 48 hours of reperfusion: n=8 
• Anti-MASP2 Antibody +40 minute unilateral left IR with 48 hours of reperfusion: 
n=6 
• aMASP-40 minute 2 antibody isotype +40 minute unilateral left IR with 48 hours of 
reperfusion: n=6 
The statistical tests used were based on the advice from the biostatisticians at Cardiff 
University, and the literature evidence, and have been discussed in the methodology chapter. 
The article ‘Principles for Valid Histopathologic Scoring in Research’ by Gibson-Corley 
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et.al (383) also guided on the use of appropriate statistical tests. Based on these discussions, 
the following tests were used: 
• Histology and Immunohistochemistry scorings were classed as non-parametric data, 
while qPCR results were classed as parametric data. 
• Results were be analysed for significance by parametric (unpaired Student’s t-tests, 
one-way ANOVA, paired Student’s t-est ) and non-parametric tests (Mann-Whitney 
U and Kruskal-Wallis) If differences were noted between three groups, then post 
hoc analysis using Neuman-Keuls (Anova) or Dunn’s (Kruskal-Wallis) were used. 
• Graphpad Prism 6 software was used for statistical analysis. Statistical significance 
was defined as P < 0.05, and ‘star marks’ as indicated in the table below depicted 
the level of significance seen 
P value Wording Summary 
< 0.0001 Extremely significant **** 
0.0001 to 0.001 Extremely significant *** 
0.001 to 0.01 Very significant ** 
0.01 to 0.05 Significant * 
≥ 0.05 Not significant ns 
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CHAPTER III:  
RESULTS – BASELINE STUDIES 
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3.1. Introduction 
Renal ischaemia-reperfusion injury is a complex mechanism involving numerous cellular 
and subcellular processes. Among those, the complement system, leukocytes and 
endothelium seem to have an important role in the inflammatory process that occurs 
following ischaemia and reperfusion. These components have an important role to play in 
the initiation and propagation of renal IRI. With my thesis focusing on these three systems, 
it was necessary to establish baseline studies to evaluate the participation of these elements 
prior to any interventional studies. 
Model: 
We chose a unilateral left renal ischaemia-reperfusion rat model. Safety profiling preferred 
a unilateral approach, as it would be less harmful for the subject. It would also enable us to 
compare the ischaemic left kidney with the right kidney, which served as an internal control. 
The drawback of this model is that we would not be able to obtain any physiological 
measurement such as serum creatinine. However, considering we are using comprehensive 
histology and immunohistochemistry scoring, we felt that it was justifiable to use the 
unilateral model. I have discussed the strengths and limitations of this model in the final 
chapter. 
Ischaemia timing: 
There is variability in literature regarding the length of ischaemia used in each model. The 
timings have varied between 20, 30, 40, 45, 60 and 120 minutes. The 40-minute group has 
also been used to been used by other researchers’ to demonstrate renal IRI, and has been 
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valid across different species (384-387). All these studies were also able to show reversal of 
injury with interventional agents. 40-minute ischemia was shown to represent the ‘fatal’ 
turning point beyond which the autophagy process transformed cell survival into cell death 
stage, but was dependent on the species and strain (388, 389). There is also some early 
evidence that autophagy coordinates various extracellular and intracellular triggers that lead 
cell viability (390). Hence keeping in context that we needed a model where changes could 
be sufficiently seen, and any intervention would be able to reverse these changes, we 
proceeded with the 40-minute time interval. 
Aims of this chapter: 
• To evaluate safety profiling of unilateral model 
• Evaluate histopathological differences between the sham and IR group using a 
comprehensive scoring scale 
• Evaluate different subsets of leukocyte infiltration using immunohistochemistry 
• Evaluate the role of complement system by measuring the activated complement 
products  
• Comprehensive evaluation of the endothelial changes following ischaemia-
reperfusion 
• To determine differences in mRNA levels between sham and IR group 
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3.2. Methods 
The sham group served as a control for the 40-minute ischaemia group. The sham group 
had exactly the same protocol as the IR group, only difference being no clamping of the left 
renal vessels. The baseline kidneys were from straight kill rats, and both the right and left 
kidneys were used for analysis. 
Groups: 
• The 40-minute IR group: n= 10 rats  
• Sham group: n=6 rats 
• Baseline group (2 rats) and both kidneys used for scoring: n=4 
Analysis: 
Kidneys retrieved at 48 hours were analysed for:  
• Histology 
• Immunohistochemistry 
• RT-PCR 
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3.3. Results 
3.3.1. Histology 
Haemtoxylin and Eosinophil (H&E) stained slides were analysed by a blinded pathologist 
and scored for injury on a scale from 0-14. The results are depicted in the graphs below. 
 
Figure 3.1: Histology Score – Sham and 40’ IR 
 
Figure 3.1: Scoring of H & E renal cortex sections from Baseline (BL) (n=4), sham (n=6) and 40-
minute unilateral IRI (n=10) in rats at 48 hours after reperfusion. A comprehensive scoring system 
(0-14) evaluated tubular, endothelial, glomerular and tubulo-interstitial cell damage. Histology 
scores are plotted as Mean +/- SD, and Mann Whitney tests used to test significance [p value < 
0.0001 (****), p= 0.0001 to 0.001 (***), p = 0.001 to 0.01(**), p = 0.01 to 0.05 (*)]. 
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Figure 3.2: Renal cortex H&E sections – Sham and 40’ IR 
 
Figure 3.2: Representative rat renal cortex H&E (x200) paraffin sections, from sham and 40-
minute IR group at 48 hours after reperfusion, assessed for tubular, endothelial, glomerular and 
tubulo-interstitial cell damage. (A) Normal appearance of renal cortex in a sham rat. The brush 
border of the tubular cells is intact with no thickening of the basal membrane. No inflammation or 
necrosis is seen (Tubular score 0). The endothelium is uniform with no swelling or disruption of the 
endothelial cells (Endothelial score 0). The glomeruli are intact with thin walled Bowman’s 
capsules and no tuft retraction (Glomerular score 0). There is no visible interstitium signifying no 
damage/abnormality within the tubulo-interstitial compartment (Tubulo-interstitial score 0). 
Overall score =0 
(B). Moderate to severe damage of the renal cortex in a 40-minute IRI rat. Glomeruli are seen with 
evidence of thickened Bowman’s capsule, and glomerular tuft retraction (Glomerular score 1). 
Within the tubules, there is evidence of inflammation and cast formation. Upto 60% of the tubular 
cells show necrosis (Tubular score 3). There is endothelial disruption with no evidence of 
endothelial loss (Endothelial score 2). In addition to the inflammation and haemorrhage seen 
within the tubulo-interstitial compartment, there is necrosis in up to 60% of the cells (Tubulo-
interstitial score 3). Overall score =9 
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3.3.2. Immunohistochemistry 
IHC was used to test a variety of markers encompassing the complement system, 
endothelium and leukocytes. The results are shown in summative graphs , with 
representative IHC pictures showing the changes.  
	
3.3.2.1.Complement studies 
The IHC markers used to assess complement system were: 
• Opsonin C3b which binds to target cell surfaces and immune complexes to 
facilitate their removal  
• C9: marker for terminal membrane attack complex  
• CD59: membrane inhibitor acting at the terminal step, and prevents the assembly of 
the MAC by inhibiting the C5b-8 catalysed insertion of C9 into the lipid bilayer 
 
Figure 3.3: Summative IHC scoring of complement markers – Sham and 40’ IR 
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Figure 3.3: IHC scoring of renal cortex sections from baseline (n=4), sham (n=6) and 40-minute 
unilateral IR (n=10) in rats at 48 hours after reperfusion. Complement markers C3, C9 and CD59 
stained as per protocol and scored 0-4 (vascular and stromal staining). IHC scores are plotted as 
Mean +/- SD, and Mann Whitney tests used to test significance [p value < 0.0001 (****), p= 
0.0001 to 0.001 (***), p = 0.001 to 0.01(**), p = 0.01 to 0.05 (*)].  
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Figure 3.4: Renal cortex IHC sections of complement markers – Sham and 40’ IR 
 
Figure 3.4: Representative rat renal cortex (x200) IHC sections, from sham and 40-minute IR, at 48 
hours after reperfusion. Complement markers C3, C9 and CD59 stained as per protocol and scored 
0-4 (vascular and stromal staining). The 40 minute-IR slides on the left depict increased deposits of 
C3 and C9 compared to the sham group indicating injury, along with decreased of CD59 staining 
in the IR group indicating loss of the inhibitory capacity of CD59 in forming membrane attack 
complex (C9). 
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3.3.2.2. Endothelial markers 
	
Figure 3.5: Summative IHC scoring of endothelial markers – Sham and 40’ IR 
 
 
 
 
 
 
Figure 3.5: IHC scoring of renal cortex sections from baseline (n=4), sham (n=6) and 40-min left 
unilateral IRI (n=10) in rats at 48 hours after reperfusion. Endothelial markers: Tissue factor, 
Thrombomodulin and P-Selectin were stained as per protocol and scored 0-4 (vascular and stromal 
staining). IHC scores are plotted as Mean +/- SD, and Mann Whitney tests used to test significance 
[p value < 0.0001 (****), p= 0.0001 to 0.001 (***), p = 0.001 to 0.01(**), p = 0.01 to 0.05 (*)].  
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Figure 3.6: Renal cortex IHC sections of endothelial markers – Sham and 40’ IR 
 
Figure 3.6: Renal cortex (x200) IHC sections from sham and 40-minute IRI in rats, at 48 hours 
after reperfusion. Endothelial markers: Tissue factor, Thrombomodulin and P-Selectin were stained 
as per protocol and scored 0-4 (vascular and stromal staining). Increased deposits of Tissue factor 
and P-Selectin were seen in the IR group, coupled with decrease deposits of thrombomodulin 
indicating endothelial damage in the IR group compared to the sham group.  
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3.3.2.3. Inflammatory Markers 
Cellular markers for lymphocytes (CD3, CD4 and CD8), macrophages (CD68) and 
neutrophils (CD 15) were used to assess inflammatory infiltrate in IR setting. 
Figure 3.7: IHC scoring of cellular markers for inflammation mediators – Sham and 40’IR 
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Figure 3.7: IHC scoring of renal cortex sections from baseline (n=4), sham (n=6) and 40-minute 
unilateral IRI (n=10) in rats at 48 hours after reperfusion. Cellular markers for inflammation 
mediators were stained as per protocol, and were counted: n/ avg 5x HPF (high power field). IHC 
scores are plotted as Mean +/- SD, and Mann Whitney tests used to test significance [p value < 
0.0001 (****), p= 0.0001 to 0.001 (***), p = 0.001 to 0.01(**), p = 0.01 to 0.05 (*)].  
IHC slides: 
Figure 3.8: Renal cortex IHC sections of cellular markers for inflammation mediators – Sham 
and 40’ IR 
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Figure 3.8: Representative rat renal cortex (x200) IHC sections from sham and 40-minute 
IRI group, at 48 hours after reperfusion. Cellular markers for inflammation mediators were 
stained as per protocol, and were counted: n/ avg 5x HPF (high power field). As evident by 
the earlier quantitative figures, there were increased infiltrate of CD3, CD4 and CD8 
lymphocytes, CD15 (neutrophils) and CD68 (macrophages) in the IR kidneys compared to 
the sham group. 
3.3.3. Real-time reverse transcription PCR (RT-qPCR) 
Reverse Transcription–quantitative PCR (RT-qPCR) is widely used for the quantification 
of gene expression at the mRNA level (443). Gene expression (mRNA) analysis refers to 
the process by which information from a gene is used in the synthesis of a functional gene 
product, and hence able to assess changes (increase/decrease) in the expression of a 
particular gene by measuring the abundance of the gene-specific transcript.  
As discussed in the methodology section, the process of RNA extraction needs to be 
stringent and devoid of any contaminants that may affect the reaction. The Nanodrop 
spectrophotometry provides data on the quantity and the purity of the RNA used. The RNA 
Integrity Number  (RIN) values indicate the quality of the RNA and indicate any 
degradation seen at all in the samples.  
Nanodrop Spectrophotometry: 
Nanodrop is one of the methods used to interpret RNA purity and quantity. The purity of 
RNA is critical in ensuring that the process of obtaining the mRNA has been devoid of any 
contaminants that could hinder the results. The nanodrop results of all the groups are 
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attached as Appendix 3, with emphasis on ratio of sample absorbance at 260/280 (ratio of 
~2.0 is generally accepted as “pure” for RNA) and at 260/230 (ratio ranges commonly 
between1.8-2.2). All the samples had absorbance characteristics of pure quality RNA and 
were devoid of evidence of contaminants that could affect the efficiency of the qPCR 
reaction. 
RNA Integrity Number Values: 
Agilent Bioanalyzer is another methodology that helps in determining the quality of RNA 
by assigning a RIN (RNA Integrity Number) to it. It also helps determining to what extent 
the RNA in the sample is degraded, as RNA extracted from tissues exhibit varying degrees 
of degradation. The RIN values of all groups are highlighted in Appendix 3. As evident by 
the RNA values, there was degradation seen which has been shown due to degradation by 
post-mortem processes and inadequate sample handling or storage (445). The eventual 
reflection of RNA degradation is mainly on cycle threshold (Ct) values and a minor effect 
on PCR efficiency (391). Further reading on the low RIN values and Ct values can be 
accessed at  
(http://www.invitrogen.com/site/us/en/home/References/Ambion-Tech-Support/rtpcr-
analysis/general-articles/rna-isolation-for-qrt-pcr.html). 
3.3.3.1. Normalising to a reference gene 
As disused in the methodology section, one of the techniques to assess changes in mRNA 
levels is to normalize RNA levels to an internal reference gene (367). The assumption is 
that reference gene is abundantly present in the tissue, and levels of expression don’t vary 
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between the treated and untreated groups. In our study, we have also adopted this method 
as there are multiple groups with different treatments and differing RNA concentration, and 
normalising against reference gene would minimise variability. Hence, we have trialled 
seven genes that have been used in the literature in previous IRI studies and adopted with 
the lowest variation among the samples.  
The CT values of the sham and the IR group of the seven genes are depicted in the graphs 
below. 
Figure 3.9: CT values of all individual genes across the individual rats 
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Figure 3.9: Ct (Cycle Threshold) values of seven genes that were evaluated by SYBR green 
fluorescence real-time reverse transcription PCR (RT-qPCR, using 7900 HT Fast Real-
Time PCR System, Applied Biosystems. The x-axis depicts the Ct values while the Y-axis 
details the individual samples used. The individual Ct values of the sham (n=6) and the 40 
minute-IR group (n=10) are depicted in the above figures.  
 
Figure 3.10: Mean + Standard Deviation values of the genes 
 
Figure 3.10: The seven reference (housekeeping) genes plotted as Mean + SD.  
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As evident by the graphs, the GAPDH demonstrated the narrowest SD (1.06) compared to 
YWAHZ (1.93), ACTB (2.19), PGK (1.90), HPRT (2.05), TBP (1.24) and B2M (1.78). 
Based on this, GAPDH was used as the reference gene for this study. 
3.3.3.2. Genes of interest 
Kidney injury markers (KIM-1 and NGAL), cellular adhesion molecules (ICAM-1, 
VCAM) and cytokine markers (TNF-alpha and IL18) were evaluated using RT-PCR. The 
results were analysed using Delta Delta Ct’ (∆∆Ct) values as described by Livak et al(392) 
with GAPDH chosen as the reference gene for the relative quantification.  
Figure 3.11: RT-qPCR analysis of six genes with expression normalized to GAPDH 
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Figure 3.11: RT-qPCR analysis of six genes with expression normalized to GAPDH, and 
values are plotted as mean ± SEM. Unpaired –t tests used to test significance [p value < 
0.0001 (****), p= 0.0001 to 0.001 (***), p = 0.001 to 0.01(**), p = 0.01 to 0.05 (*)]. 
Significant upregulation of both the kidney injury molecules- KIM-1 and NGAL are seen in 
the IR group compared to the sham. The adhesion molecules: ICAM-1 and VCAM-1 are 
also upregulated in the IR group compared to sham. Cytokines TNF alpha and IL-18 are 
also upregulated in the IR group compared to sham. 
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3.4. Discussion of Results 
Histology: 
We used a comprehensive 14-point scale to characterise injury encompassing tubular, 
glomerular, endothelial and tubulointerstitial damage. As shown in Figure 3.1, there was 
significant injury seen in the ischaemia group compared to the sham group and the baseline 
kidneys. Figure 3.2 clearly defines the changes seen in the IR group compared to the sham 
group with predominantly tubular, endothelial and tubule-interstitial injury contributing to 
the injury scoring compared to glomerular damage.  
Immunohistochemistry: 
Complement system: 
Following activation of the complement system, activated C3b and C9 (marker for terminal 
membrane attack complex) act as effectors of the complement system in addition to C3a 
and C5a.   As shown in figure 3.3 and 3.4, there was increase in C3b and C9 deposits in the 
renal interstitium and endothelium in the IR group compared to the controls; this is 
evidence of activation of the complement cascade. It was also interesting to note that we 
were able to stain for C3 in baseline (straight kill) kidneys indicating that there is residual 
level of C3 present that can be produced locally by epithelial and endothelial cells. 
However, there is still the need for an ischaemic insult to propagate the formation of C9 as 
there was no C9 seen in baseline kidneys and CD59 was still present. The increased 
deposits seen in the IR group may be a combination of local and systemic response to 
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ischaemia that eventually leads to formation of MAC and membrane injury. The 
phenomenon has been discussed in the literature as well (327, 328) 
CD59 is a GPI-anchored membrane protein that acts as inhibitor acting at the terminal step, 
and prevents the assembly of the MAC by inhibiting the C5b-8 catalysed insertion of C9 
into the lipid bilayer (217). CD55 and CD59 act synergistically to inhibit complement-
mediated renal IRI, and its deficiency exaggerated renal IRI (393). So effectively, injury 
leads to disappearance of CD59 that was seen with IR. CD59 was seen in baseline kidneys 
as well, and the sham group also showed some reduction in deposits compared to the 
baseline kidneys, however this was not significant.  
In summary, the complement system is activated with ischaemia leading to increased 
expression of C3 and C9, with disappearance of local regulator CD59. This phenomenon 
has been shown in literature (394), but most of the studies have shown it with CD59 as a 
target with reciprocal increase in c3 and c9, while we have shown that injury leads to loss 
of CD59 regulatory function with increase in MAC (C9) on cells. 
Endothelium: 
We used three endothelial markers in this study: Tissue factor (TF), Thrombomodulin (TM) 
and P-Selectin. Thrombomodulin is present normally in the endothelial cell possessing anti-
inflammatory and anti-coagulant functions with the breakdown product in serum used to 
evaluate endothelial injury. Tissue factor on the other hand is released on injury from the 
sub-endothelial matrix, and promotes coagulation, thus accentuating the renal injury. Both 
these markers have been used to evaluate endothelial injury in isolation, but never in 
conjunction (262, 395). As evident in graphs 3.5 and 3.6, the IR group had increase in TF 
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deposits with contralateral decrease in TM deposits. P-Selectin is present, readily available 
within endothelial cells, in cytoplasmic deposits called Weibel-Palade bodies and is an 
adhesion molecule that promotes leukocyte recruitment and is increased in injury (84). 
Similarly, there was increased deposition of P-Selectin in the IR group compared to sham. 
In summary, we have evaluated the endothelium using three markers and have all shown 
consistent injury with ischaemia, and more importantly, all three being used and reported 
together is probably the first time in literature. 
Leukocytes: 
Cellular markers for lymphocytes (CD3, CD4 and CD8), macrophages (CD68) and 
neutrophils (CD 15) were used to assess inflammatory infiltrate in this study. All these cells 
were significantly increased in the ischaemia group indicating the inflammatory response 
that ensues following IR. As shown in graphs 3.8 and 3.8, there was also slight raise in 
CD68 and CD15 cells in the sham group compared to the baseline kidneys, indicating the 
laparotomy an recovery phase also triggers inflammatory pathways. The individual cells 
have been shown to be present in the post-ischaemic kidney in multiple studies (17, 112), 
and we have evaluated them together in this study. 
RT- qPCR: 
The most widely used and reliable technique to analyse variation in mRNA levels is to 
normalize RNA levels to an internal reference gene (370). The first step in this was to 
establish a reliable reference gene, and as evident by graphs 3.9 and 3.10, the GAPDH 
demonstrated the narrowest dispersion (1.06) compared to other reference genes. Hence, 
the genes of interest were normalised to GAPDH. 
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Kidney injury molecules KIM-1 and NGAL were upregulated in the IR group indicating 
injury, and correlating with the histology score and literature (396). Adhesion molecules: 
ICAM-1 and VCAM-1 were also upregulated keeping in trend with literature evidence, and 
reinforcing the immunohistochemistry findings of endothelial damage and activation (99). 
The cytokine TNF- alpha was also significantly raised in the IR group indicating the 
inflammatory response secondary to endothelial damage and leukocyte recruitment. IL-18 
showed a trend to upregulation in the IR group, though this did not reach statistical 
significance.  
Summary of Results: 
In conclusion, the IR group compared to sham group has demonstrated: 
• Significant endothelial injury 
• Significant leukocyte infiltration  
• Complement activation and MAC mediated cellular injury, associated with loss of 
local complement regulator protein CD59 
• Increase in mRNA levels for kidney injury molecules, cytokines and adhesion 
molecules  
• Low morbidity and mortality (discussed in the next chapter) 
The results of this chapter will serve as the foundation for the next two chapters to assess 
changes with interventional agents. 
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CHAPTER IV: 
RESULTS - ANTI-THYMOCYTE GLOBULIN 
AND RENAL ISCHAEMIA - REPERFUSION 
INJURY 
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4.1. Introduction 
Anti-Thymocyte Globulin (ATG) is polyclonal antibody that binds primarily to peripheral 
blood lymphocytes, and displays differential specificity to antigens present on a variety of 
cells involved in immune responses, apoptosis, signal transduction, cell adhesion and 
trafficking (249, 296, 297). The predominant effect of ATG is through T-lymphocyte 
depletion, along with reduction in B-lymphocyte and Natural Killer cell counts (304).  
With such a wide mode of action, ATG should potentially have effects on the cells 
mediating renal ischaemia-reperfusion injury. There have been only a handful studies 
looking into the effects of ATG on renal IRI, and they have had equivocal results. In a 
mouse model evaluating the effects of mouse anti-thymocyte globulin (mATG) on warm 
kidney IRI (models: 30 min bilateral, 60 min bilateral and 45 min unilateral), though there 
was consistent depletion of T-cells in blood, ATG did not confer functional or structural 
protection from the IR injury (311). In a rat transplant model, ATG given to recipient rats 2 
hours before transplantation but not at the ‘time of reperfusion’ (syngenic kidneys) showed 
reduced tubular injury and better graft function (312). Similarly, ATG treated Wistar donor 
kidneys when transplanted into bilaterally nephrectomised recipient rats, the transplanted 
kidney analysed at 24 hours showed protection from renal IRI (313).  
There has been considerable interest in therapeutic manipulation of leucocytes to improve 
outcome following renal IRI, and my results in Chapter 3 underscore the substantial 
leucocyte influx seen following renal IRI. However, the evidence from the previous 
intervention studies with ATG described above is equivocal.  
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Hence, the main aims of this chapter are to evaluate the overall effects of r-ATG on IRI 
with specific objective being 
• Evaluate the effects of r-ATG on leukocyte infiltration 
• Evaluate the effects of ATG on endothelial damage 
• Evaluate the effects of ATG on mRNA levels of genes of interest used as sentinels 
for Acute Kidney Injury 
4.2. Methods 
ATG used in our study was a ‘rabbit anti-rat thymocyte immonuglobulin (rATG)’ produced 
analogously to commercial ATG (Thymoglobulin®), kindly provided by Genzyme 
Corporation (Cambridge, MA, USA). Briefly, rabbits were immunized with a mixture of 
thymocytes of four strains of rats (Sprague Dawley,F344 Fisher, Lewis and Long Evans). 
Thymocyte suspensions were prepared using thymi from several donor rats. Fifty New 
Zealand White rabbits were immunized twice, two weeks apart, and terminally bled two 
weeks after the last immunization. Total rabbit IgG obtained from the serum was pooled 
and purified similarly to Thymoglobulin® Genzyme, Cambridge, MA, USA). Control 
rabbit IgG was purified from whole normal rabbit serum (312). The dose used was 
recommended by the company, and has been used in other studies as well (313). The four 
groups for this study were: 
Groups: 
• IR group (n=10): 40 minutes of left unilateral renal ischaemia followed by 48 hours 
of reperfusion 
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• ATG group (n=8) received rat-specific ATG IV (10mg/kg BW) prior to the 
laparotomy followed by 40 minutes of left unilateral renal ischaemia, followed by 
48 hours of reperfusion 
• ATG Isotype group (n=8) received (10mg/kg BW) of a non-specific isotype 
immunoglobulin from the same laboratory prior to laparotomy, followed by 40 
minutes of left unilateral renal ischaemia followed by 48 hours of reperfusion 
• Sham group (n=6)  
Analysis: 
• Blood samples taken at T0 (prior to ATG administration) and at 48 hours (T1) 
analysed for CD3 blood count using flow cytometry to assess ATG efficacy 
• Kidneys retrieved at 48 hours analysed for  
Histology 
Immunohistochemistry 
Rt-qPCR studies 
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4.3. Results 
4.3.1. CD3 Count analysis 
ATG effect can be measured by blood CD3 count analysis, and this method is used in 
clinical transplantation as well. Initially, we took blood samples at baseline, 24 hours and at 
48 hours. As the CD3 count was depleted still at 48 hours, adhered to 48-hour blood 
collection and thus preventing the need to re-anaesthetise the rat at 24 hours for tail tip. 
Figure 4.1: CD3 count analysis from ATG and Isotype groups 
 
Figure 4.1: Graphs depicting the CD3 count analysis from the ATG group (n=7) and the 
isotype group (n=8). X-axis denotes the percentage expression of CD3 cells, and the Y-axis 
denotes the two time lines of blood sampling for CD3 count analysis: TO and t48 hours. 
Paired-t test shows significant reduction in the CD3 count in the ATG group, while no 
difference was seen in the Isoype group. 
 * There are only seven ATG rat serum represented, as we had initial technical issues with the first sample; 
hence for the first rat we used correlations with IHC CD3 count, which proved reliable 
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As evident by the graphs, the ATG group showed significant depletion of CD3 cells at 48 
hours compared to the Isotype group implying that in this Lewis rat species, the ATG dose 
was effective, and effect lasted until 48 hours. The isotype group had a mixed response, but 
no depletion seen 
4.3.2. Histology 
A comprehensive histopathological scoring scale was used to evaluate renal injury.  
Figure 4.2: ATG studies – Histology scoring of renal cortex sections 
 
Figure 4.2: Scoring of renal cortex sections from sham (n=6), 40-minute unilateral IRI 
(n=10), ATG (n=8) and ATG isotype (IgG; n=8) in rats at 48 hours after reperfusion. 
Histology scores are plotted as Mean +/- SD, and Kruskal-Wallis tests used to test 
significance between the IR, ATG and IgG groups. If significance shown between groups, 
post hoc analysis (Dunn’s test) was used to locate the significance. [p value < 0.0001 
(****), p= 0.0001 to 0.001 (***), p = 0.001 to 0.01(**), p = 0.01 to 0.05 (*)] 
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Figure 4.3: ATG studies – Renal cortex H&E sections 
 
Figure 4.3: Rat Renal cortex H&E (x200) paraffin sections from IRI, IgG (ATG Isotype) 
and ATG, following 40 minutes of ischaemia and 48 hours after reperfusion. The slides 
were assessed for tubular, endothelial, glomerular and tubulo-interstitial cell damage. 
Magnifications as inserts.   
IRI: Untreated control animal showing venous thrombosis, multifocal necrosis and severe 
neutrophil infiltration (H&E). Insert: Severe neutrophil infiltration and partial defacement 
of vascular endothelium. Overall score = 9 (tubular =3, endothelial=2, glomerular=1 and 
tubulointerstitial=3) IgG: Rats pre-treated with isotype IgG (control) showing vascular 
congestion, haemorrhage and moderate neutrophil infiltration, more evident in the insert. 
Overall score=7 (tubular =2, endothelial=2, glomerular=1 and tubulointerstitial=2) 
rATG: Rats pre-treated with ATG. The slide depicts preservation of anatomical integrity of 
the kidney with no endothelial damage and absence of neutrophil infiltration, which is 
obvious in the magnified insert. Overall score=2 (tubular =1, endothelial=0, 
glomerular=0 and tubulointerstitial=1). 
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4.3.3. Immunohistochemistry 
IHC was used to test cellular markers encompassing the leukocytes, endothelium and 
complement stainings. The results are shown in summative graphs, with representative IHC 
pictures showing the changes.  
4.3.3.1. Leukocytes 
Cellular markers for lymphocytes (CD3, CD4 and CD8), macrophages (CD68) and 
neutrophils (CD 15) were used to assess inflammatory infiltrates.  
 
Figure 4.4: ATG studies – IHC scoring of cellular markers for inflammation mediators 
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Figure 4.4: IHC scoring of renal cortex sections from sham (n=6), 40-minute unilateral IRI 
(n=10), ATG ( n=8) and ATG isotype (IgG; n=8) in rats at 48 hours after reperfusion. 
Cellular markers for inflammation were stained as per protocol, and were counted: n/ avg 
5x HPF (high power field). IHC scores are plotted as Mean +/- SD, and Kruskal-Wallis 
tests used to test significance between the IR, ATG and IgG groups. If significance shown 
between groups, post hoc analysis (Dunn’s test) was used to locate the significance. [p 
value < 0.0001 (****), p= 0.0001 to 0.001 (***), p = 0.001 to 0.01(**), p = 0.01 to 0.05 
(*)] 
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Figure 4.5: ATG studies – Renal cortex IHC sections of cellular markers for inflammation 
mediators 
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Figure 4.5: Representative rat renal cortex (x200) IHC sections from 40-minute unilateral 
IRI, ATG and ATG isotype (IgG) groups at 48 hours after reperfusion. Cellular markers for 
inflammation were stained as per protocol, and were counted: n/ avg 5x HPF (high power 
field). Row 1 and Row 2 depict CD3 and CD4 staining in all the three groups, with 
decrease in the ATG group compared to IR and isotype group. Row 3 and 4 show 
decreased CD8 and CD68 deposits in both the ATG and Isotype group compared to IR 
group. Row 5 show decreased neutrophil (CD15) infiltration in the ATG group compared 
to both the Isotype and IR group. 
4.3.3.2. Endothelium 
Thrombomodulin and Tissue Factor were used as markers to assess endothelial damage, 
and these markers have not been used in ATG studies before. Results depicted as 
summative graphs and representative slides. 
Figure 4.6: ATG studies – Summative IHC scoring of endothelial markers 
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Figure 4.6: IHC scoring of renal cortex sections from 40-minute unilateral IRI (n=10), 
ATG (n=8) and ATG isotype (IgG; n=8) in rats at 48 hours after reperfusion. Endothelial 
markers Tissue factor and Thrombomodulin were stained as per protocol and scored 0-4 
(vascular and stromal staining). IHC scores are plotted as Mean +/- SD, and Kruskal-
Wallis tests used to test significance between the IR, ATG and IgG groups. If significance 
shown between groups, post hoc analysis (Dunn’s test) was used to locate the significance.  
Figure 4.7: ATG studies – Renal cortex IHC sections of endothelial markers 
 
Figure 4.7: Representative rat renal cortex (x200) IHC sections from 40-minute unilateral 
IRI, ATG and ATG isotype (IgG) groups at 48 hours after reperfusion. Endothelial 
markers: Tissue factor and Thrombomodulin were stained as per protocol and scored 0-4 
(vascular and stromal staining). Row1 shows staining for tissue factor, which is increased 
in IR group (compared to sham, slide not shown) with decreased deposits in both ATG and 
IgG groups. Row 2 shows thrombomodulin staining that is present normally (sham), but is 
decreased with injury (IR) and protected in both ATG and IgG groups. 
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4.3.3.3. Complement C3 
As discussed in the first chapter, Complement C3 deposits are increased following injury. 
We evaluated activated C3b deposits in this study on the hypothesis that decreased 
inflammatory infiltrate effect may have effect on C3 deposits. 
 
Figure 4.8: ATG studies – Summative IHC scoring of complement markers 
 
Figure 4.8: IHC scoring of renal cortex sections from 40-minute unilateral IRI (n=10), 
ATG (n=8) and ATG isotype (IgG; n=8) in rats at 48 hours after reperfusion. Complement 
marker C3 was stained as per protocol and scored 0-4 (vascular and stromal staining). The 
graph depicts the IHC scores plotted as Mean +/- SD,and Kruskal-Wallis tests used to test 
significance between the IR, ATG and IgG groups. If significance shown between groups, 
post hoc analysis (Dunn’s test) was used to locate the significance [p value < 0.0001 
(****), p= 0.0001 to 0.001 (***), p = 0.001 to 0.01(**), p = 0.01 to 0.05 (*)] 
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Figure 4.9: ATG studies - Renal cortex IHC sections of complement markers 
 
Figure 4.9: Representative rat renal cortex (x200) IHC sections 40-minute unilateral IRI, 
ATG and ATG isotype (IgG) groups. Complement marker C3 was stained as per protocol 
and scored 0-4 (vascular and stromal staining) based on intensity of staining. The slides 
show increased deposits of C3 in renal interstitium in the IR and the IgG group compared 
to ATG treated kidneys. 
4.3.4. RT-qPCR 
Kidney injury markers (KIM-1 and NGAL), cellular adhesion molecules (ICAM-1 and 
VCAM) and cytokine markers (TNF-alpha and IL18) were evaluated using RT-PCR. The 
results were analysed using Delta Delta Ct’ (∆∆Ct) method) with GAPDH chosen as the 
reference gene for the relative quantification.  
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Figure 4.10: ATG studies – RT-qPCR analysis of six genes expression normalized to GAPDH 
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Figure 4.9: RT-qPCR analysis of six genes with expression normalized to GAPDH 
(reference gene), and values are plotted as mean ± SEM. One way-Anova used to test 
significance between the IR, ATG and IgG groups, and if significance seen, post hoc 
(Newman-Keuls test) analysis carried out to locate the significance. [p value < 0.0001 
(****), p= 0.0001 to 0.001 (***), p = 0.001 to 0.01(**), p = 0.01 to 0.05 
	
4.3.5. Discussion of Results 
CD3 blood count: 
As evident in Graph 4.1, ATG had a profound effect on decreasing the CD3 count at 48 
hours compared to the baseline. The ATG Isotype had a mixed response with majority 
showing increase in CD3 count and some showing decrease; however it did not have any 
significant effect on the CD3 count. CD3 count is used to measure the effect of ATG in 
clinical studies (358), and our methodology correlated well with established literature. ATG 
has a long-half life on pharmacokinetics assays in human study, and this may explain the 
prolonged effect of ATG seen (397). 
Histology: 
ATG offered significant structural protection compared to the IR and the Isotype group. 
The H&E staining demonstrated endothelial protection and reduced neutrophil infiltration. 
When analysing the histopathological scores, it was evident that tubular and endothelial 
protection was prominent in the ATG treated group compared to the Isotype and the IR 
group.  
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Immunohistochemistry: 
Leukocytes: 
Effect of ATG on leukocytes is predominantly via lymphocyte depletion and this was 
evident on our study where there was significant depletion of CD3, CD4 and CD8 
lymphocyte cells compared to the IR group. ATG also had significant depletion of CD68 
(macrophages) and CD15 (neutrophils) cells, and this finding contributes to the finding that 
ATG has an effect on wide array of leukocytes (313). ATG effects on leukocytes are well 
defined in clinical practice especially in transplantation and haematological malignancies 
(249). Previous studies have demonstrated lymphocyte depletion, with one study showing 
decrease in macrophage count, but we have shown a wider array of the leukocytes being 
affected by ATG in renal IRI. The Isotype also had some effect on the CD8 and CD68 cells 
(decreased count), but this did not lead to any effect on the histological scoring. The effect 
of isotype has been discussed under the discussion chapter.  
Endothelium: 
There have been no previous studies looking into the effect of ATG on the endothelium. A 
study looking at the effects of ATG and other immunosuppressants on microvascular 
thrombus formation in normal and post ischemic tissue in mice, reported a thrombogenic 
effect of ATG with increase in serum concentrations of P-Selectin and VCAM (308). 
However, the aims of this study were different, and the model was different. Most of the 
studies have evaluated the adhesion molecules (306) but we are the first to investigate 
effect of ATG and its Isotype on Tissue factor and Thrombomodulin. ATG treated rats 
showed reduced TF expression and preserved TM expression compared to the IR group. 
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Interestingly, even the Isotype control showed endothelial protection. These findings are 
new in literature. From this we can hypothesise, endothelial protection alone would not be 
sufficient for attenuating IRI, and augments our hypothesis that IRI is a complex interplay 
between multiple mediators and affecting just one mediator may not offer desired results. 
The ATG also had significant effect of leukocyte infiltrates and this may partly explain the 
effects seen on injury scores by ATG.  
Complement C3: 
We evaluated C3 deposits in the endothelium and interstitium. We hypothesised that 
considering ATG has a profound effect on leukocyte infiltration and on endothelium, there 
may be decreased effect on complement activation leading to reduced C3 production 
locally, and systematically. As evident by figure 4.4, there were decreased complement 
deposits in both the interstitium and the endothelium in the ATG treated rats compared to 
the Isotype or IR group.  
RT-qPCR: 
ATG significantly down regulated both the kidney injury molecules: KIM-1 and NGAL 
compared to the IR and Isotype group, indicating renal protection. This correlates with the 
histological findings. There was no differences seen in the ICAM expression between the 
groups, and other authors have reported similar effect (313). The VCAM expression was 
increased in the ATG group, and this finding was also observed in a mice skin model where 
ATG was used as an interventional agent (308), while there was no effect of ATG on 
VCAM on human umbilical endothelial cells (309). TNF-alpha expression was 
significantly increased in the ATG group compared to the isotype or the IR group. This 
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phenomenon has been seen in humans receiving ATG treatment where increase in serum 
TNF-alpha levels were observed (398). Other groups have shown increased TNF-alpha 
levels in kidney with ATG treatment in brain dead rat model at 2 hours (313). Decreased 
leukocyte count should probably lead to decreased TNF-alpha count as seen with ATG on 
other IRI models (364, 399), however it’s also been shown that TNF- alpha activation can 
happen through many mechanisms. ATG is known to cause profound cytokine release 
following administration, and this may have contributed to the effect seen in our study.  No 
differences were seen in IL-18 expression between the groups, and this may be due to the 
degraded RNA samples, or frankly, no effect of ATG on IL-18 levels. 
Summary of Results: 
Our study has clearly demonstrated that ATG attenuates IRI contradicting the previous 
report from Jang et.al who showed no structural protection from renal IRI (models: 30 min 
bilateral, 60 min bilateral and 45 min unilateral) (311). Their model was similar to ours 
with differing grades of severity, and in spite of lymphocyte depletion, the kidneys were 
not protected. The main difference between their study and ours was the administration of 
ATG. In out study, ATG was given IV just prior to the laparotomy, while they gave ATG 
intraperitoneally either 2-3 days before, or just after reperfusion.  Timing of ATG may also 
be crucial, as we have adopted a model close to clinical practice. In a transplant model, 
ATG given 2 hours pre-transplant to recipients showed protection of the kidney, but no 
protection was observed when ATG was given just prior to reperfusion (312).   
However, we have to be careful in interpreting results from different species and different 
models. Most of the ATG effects on leukocytes and adhesion molecules were seen in 
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primate models. The effect of ATG on rat renal transplant models are also difficult to gauge 
as there has been only one article (313) who administered ATG to donor rats, and 
transplanted their kidneys into recipients with a 24-hour observation. The effects on 
leukocytes and lymphocytes seem to be consistent across the board, however none of these 
studies evaluated the endothelial response, which we have incorporated. 
In conclusion, we can summarise the following findings from our study 
• ATG offers significant protection from renal IRI in this warm model of unilateral 
IRI with ATG administered just prior to laparotomy 
• ATG causes significant decrease in leukocyte infiltrates  
• ATG and its Isotype showed significant endothelial protection which is new in 
literature, however the Isotype effect was not translated into renal protection 
• ATG decreases inflammatory response and reduces Complement C3 deposits 
• ATG down regulated expression of kidney injury molecules 
 
 
 
 
 
	 153	
 
 
 
 
 
CHAPTER V: 
COMPLEMENT SYSTEM MODULATION: sCR1 
AND ANTI-MASP2 
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This chapter is discussed in two sections: 
• sCR1 and its effects on renal IRI 
• Anit-MASP2 antibody and its effects on renal IRI  
5.1. Soluble Complement Receptor 1(sCR1) 
5.1.1. Introduction 
CD35/Complement Receptor-1 (CR1) is a transmembrane glycoprotein that facilitates the 
decay of C3/C5 convertase in both the classical and alternate pathways, and acts as a co-
factor for factor I in the degradation of C3b and C4b(214). sCR1 is a complement regulator 
that has been shown to inhibit the activation of classical and alternative pathways in vitro 
and suppressed complement activation in vivo (257). sCR1 has been shown to attenuate IR 
injuries in myocardium, liver and intestinal models, however, reports of its effect on renal 
IRI are sparse with some beneficial effects seen in a renal transplant model with a longer 
period of observation and repeated doses of sCR1 (327).   
The aims of the this chapter were to evaluate the overall effects of sCR1 on renal IRI, with 
specific objectives being:  
• Evaluate the effects of sCR1 on serum complement activity, and on the activated 
products of the complement system: C3b and CD59 
• Evaluate the effects of sCR1 on leukocytes  
• Evaluate the effects of sCR1 on endothelium 
	 155	
5.1.2. Methods 
The sCR1 utilized in this study was a kind gift of SmithKline Beecham, Pharmaceuticals, 
Harlow, Essex, UK and has been used by previous investigators (320, 327). The dose used 
was similar as previous publications on sCR1 (5.3mg/ml): 25 mg/kg body weight.  
The three groups for this study are 
• IR group (n=10): 40 minutes of left unilateral ischaemia followed by 48 hours of 
reperfusion 
• sCR1 group (n=8) received sCR1(25mg/kg BW) administered intravenously 20-
minutes prior to the laparotomy, followed by 40 minutes of left unilateral ischaemia 
and 48 hours of reperfusion 
• Sham group (n=6)  
Analysis: 
• CH50 Complement assay: Blood samples: TO (prior to laparotomy), T1 (prior to 
reperfusion), T2 (24 hours) and T3 (48 hours) 
• Kidneys harvested at 48 hours were analysed for histological changes. 
Immunohistochemistry (IHC) and real-time PCR were used to assess complement 
deposits and cellular infiltration 
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5.1.3. Results 
5.1.3.1. Complement activity and CH50 analysis 
Complement haemolytic activity (CH50) is a functional test of the complement cascade, 
and is a standard test used to determine the effect of sCR1 on complement activity in serum 
(320, 327). CH50 is based on the lysis of sensitised sheep erythrocytes in the presence of 
Ca++ and Mg++, and the methods have been discussed earlier.  
Figure 5.1: SCR1 Studies – Complement activity in rats at 1/20 dilution 
 
Figure 5.1: Graph depicting the complement activity of (n=8) rats at 1/20 dilution. The Y-
axis represents the time scales of blood being taken over a 48-hour period. The X-axis 
denotes the percentage lysis of sheep erythrocytes read on the optical reader.  
The graph clearly shows that at T0 (prior to laparotomy), the complement system is 
competent, leading to 100% lysis of sheep erythrocytes. Following sCR1, the T1 sample 
shows ablation of the complement system with decreased haemolysis of the sheep 
erythrocytes. By 24 hours, the complement system is completely back to baseline activity, 
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implying that sCR1 is efficacious in ablating the complement system for a short period of 
time.  
5.1.3.2. Histology 
A comprehensive histopathological scoring scale was used to evaluate renal injury. The 
results are shown as summative graphs for the groups, with representative H&E pictures 
showing the pathological changes. 
	
Figure 5.2: SCR1 studies – Histology scoring of renal cortex sections 
 
Figure 5.2: Scoring of renal cortex sections from sham (n=6), 40-minute unilateral IR 
(n=10) and sCR1 treated (n=8) rats at 48 hours after reperfusion, stained with H&E and 
assessed using a comprehensive scoring system comprising of tubular, endothelial, 
glomerular and tubulo-interstitial cell damage. Histology scores are plotted as Mean +/- 
SD, and Mann Whitney tests used to test significance [p value < 0.0001 (****), p= 0.0001 
to 0.001 (***), p = 0.001 to 0.01(**), p = 0.01 to 0.05 (*)] 
Sham IR sCR1
0
5
10
15
Groups
His
tol
og
y s
co
rin
g
Histology
****
	 158	
Figure 5.3: SCR1 studies – Renal cortex H&E sections 
 
Figure 5.3: Representative Rat Renal cortex H&E (x200) paraffin sections from IR and 
sCR1group following 40 minutes of ischaemia and 48 hours after reperfusion. The slides 
were assessed for tubular, endothelial, glomerular and tubulo-interstitial cell damage.  
IRI: Untreated control animal showing venous thrombosis, multifocal necrosis and severe 
neutrophil infiltration (H&E). Overall score = 9 (tubular =3, endothelial=2, glomerular=1 
and tubulointerstitial=3) 
sCR1: Rats pre-treated with sCR1. The slide depicts decreased neutrophil with no 
endothelial damage. Overall score=2 (tubular =0, endothelial=0, glomerular=1 and 
tubulointerstitial=1). 
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5.1.3.3. Immunohistochemistry 
IHC was used to test markers encompassing the complement system, endothelium and 
leukocytes. The results are shown in summative graphs, with representative IHC pictures 
showing the changes.  
5.1.3.3.1. Complement markers 
	
Figure 5.4: SCR1 studies – Summative IHC scoring of complement markers 
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Figure 5.4: IHC scoring of renal cortex sections from sham (n=6), 40-minute unilateral 
IR(n=10) and sCR1 treated (n=8) in rats at 48 hours after reperfusion. Complement 
markers C3, C9 and CD59 stained as per protocol and scored 0-4 (vascular and stromal 
staining). IHC scores are plotted as Mean +/- SD, and Mann Whitney tests used to test 
significance [p value < 0.0001 (****), p= 0.0001 to 0.001 (***), p = 0.001 to 0.01(**), p 
= 0.01 to 0.05 (*)]. 
Figure 5.5: SCR1 studies – Renal cortex IHC sections of complement markers
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Figure 5.5: Rat Renal cortex IHC sections (200x) from IR and sCR1 groups, following 40 
minutes of ischaemia and 48 hours after reperfusion. Complement markers C3, C9 and 
CD59 stained as per protocol and scored 0-4 (vascular and stromal staining). The 40’ IR 
slides are on the left depict increased deposits of C3 and C9 compared to the sCR1 group, 
which have decreased deposits. There is also decreased CD59 staining in the IR group 
compared to relative protection in the sCR1 group.  
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5.1.3.3.2. Endothelium 
Figure 5.6: SCR1 studies – Summative IHC scoring of endothelial markers 
 
 
Figure 5.6: IHC scoring of renal cortex sections from sham (n=6), 40-minute unilateral IR 
(n=10) and sCR1 treated (n=8) in rats at 48 hours after reperfusion. Endothelial markers 
Tissue factor, Thrombomodulin, and P-Selectin were stained as per protocol and scored 0-
4 (vascular and stromal staining). IHC scores are plotted as Mean +/- SD, and Mann 
Whitney tests used to test significance [p value < 0.0001 (****), p= 0.0001 to 0.001 (***), 
p = 0.001 to 0.01(**), p = 0.01 to 0.05 (*)].  
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Figure 5.7: SCR1 studies – Renal cortex IHC sections of endothelial markers 
 
Figure 5.7: Rat Renal cortex IHC (x200) sections from IR and sCR1 group, following 40 
minutes of ischaemia and 48 hours after reperfusion. Endothelial markers: Tissue factor 
and Thrombomodulin, and P-selectin were stained as per protocol and scored 0-4 
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(vascular and stromal staining. There are decreased deposits of Tissue factor and P-
Selectin in the sCR1 treated rats (right column) compared to the IR group (left column). 
There is also presence  of thormbomodulin in the sCR1 group compared to the IR group. 
The quantitative figures are provided in figure 3.. 
5.1.3.3.3. Inflammatory Cells 
Cellular markers for lymphocytes (CD3, CD4 and CD8), macrophages (CD68) and 
neutrophils (CD 15) were used to assess inflammatory infiltrates.  
Figure 5.8: SCR1 studies – Summative IHC scoring of cellular markers for inflammation 
mediators 
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Figure 5.8: IHC scoring of renal cortex sections from sham (n=6), 40-minute unilateral IR 
(n=10) and sCR1 treated (n=8) in rats at 48 hours after reperfusion. Cellular markers for 
inflammation mediators were stained as per protocol, and were counted: n/ avg 5x HPF 
(high power field). IHC scores are plotted as Mean +/- SD, and Mann Whitney tests used to 
test significance [p value < 0.0001 (****), p= 0.0001 to 0.001 (***), p = 0.001 to 0.01(**), 
p = 0.01 to 0.05 (*)]. 
Sham IR sCR1
0
20
40
60
Groups
IH
C
 s
co
rin
g
CD4
***
Sham IR sCR1
0
10
20
30
40
Groups
IH
C
 s
co
rin
g
CD8
****
Sham IR sCR1
0
20
40
60
Groups
IH
C
 s
co
ri
ng
CD68
***
Sham IR sCR1
0
10
20
30
Groups
IH
C
 s
co
ri
ng
CD15
****
	 166	
Figure 5.9: SCR1 studies – Renal cortex IHC sections of cellular markers for inflammation 
mediators 
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Figure 5.9:  Rat Renal cortex IHC sections (200x) from IR and sCR1 groups, following 40 
minutes of ischaemia and 48 hours after reperfusion Cellular markers for inflammation 
mediators were stained as per protocol, and were counted: n/ avg 5x HPF (high power 
field). There is decreased infiltrate of CD3, CD4, CD8, CD15 and CD68 cells in the sCR1 
treated group compared to the IR group.  
5.1.3.4. RT-qPCR 
Kidney injury markers (KIM-1 and NGAL), cellular adhesion molecules (ICAM-1 and 
VCAM) and cytokine markers (TNF-alpha and IL18) were evaluated using RT-PCR. The 
results were analysed using Delta Delta Ct’ (∆∆Ct) values with GAPDH chosen as the 
reference gene for the relative quantification.  
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Figure 5.10: SCR1 studies – RT-qPCR analysis of six genes expression normalized to GAPDH 
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Figure 5.10: RT-qPCR analysis of six genes with expression normalized to GAPDH. Values 
are plotted as mean ± SEM. Unpaired –t tests used to test significance [p value < 0.0001 
(****), p= 0.0001 to 0.001 (***), p = 0.001 to 0.01(**), p = 0.01 to 0.05 (*)].  
There was no statistical difference seen in any of the genes of interest between the IR and 
the sCR1 treated group. 
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5.1.4. Discussion of Results 
CH50 Analysis: 
As evident by the graph 5.1, the 1/20 dilution of sCR1 rat serum showed ablation of the 
complement activity just prior to reperfusion, and the complement system was back to near 
normal by 24 hours. In our model, the sCR1 was injected 20 minutes prior to laparotomy 
followed by ischaemia time of 40 minutes. Pharmacokinetics of sCR1 revealed that the 
sCR1 levels (25mg/kg IV) was reduced to 50% within 30 minutes and declined to trace 
levels by 24 hours (327). This may explain the reconstitution of the complement pathway at 
24 hours, and is directly proportional to the pharmacokinetics of the sCR1. 
Histology: 
sCR1 showed significant structural protection compared to the IR group. Figure 5.3 shows 
the key differences between the sCR1 and IR group on H &E staining, predominantly being 
tubular and endothelial protection with decreased neutrophil infiltrate. 
Immunohistochemistry: 
Complement 
The complement cascade leads to formation of C3b, anaphylotoxins and C5B-9 as end 
product. We evaluated C3b and C9 deposition in both the endothelium and the renal 
interstitium. sCR1 significantly reduced C3 deposits indicating suppression of the 
complement system cascade. This led to decreased assembly of MAC (C9) in the cells in 
the sCR1 treated rats. We also evaluated the local regulatory protein CD59, which in 
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normal circumstances acts as local complement regulator. Loss of CD59 with injury in the 
IR group, was protected in sCR1 treated kidneys. The effect of reduced complement 
staining’s were predominantly seen at the endothelium level compared to the tissues, 
highlighting that endothelial protection offered by complement system ablation may be a 
key mechanism for attenuating IR injury 
The phenomenon of sCR1 induced decreases in C3 and MAC has been shown in renal 
transplant models(327), and other IRI models (320). However, there is no warm renal IRI 
model used before for comparison. The renal transplant model is a step-up compared to our 
model, but our methods and drug dosing were different to the transplant model. 
Endothelium 
To further investigate the effect of sCR1 on endothelium, we investigated markers of 
endothelial activation/injury: Tissue factor, Thrombomodulin and P-Selectin. As depicted 
in figures 5.6 and 5.7, there were decreased deposits of Tissue factor and P-Selectin in 
sCR1 treated rats compared to IR group indicating endothelial protection. Similarly, 
Thrombomodulin was present in sCR1 treated animals indicating endothelial structural 
integrity.  
There is very limited evidence of the effect of sCR1 on vascular endothelium in literature. 
Pratt et.al demonstrated histological protection of endothelium in a renal transplant model 
(327). In a hepatic IRI model, sCR1 was shown to reduce leukocyte sticking to 
endothelium, but they did not evaluate endothelial injury or used markers to quantify it 
(321). In our study, we have evaluated three specific markers for endothelial injury and 
shown endothelial protection on immunohistochemistry and histology. 
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Leukocytes 
sCR1 treated rats showed marked decrease in all the evaluated leukocyte markers: CD3, 
CD4, CD8, CD15 and CD68 cells compared to the IR group. This effect may be partly 
attributed to endothelial protection, and also suppression of the complement system. C3a 
and C5a (anaphylotoxins) are key players in recruitment of leukocytes to site of injury, and 
the suppression of the complement cascade at C3 convertase level prevents the formation of 
these anaphylotoxins, and subsequent leukocyte recruitment. Similar effects of sCR1 on 
leukocytes have been seen on other IRI models involving liver and myocardium in 
literature (318, 328). 
 RT-qPCR: 
The kidney injury molecules: KIM-1 and NGAL both showed down-regulation compared 
to the IR group, however it did not reach statistical significance. There was also similar 
down-regulation of cytokines TNF-alpha and IL-18, but did not reach statistical 
significance. There were no differences in the expression of VCAM and ICAM. 
Of the few studies using sCR1/TP-10 in renal ischaemia, there has been no RT-qPCR done 
on these renal samples. So, it is difficult to compare against literature evidence. The ATG 
group had a significant effect on the injury scoring compared to sCR1 (mean histology 
scores: IR (8.70) vs. ATG (1.25) vs. sCR1 (3.25), and the probability exists that the down 
regulation of kidney injury molecules may be directly proportional to the ‘degree’ of 
protection offered. The other explanation may be due to the degradation of the mRNAs 
seen in the scR1 samples that precluded the Ct values to reach significance. 
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Summary of Results: 
In conclusion, we can summarise the following findings from this part of our study 
• Single dose sCR1 offered protection from renal ischemia reperfusion injury through 
reduced complement activation 
• sCR1 treated rats showed reduced leukocyte infiltrates which may be due to reduced 
anaphylotoxins 
• sCR1 offered significant endothelial protection  
• The complement system was ablated at the time of reperfusion and was 
reconstituted by 24 hours, thus indicating that suppression of complement system 
during the phase of ischemia and reperfusion may provide an avenue for mitigating 
IRI.   
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5.2. Anti-MASP2 antibody and Lectin pathway 
5.2.1. Introduction 
Lectin pathway is activated by the binding of multimolecular lectin complex with a 
carbohydrate moiety on pathogens, with the three MBL-associated serine proteases MASP-
1, MASP-2 and MASP-3 able to bind to the carbohydrate recognition subcomponents and 
activate the lectin pathway (329). MASP-2 cleaves C4 and C2 to form C3 convertase, and 
this cleaving effect was shown by recombinant MASP-2 suggesting that MBL was able to 
activate the lectin pathway via MASP-2 (331). Murine studies have shown sMAP (small 
MBL-associated protein (sMAP) deficient mice showing decreased expression of MASP-2, 
and injection of recombinant sMAP and MASP-2 reconstituted the MBL-MASP-sMAP 
complex in deficient serum, suggesting that MASP-2 was essential for the activation of C4 
in the activation of the lectin pathway (332). 
A recent study employing MASP-2 deficient mice showed protection from myocardial and 
intestinal IR injuries, and this was further supported by the use of an inhibitory monoclonal 
antibody (selectively binds to MASP-2) pre-ischemia that reduced intestinal tissue IRI 
(329). Furthermore, this study also showed that lectin pathway could activate complement 
C3 in the absence of C4 via a unique MASP-2–Dependent C4-Bypass, and lectin pathway-
mediated activation of C3 in the absence of C4 was demonstrated in vitro and shown to 
require MASP-2, C2, and MASP-1/3. In a later study, in a murine study of renal 
transplantation, WT grafts transplanted into MASP-2-deficient recipients showed structural 
and functional protection of transplanted kidney. In the absence of donor or recipient 
complement C4, the WT to WT phenotype was preserved, indicating that the MASP-2-
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mediated damage could occur through MASP-2-dependent activation events independent of 
C4 (400). 
The effect on anti-MASP-2 antibody (329) in renal IRI has not been explored, and we 
trialled  this antibody with the aims of evaluating the effects of Anti-MASP 2 antibody on 
renal IRI in a rat model. 
5.2.2: Methods 
The anti-MASP-2 antibody was provided by Omeros Inc., Seattle, WA and has been used 
to evaluate its efficacy in intestinal IR model (329). Its preparation is as follows: 
recombinant antibodies against MASP-2 (AbDH3 and AbD04211) were isolated from 
Human Combinatorial Antibody Libraries (Serotec; AbD) using recombinant human and 
rat MASP-2A as antigens. An anti-rat Fab2 fragment that potently inhibited lectin pathway-
mediated activation of C4 and C3 in mouse plasma was converted to full-length IgG2a 
antibody. Polyclonal anti-murine MASP-2A antiserum was raised in rats.  
The three groups for this study are 
• IR group (n=10): 40 minutes of left unilateral ischaemia followed by 48 hours of 
reperfusion 
• Anti-MASP2 group (n=6): antibody (1 mg/kg body weight, manufacturer 
recommended) administered intravenously just prior to the laparotomy followed by 
40 minutes of left unilateral ischaemia and 48 hours of reperfusion 
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• Anti-MASP2 Isotype (n=6) received the isotype (1 mg/kg body weight, 
manufacturer recommended) administered intravenously just prior to the 
laparotomy followed by 40 minutes of left unilateral ischaemia and 48 hours of 
reperfusion 
• Sham group (n=6)  
Analysis: 
• Lectin Pathway Inhibition: Blood samples: TO (prior to laparotomy), T1 (prior to 
reperfusion), T2 (24 hours) and T3 (48 hours) 
• Kidneys harvested at 48 hours were analysed for histological damage and RT-qPCR 
studies 
 
5.2.3. Results 
5.2.3.1. Lectin Pathway Ablation 
Omeros Corporation (USA) provided guidance for methods to check the ablation of lectin 
pathway activity in serum, which was adapted in our lab under the guidance of Dr Brad 
Spiller. Functional activity of the lectin pathway in rat serum was assessed by detection of 
C4b deposition on mannan-coated plates. The methodology is discussed in the methods 
section. 
In our study using the current methodology and dosing, we were unable to show LP 
pathway ablation at T1 (prior to reperfusion) and T2 (24 hours) as evident by residual C4b 
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deposits. We were unable to pinpoint if this effect was due to residual Classical pathway 
activation or a bypass mechanism of activating C4 that the antibody was not able to 
suppress. This aspect is further analysed later in this chapter.  
5.2.3.2. Histology 
A comprehensive histopathological scoring scale was used to evaluate renal injury. 
Figure 5.11: MASP studies – Histology scoring of renal cortex sections 
 
 
 
Figure 5.11: Scoring of renal cortex sections from sham (n=6), 40-minute unilateral IR 
(n=10), Anti-MASP2 (n=6) and Anti-MASP2 Isotype (Iso, n=6) at 48 hours after 
reperfusion, stained with H&E and assessed using a comprehensive scoring system 
comprising of tubular, endothelial, glomerular and tubule-interstitial cell changes. 
Histology scores are plotted as Mean +/- SD, and Kruskal-Wallis test used to test 
significance between the IR and the treatment groups. 
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Figure 5.12: MASP studies – Renal cortex H&E sections 
 
Figure 5.12: Rat Renal cortex H&E (x200) paraffin sections from sham (n=6), 40-minute 
unilateral IR (n=10), Anti-MASP2 (n=6) and Anti-MASP2 Isotype (Iso, n=6) at 48 hours 
after reperfusion, stained with H&E. The slides were assessed for tubular, endothelial, 
glomerular and tubulo-interstitial cell damage.  
IRI: Untreated control animal showing venous thrombosis, multifocal necrosis and severe 
neutrophil infiltration (H&E). Overall score = 10 (tubular =3, endothelial=2, 
glomerular=2 and tubulointerstitial=3). Anti-MASP2: Anti-MASP2 antibody shows 
neutrophil infiltrate along with tubular injury and cast formation. There is endothelial 
swelling along with glomeruli tuft retraction. Overall score=8 (tubular=3, endothelial=2, 
glomerular=2 tubulointerstitial=1). 
Anti-MASP2 Isotype: The slide shows neutrophil infiltrate along with tubular injury and 
cast formation. There is endothelial swelling along with glomeruli tuft retraction. 
Tubulointerstitial damage seen with necrosis in parts. Overall score=9 (tubular=3, 
endothelial=2, glomerular=2 tubulointerstitial=2). 
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5.2.3.3. RT-qPCR 
Kidney injury markers (KIM-1 and NGAL), cellular adhesion molecules (ICAM-1 and 
VCAM) and cytokine markers (TNF-alpha and IL18) were evaluated using RT-PCR. The 
results were analysed using Delta Delta Ct’ (∆∆Ct) values with GAPDH chosen as the 
reference gene for the relative quantification.  
Figure 5.13: MASP studies – RT-qPCR analysis of six genes with expression normalized to 
GAPDH 
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Figure 5.13: RT-qPCR analysis of six genes with expression normalized to GAPDH. Values 
are plotted as mean ± SEM. One-way-Anova used to test significance between the IR, Anti-
MASP2 and Anti-MASP2 Isotype groups. There were no differences seen in the genes of 
interest between the IR and the intervention groups. 
 
5.2.4. Discussion of results 
This is the first time we have trialled this antibody, and had limited stock available. The 
dosing schedule was as advised by the manufacturer.  
Histology: 
As evident by the graphs 5.11 and 5.12, there was no protection offered by anti-MASP-2 
antibody on the IR injury 
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RT-qPCR: 
There was no difference seen in the mRNA levels of kidney injury molecules (KIM-1, 
NGAL), adhesion molecules ( ICAM-1, VCAM) and cytokine levels ( TNF-alpha, IL-18). 
Lectin pathway (LP) ablation: 
We were unable to block the lectin pathway completely and there were still C4 deposits 
seen in the plate for T1 and T2 samples. The reasons I see that may have contributed to the 
effect not seen: 
• The dosing was as advised by Omeros, Inc at 1mg/kg BW. The dose they used in 
the original study was 0.6mg/kg BW and we used 1mg/kg BW as advised. In the 
original study, they were able to show LP ablation at 6 hours and lasting effect for 
48 hours in a mouse model. Our 24-hour samples did not show ablation as evident 
by C4 deposits. Though pharmacokinetics was not part of the methodology, on 
checking for the probable dilution required, nearly 20% concentration was required 
which would amount to nearly 3-4x the does currently used. 
• The antibody was shown to be effective on a mice myocardial and intestinal 
reperfusion model and the dose was effective on that particular model. No studies 
have been carried out on the rat renal model in literature, and whether MASP-2 
blockade would work in renal IRI still needs to be established. 
• Probability that there is always a residual level of complement activation in the 
assays that is resistant to anti MASP-2 antibody. Also, it is difficult to interpret 
whether there was any contribution of the classical or alternate pathways to the 
effect seen. 
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Summary of Results: 
Ideally, I would have liked to develop this model further, however due to paucity of time, I 
am reporting the outcomes seen in the preliminary study and if given an opportunity to 
develop this model, this would be the methodology I would employ 
• Determine baseline LP activity in IR and sham groups to determine any 
involvement of the LP, ideally in a mouse model so that knock-out mice could be 
used to classify and quantify changes 
• Determine involvement of Classical and Alternate pathway involvement by using 
knock-out mice model 
• Determine assays to measure MASP-2 in IR and sham models 
• Determine pharmacokinetics of the Anti-MASP2 antibody to determine the 
appropriate dosing, timing of delivery (compared to IR event), mean half life and 
effect on LP pathway 
• Immunohistochemistry to determine complement deposits and probably in a model 
with varying time periods of reperfusion (24-hours, 48 hours and 5 days) 
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CHAPTER VI: 
DISCUSSION AND CONCLUSIONS 
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6.1. Discussion of methodology 
6.1.1. Choice of Model 
Animal studies are a key resource for investigating renal ischemia-reperfusion injury, and 
potential novel therapies. Important considerations in selecting a model include species (eg. 
rat vs. mice vs. swine), the methodology of injury and the timing of analysis (eg. 24 hours 
vs. 48 hours vs. days).  To test therapeutic manipulation of leucocytes and complement, I 
have adopted a unilateral model of renal ischaemia, in the Lewis rat, and a 40’ minute 
ischemia period. This was selected based on prior demonstration in the literature of 
reproducible, significant injury, that may be ameliorated by therapy (348, 349).  
6.1.2. Alternative model approaches 
It is important to acknowledge the limitations of this model, and potential 
advantages/disadvantages of the model adopted for this work. 
The major disadvantage of rat when compared to mouse models is the relative difficulty of 
genetic manipulation in the rat. However, there were additional considerations for my 
planned testing of therapies. For example, frequent blood sampling and circulatory volume 
are issues in the mouse –frequent blood sampling in studies would potentially complicate 
the models. An important future direction may be adaption of the model to use of mice, 
allowing additional genetic approaches to pathway manipulation to be used in conjunction 
with testing of therapeutic approaches in the rat. A second alternative is a large animal 
species, for example a porcine model. This would have additional advantages in terms of 
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histopathological similarity and increased similarity of pathological and therapeutic 
responses, but brings major additional resource and infrastructure considerations. 
The unilateral model would also limit measurement of physiological functional 
measurements like serum creatinine and other serum markers for kidney damage. Having 
established a safety profile with our animal work, a bilateral renal IRI model would be the 
next step forward, and we have adopted this for the next project. The right kidney also 
served as internal controls and has been discussed in the methodology chapter.  
The 40’ minute ischaemia time showed moderate degree of injury in our study. It can be 
speculated that having a more increased time of ischaemia (60 minutes/120 minutes) could 
have shown a higher degree of injury especially if interventions are used to attenuate the 
injury. On the contrary, more severe injury may also have carried increased morbidity to 
the rat, but having produced a model that was safe, reproducible and efficient, future work 
would evolve into exploring more severe models of injury. 
6.1.3. Mortality and Morbidity 
Morbidity included wound infection/dehiscence, failure to thrive and any other features that 
would have needed the animal to require additional treatment, or early sacrifice. In this 
study, we had two mortalities and no morbidities.  The two mortalities were unexpected and 
happened very early in the project, and have been discussed below. 
• Rat 1 (IR group): the subject experienced laboured breathing 30 minutes into 
ischaemic time and showed some recovery following titration of anaesthesia. At 
the time of closure, the rat appeared pale and was recovered in a warm chamber 
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to negate any hypothermic insult. However, the rat passed away in the camber 
itself, and a systematic post mortem was carried out to identify any iatrogenic 
causes. Laparotomy and thoracotomy revealed no bleeding or other explainable 
causes 
• Rat 2 (sham group): the subject was well until the end of 40 minute observation 
period, and was recovering in the heat chamber. However, within 5 minutes it 
passed away, and a systematic post-mortem carried out did not show any 
iatrogenic causes 
Overall, we had a relatively safe and efficient model that adhered to the Animals (Scientific 
Procedures) Act 1986 (ASPA). 
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6.2. Discussion of Results 
Renal ischaemia-reperfusion is an important clinical problem affecting patient’s health, and 
has wide ranging effects on the health service and health economy. My research has 
focussed on three important components of the IRI mechanism, and my results have shown 
that modulating these can attenuate renal IRI. In the next few sections, I will evaluate the 
results under these three components with a perspective on clinical application, and future 
avenues.  
6.2.1. Leukocytes 
Ischaemia-Reperfusion injury is an inflammatory process characterised by leukocyte 
infiltrates, a finding seen in this study and correlates with literature. As discussed in the 
introduction chapter, there is a family of leukocytes (neutrophils, lymphocytes, 
macrophages, NK cells, Tregs etc.) which all have a role in the mediation and propagation 
of IRI. The inflammatory state of the IR kidney may lead to fibrosis and chronic kidney 
disease in the long term. Leukocyte infiltration also coincides with platelet accumulation 
and activation of coagulation cascade, which further accentuate renal injury. The 
complexity and diversity in leukocyte recruitment at the site of injury, from endothelial 
stimulus to anaphylotoxins, makes it challenging to address. Though the individual cells 
and their antagonists have shown promise in individual studies, they still haven’t translated 
into clinical practice. 
Previous studies using Activated protein C (physiological anticoagulant with anti-
inflammatory and anti-apoptotic activities), vinblastine and nitrogen mustard have shown 
leukopenia-induced benefits in other hepatic and spinal cord IRI (293, 294). Recently, 
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thrombomodulin-dependent APC was shown to ameliorate renal IRI in a murine model 
(401). Neuronal guidance cues: Slit and Roundabout (Robo) have shown to prevent the 
migration of multiple leukocyte subsets towards inflammatory chemoattractants, and 
possess anti-platelet functions in vitro and in vivo (402).  The last two articles had potential 
benefit on the platelet and coagulation cascade in addition to the leukocyte influence, 
indicating that a multi-system mediator is needed to address the complex mechanisms of 
IRI. 
ATG and Isotype: 
Rat specific ATG in our study ameliorated IRI via significant reduction in leukocyte 
infiltrate and endothelial protection. It can be hypothesized that the leukocyte depletion 
using ATG may be a combination of direct effect on the leukocytes themselves, or 
secondary to the endothelial protection (TM and TF). The recent evidence of TM-linked 
APC and its benefits in renal IRI can be linked to our study where ATG showed TM 
protection. We haven’t measure APC in our study, and this may be an avenue to be 
explored. We also showed decreased C3 deposits in the renal tissue and endothelium with 
ATG treatment. This is probably due to decreased activation of the complement system 
from the endothelium and along with the dampened inflammatory response. 
One of the interesting findings was the Isotype Ig effect on the endothelial cells and 
inflammatory cells (CD8 and CD68 cells). The ATG isotype is a rabbit IgG purified from 
whole normal rabbit serum. IVIg (Intravenous Immunoglobulin products) has been used for 
the treatment of primary immunodeficiency disorders, inflammatory diseases (Kawasaki 
disease, Guillain-Barre syndrome, myasthenia gravis etc.), in reduction of anti-HLA 
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antibodies in human leukocyte antigen (HLA) sensitized patients and in treatment of 
antibody-mediated rejection (AMR) (403). AMR,also known as B-cell-mediated/ humoral 
rejection, is treated with plasmapheresis and IVIg (404). As the isotype is also an 
immunoglobulin, we feel that some of the effects seen may be partly due to its ‘antibody’ 
nature, however it did not confer protection against IRI. This alludes to the possibility that 
just endothelial protection in itself may not confer overall structural protection. 
6.2.2. Complement System 
The complement system has had a renaissance in the last few years, and is being 
increasingly recognised as being a key mediator of renal ischaemia-reperfusion injuries. In 
one of the earliest sentinel papers, role of complement in renal IRI was questioned as C3 
knock-out mice did not show protection compared to WT (405). However, in this model, 
the warm ischaemia time was only 20-30 minutes, and many subsequent articles questioned 
the validity of such a short ischaemic time in inducing complement activation, or renal 
injury. In the same decade, Zhou et.al showed that C3-, C5-, and C6-deficient mice were 
protected from renal IR injury, whereas C4-deficient mice were not protected, thus 
implying a role for alternative pathway (19). In this study, the renal ischaemia time was 40-
58 minutes with predominant injury seen in the tubular epithelium with relative sparing of 
the renal endothelium. This implies that in any model of IRI, the ischaemic time could have 
a bearing on the aims of the study, and has to sufficient enough to activate/upregulate the 
cells in question. Recent review articles have suggested that among all the pathways 
implicated in mediating renal IRI, alternative and lectin pathways probably have a more 
definitive role than the classical pathway (406, 407). 
	 190	
Complement-targeted therapeutics: 
The complement system in involved a host of clinical pathologies, from autoimmune 
disorders to ischaemia-reperfusion injuries in almost every organ. Its involvement is more 
easily characterised due to the simplicity of the cascade and a definitive end product 
(MAC) that can be measured.  
Complement-targeted therapeutics currently target five main avenues (408): 
• Serine proteases that are integral to the complement cascade (C1r, C1s, C2a, 
MASP-1, MASP-2, factor D, factor B, factor I) with only C1-inhibitor (C1-INH) 
currently used in clinical practice for treatment of hereditary angioneurotic edema 
• Complement antibodies like monoclonal antibodies to C5, and this has translated 
into clinical practice in the form of Eculizumab which is used in the treatment of 
Paroxysmal nocturnal hemoglobinuria, atypical HUS and refractory humoral 
allograft rejection (409) 
• Complement component inhibitors which target specific complement components 
like drug Compstatin (prevents the cleavage of C3 to its active fragments C3a and 
C3b) and drug Pegaptanib (short aptamer molecule directed against C5) (410) 
• Anaphylatoxin receptor antagonists that selectively inhibit the binding of C5a to its 
receptors (C5a receptor and C5L2), like PMX-53 which is still in animal trials (411) 
• Soluble Complement Regulators like sCR1/TP-10, TP20 (sCR1 with sialyl LewisX 
–glycosylation), Mirococept/APT070 (a truncated sCR1 with a membrane-tethering 
motif) and soluble forms of MCP, DAF and CD59 which are still in early 
development phase (408) 
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Though complement system research has been on going for the last many years, very few 
studies have translated into clinical practice. sCR1/TP-10 has been applied into clinical 
practice especially in human coronary artery bypass studies, however results were 
inconclusive. Single dose sCR1 immediately before surgery (like in our model) was found 
to inhibit complement activation for up to 3 days postoperatively with significant 
improvement of the clinical end-points in males, but no benefits in female patients (412).  
 sCR1 and renal IRI: 
As discussed earlier in the results section, there is a paucity of research in the field of 
complement and renal IRI. sCR1 showed promise in a transplant model, however it did not 
translate into further studies. In our study, we have clearly demonstrated the role of 
complement cascade in the IRI process, and the effect of sCR1 in attenuating the renal IRI. 
sCR1 also showed  decreases leukocyte infiltrate which is most likely related to the 
prevention of formation of the anaphylotoxins. The endothelial protection especially using 
three markers is new to literature, and may offer further avenues to explore in future. We 
also demonstrated the loss of local complement regulator CD59 with injury, and protection 
with sCR1.  We also showed that ablation of complement system in the ischaemia-
reperfusion phase offers a ‘time slot’ where complement intervention could be initiated. 
The results should be borne in mind with the model used in our study. We had a moderate 
injury scale, and a 48-hour observation period. Whether the effects will vary with increased 
severity of injury (60-120 mins of ischaemia) or longer observation period needs to be 
explored. The ideal model would be a transplant model with treatment started in donor and 
	 192	
carried all the way in to the recipient.  We hope to establish such a model in the future 
based on the findings from this study.  
6.2.3. Endothelium 
Endothelium is the main target, activator and propagator of renal IRI. Endothelial 
protection using sphingosine 1-phospate (that maintains endothelial cell integrity and 
inhibits lymphocyte extravasations) or prostacyclin analogue iloprost have conferred 
protection against IRI (12, 337). Coating of renal endothelial cells with vaccinia virus 
complement control protein (VCP) via fusogenic lipid vesicle (FLVs) delivery system prior 
to renal IR in a rat model showed structural and functional protection from IRI (338). 
Endothelium also expresses various adhesion molecules that facilitate leukocyte adhesion 
and rolling. Blocking the action of these adhesion molecules also has shown protection 
from IRI, and has been reviewed in the introduction chapter. Manipulating endothelial 
dysfunction offers an attractive proposition, but the complex and intricate relations that 
endothelium shares with a variety of mediators may make it hard for it to be an ‘isolated 
treatment target’.   
The early stages of IR lead to endothelial damage, with the ensuing hypoxia shown to 
activate angiogenic factors like vascular endothelial growth factor (VEGF), and mediators 
like Hypoxia Inducible Factor-1α (HIF-1α) and mTOR, that facilitate the angiogenic 
response (413). Targeting these mediators early in the IR phase may also offer an avenue to 
improve the vascular response to IR. Endothelial activation also leads to aggregation of 
platelets, and activation of the coagulation cascade. In a swine transplant model, addition of 
antithrombin to the collection and preservation protocols showed protection of the 
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transplanted grafts with reduced inflammatory infiltrate and endothelial protection (413). 
The activated coagulation cascade leads to formation of fibrin plugs with activated platelets 
leading to hemostasis, but now evidence is emerging showing the ability of the coagulation 
system to orchestrate long term inflammatory and fibroproliferative responses (414), and 
future studies should evaluate this with both short-term (days) and long-term models 
(weeks). 
Endothelium and IRI: 
In our study, histological scoring, immunohistochemical stainings and RT-qPCR evaluated 
the endothelial response to IRI. Compared to the sham group, the IR group demonstrated 
significant endothelial injury. Both ATG and sCR1 offered significant endothelial 
protection. This may be secondary to the dampened inflammatory response or the ablated 
complement cascade. Measuring coagulation cascade products should be explored in future 
studies especially with increasing evidence that angiogenic factors orchestrate 
fibroproliferative response. Studies should also be considered in clinical practice to 
evaluate transplant renal biopsies post ATG induction for endothelial response. 
Complement modulation is being introduced clinical practice at organ storage level, and 
using biomarkers for endothelial injury will add another dimension to these studies. 
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6.3. Conclusions 
To conclude, I set out on this project with the hypothesis that there are ‘three’ key 
determinants of outcomes following IRI in the context of kidney transplantation: The 
responses of leukocytes, endothelium and the complement system. I have performed 
experimental work to advance understanding of these processes. My main objectives prior 
to the study (italics) and my conclusions from this study are: 
1. To determine the nature of ischaemia-reperfusion injury and classifying the leukocyte 
infiltrates, evaluate endothelial damage and discuss the role of the complement system. 
I have comprehensively shown that IRI is an inflammatory process with increased 
leukocyte infiltrates and upregulated cytokine response following injury. I have quantified 
endothelial damage on a wide scale using histology, immunohistochemistry and RT-qPCR, 
and have used markers that have not been used before to quantify endothelial damage. I 
have also evaluated activated complement system products (C3, C9), and also demonstrated 
the loss of local complementary regulator (CD59) in this model. In the IRI process, all the 
three key determinants were involved and contributed to the injury. 
2. Using ATG as a ‘leukocyte modulator’ and determining whether it attenuates IR injury 
in rats as the reports are inconclusive. We will also ascertain the effect of ATG on the 
leukocytes and the endothelium. 
Contrary to previous reports, I have shown that ATG confers protection from renal IRI in 
this model. The leukocyte response is well documented in the literature, and I have shown 
again in this study, albeit be using more markers (CD3, CD4, CD8, CD15, CD68). I have 
also shown new insights into the effect of ATG on the endothelium, with the protection 
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offered contributing to reduction in the injury scores. I have also shown decreased 
complement C3 deposits indicating a decreased activation of the complement system, 
which is also new in literature and this is probably due to reduced injury, but further studies 
would be needed to see if any specific pathway of complement activation is targeted by 
polyclonal ATG.  
3. Using SCR-1 and anti-MASP-2 antibodies, we aim to modulate the effects of the 
complement system on renal ischaemia reperfusion, along with evaluating the effects on 
leukocytes and the endothelium 
With regards to sCR1, we demonstrated that a single dose of SCR1 was able attenuate IRI, 
which coincidentally links with TP-10 studies in cardiac bypass, and is new in literature 
especially the model we have used. I have also shown that attenuation of complement 
system is the IR phase offers an avenue to mitigate IRI, and these interesting finding needs 
to be explored in future models. I have also shown endothelial protection using sCR1 on a 
comprehensive scale, and demonstrated reduced leukocyte infiltrates.  Unfortunately, I was 
unable to fully evaluate the anti-MASP-2 antibody in this current period of research, but 
have set out plans in the methodology section that can pave way for future research project.  
Clinical perspective: 
Clinical transplantation involves the donor, the organ and the recipient, and all these three 
elements contribute to IRI. ATG currently is being used in clinical practice and has some 
benefits in reducing the DGF/IRI in clinical practice, but the results are equivocal. My 
research study and other animal studies have shown that ATG can attenuate IRI in the 
native kidney and in transplant models (donor ATG treatment).  Currently, due to ethical 
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issues, donor treatment prior to donation is still in infancy. We are aware that ATG 
preservation solutions are being trialled and we await the outcomes from that.  With regards 
to recipient treatment, ATG has shown to affect leuckocyte count and is used in induction 
and rejection episodes following transplantation, mainly as an immunological agent.  
Further clinical studies may demonstrate the effect of ATG on endothelium, and needs to 
be explored. There are multiple variables in the IRI process, and the polyclonal antibody 
nature of ATG makes it an ideal IRI attenuating drug and further studies, both animal (with 
increased severity and transplantation models) and clinical may help define the role of ATG 
as an IRI attenuating agent. 
Complement inhibition also offers an attractive proposition with human studies confirming 
the role of complement system. However, the review of complement-targeted therapeutics 
revealed that very few drugs have made it to the clinical shelf. The reasons are 
multifactorial, but the overriding reason seems to be the complexity of targeting one system 
that has multiple interactions with other systems. There is reason for optimism, but needs to 
carefully explored in models having severe injury /transplant models. Currently, Cardiff is 
part of a multicentre randomised controlled trial in renal transplantation, EMPIRIKAL, 
where mirococept (similar to sCR1) will be given as a treatment to the donor kidney prior 
to transplantation. The outcomes from this study will also define the role of preservation 
solutions with additives in attenuating IRI. 
Overall, I have shown that IRI is mediated by three key elements that interact in complex 
mechanisms, and having a drug that targets all these systems may offer any avenue to 
attenuate IRI in the transplantation setting.  
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APPENDICES 
Appendix A: Protocol 
ATG protocol 
Operative part: 
• General Anaesthesia 
• Time zero blood sample from tail tip (T0) 0.00 minutes 
• Inject ATG at the desired dose in the penile vein 
• Laparotomy + Left renal pedicle IRI for 40.00 minutes 
• Recovery 
 
48 hours later: 
• Blood sample (T1) and retrieval of kidneys : 48 hours 
 
Blood sampling: 
• 24 blood sample was collected in EDTA lined tubes/syringe (by Dr. Brad Spiller) 
• 48 hour sample collected in EDTA eppendorfs from the inferior vena cava 
• Protocol for CD3 analysis explained later in this chapter 
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sCR1 PROTOCOL 
sCR1 dose: 5.3 mg/ ml      Dosage: 25mg/kg body weight 
Operative part: 
• General Anaesthesia 
• Time zero blood sample from tail tip (T0) : 0.00 minutes 
• Inject sCR1 at the desired dose in the penile vein 
• Laparotomy + Left renal pedicle IRI : 20 minutes 
• 1 hour post blood sample prior to reperfusion (T1) : 60 minutes 
• Recovery 
 
24 hours later: 
• GA and blood sample (T2) : 24 hours 
 
48 hours later: 
• Big blood sample (T3) and retrieval of kidneys : 48 hours 
 
Blood sampling: 
• Tail tip into 500ul tubes  and place it on ice 
• Spin at 1300 G for 15 minutes at 5 degree centigrade 
• Transfer amber plasma cells into fresh tubes  
• Store in -70 deg centigrade 
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Anti-MASP2 ab protocol 
 
Anti- MASP2 antibody dose: 1 mg/kg body weight 
Each vial: 250 ug – mixed with cold saline and appropriate volume injected according to 
the body weight 
Operative part: 
• General Anaesthesia 
• Time zero blood sample from tail tip (T0)- 0.00 minutes 
• Inject MASP2 at the desired dose in the penile vein 
• Laparotomy + Left renal pedicle IRI at 20.00 minutes 
• 1 hour post blood sample prior to reperfusion (T1) at 60 minutes 
• Recovery 
24 hours later: 
• GA and blood sample (T2) : 24 hours 
48 hours later: 
• Big blood sample (T3) and retrieval of kidneys : 48 hours 
Blood sampling: 
• Tail tip (0.1 to 0.2 mls) into 500ul tubes , and place it on ice 
• Spin at 1300 G for 15 minutes at 5 degree centigrade 
• Transfer amber plasma cells into fresh tubes  
• Store in -70 deg centigrade 
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Appendix B: Reagents and Materials 
Reagents: 
1. Hydrogen Peroxide solution, 30 wt. % in H2O, ACS reagent, ACS REAGENT 
(Cat :21,676-3, Lot – S28647-265, Sigma- Aldrich)  
2. Phosphate Buffered SALINE ( 10X solution, BP 399-20, Fischer Scientific limited, 
Lot – 102355)   
3. Amboceptor (2 ml, Catalog Number: 9002; Institut Virion\Serion GmbH 
4. Sulfuric acid solution 5M (10N) volumetric analysis (J/8400/24, Fischer Scientific 
Ltd) 
5. Tween 20 (BP337-500, Fischer Scientific Ltd) 
6. OPD EASY-tablets for ELISA, 2mg/tablet( Code : 327972000 ; Acros Organics) 
7. Code Number:  711-035-152   
8. Peroxidase AffiniPure Donkey Anti-Rabbit IgG (Code Number:  711-035-152 , 
Jackson Immuno Research Lab) 
9. Complement Fixation Tablets (Product No. BR0016, Oxoid Limited, UK) 
10.  Mannan from Saccharomyces cerevisiae (Product Number: M7504, Sigma- 
Aldrich) 
11. Veronal Buffered Saline ( NC9460913;  Fischer Scientific limited 
12. 96 well high affinity plate (Immuno 96 MicroWell™ Solid Plates, . MaxiSorp. 
Thermo Scientific Nunc MicroWell ELISA, ), maxisorb-442404,  
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qPCR Related : 
1. MicroAmp Fast optical 96-well reaction plate with Barcode, 0.1 mL ( Cat: 
4346906, Applied Biosystems, Invitrogen) 
2. MicroAmp Optical Adhesive Film PCR Compatible,( Cat :4311971, Applied 
Biosystems, Invitrogen) 
3. QPCR Analyses– 7900 HT Fast Real-Time PCR System, Applied Biosystems 
4. RNAse free Water, Millipore Milli-Q Synthesis 
5. Power SYBR® Green PCR Master Mix and  Power SYBR® Green RT-PCR 
Reagents Kit (Catalog Number 4368577, 4367659, 4367660, 4368706, 4368702, 
4368708 (Master Mix) and 4368711 (RT-PCR Reagents Kit), Applied Biosystems, 
Life Technologies). 
6. NanoDrop-1000 spectrophotometer (Thermo Fisher, Pittsburgh, PA) 
7. Bioanalyzer 2100 (Agilent Technologies, USA) 
8. TRIzol® Reagent ( Cat: 15596-026, Invitrogen) 
9. Chloroform (Cat:  C2432, Sigma-Aldrich) 
10. 2-Propanol (Cat: I9516, Sigma-Aldrich) 
11. Ethanol Absolute ( Cat: E/0650DF/17, Fischer Scietific) 
12. High Capacity cDNA Reverse Transcription Kit (Cat: 4368814,  Invitrogen) 
13. Ethanol absolute (Cat:  1.08543.0250,  Merck KGaA)  
14. FlameStrip Strips for QPCR ( Cat: 4ti-0785/B, 4titude Ltd) 
 
Immunohistochemistry: 
1. DAKO EnVision™ Detection Systems Peroxidase/DAB, Rabbit/Mouse (Cat no: 
Code K5007, DAKO) 
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Appendix C: Nano drop and RIN values 
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